,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,3,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
2,5,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
3,7,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
4,9,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
5,13,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
6,19,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
7,21,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
8,23,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
9,25,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
10,31,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
11,33,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
12,35,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
13,37,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
14,39,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
15,41,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Confirmatory,,
16,43,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Confirmatory,,
17,45,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
18,47,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
19,49,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
20,53,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
21,55,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
22,59,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
23,65,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
24,67,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
25,71,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
26,73,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
27,77,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,Confirmatory,,
28,79,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
29,81,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
30,83,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Confirmatory,,
31,85,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,Confirmatory,,
32,87,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line,Confirmatory,,
33,89,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,Confirmatory,,
34,91,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Confirmatory,,
35,93,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Confirmatory,,
36,95,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,Confirmatory,,
37,97,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,Confirmatory,,
38,99,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
39,101,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
40,103,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
41,105,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
42,107,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
43,109,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
44,113,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
45,115,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
46,119,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
47,121,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
48,123,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
49,125,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
50,131,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
51,133,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,Confirmatory,,
52,137,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
53,139,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
54,141,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
55,143,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
56,145,1,1,,75273,4735,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
57,155,1,1,,75273,4735,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
58,157,1,1,,75273,4735,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
59,161,1,1,,75273,4735,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
60,165,1,1,,75273,4735,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
61,167,1,1,,75273,4735,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
62,175,1,1,,75273,4735,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
63,248,1,1,,75273,4735,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
64,1195,1,2,,48416390,4735,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
65,1332,1,1,,49698900,4735,Active,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
66,8665,4,4,,103167313,4735,Active,,,0.04,IC50,Cytotoxicity against human lung cell carcinoma A549 cell line,Confirmatory,15115412.0,
67,15946,3,3,,103167313,4735,Unspecified,,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),Other,7699707.0,
68,20843,3,4,,103167313,4735,Unspecified,,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals at a dose of 22.1 (uM/kg/day),Other,7699707.0,
69,31892,3,3,,103167313,4735,Unspecified,,,,,Thermal denaturation in alternating poly(dA-dT)poly(dA-dT) homopolymer (AT),Other,8510102.0,
70,31893,3,3,,103167313,4735,Unspecified,,,,,Thermal denaturation in sonicated poly(dA)-poly(dT) homopolymer (AT),Other,8510102.0,
71,46152,3,4,,103167313,4735,Unspecified,,,,,Binding affinity for calf thymus DNA by measuring the change in midpoint of the thermal denaturation curves,Other,15115412.0,
72,53470,5,1,,103167313,4735,Unspecified,300669716.0,,,,Inhibitory dose against oncornaviral DNA polymerase activity of moloney murine leukemia virus,Other,6157024.0,
73,54258,3,4,,103167313,4735,Unspecified,,,,,Binding affinity for calf thymus DNA measured as change in melting temperature,Other,11591500.0,
74,54270,3,3,,103167313,4735,Unspecified,,,,,DNA binding affinity using calf thymus DNA.,Other,12620080.0,
75,54271,3,3,,103167313,4735,Unspecified,,,,,DNA binding affinity using poly(dA-dT).,Other,12620080.0,
76,54423,4,1,,103167313,4735,Unspecified,,,,,Denaturation temperature change on binding to AT to poly (dA)-poly(dT),Other,1738139.0,
77,54424,4,1,,103167313,4735,Unspecified,,,,,Denaturation temperature change on binding on GC to poly(dGC)-poly(dGC),Other,1738139.0,
78,54425,4,1,,103167313,4735,Unspecified,,,,,"DNA binding property estimated by measuring denaturation temperature on GC to poly (dGC)-poly(dGC), normalized to ethidium bromide",Other,1738139.0,
79,54426,4,1,,103167313,4735,Unspecified,,,,,Denaturation temperature change on binding to calf thymus DNA,Other,1738139.0,
80,54427,4,1,,103167313,4735,Unspecified,,,,,DNA binding activity as denaturation temperatures on AT to poly (dA)-poly(dT) normalized to ethidium bromide,Other,1738139.0,
81,54428,4,1,,103167313,4735,Unspecified,,,,,Delta Tm (thermal denaturation) in sonicated calf thymus DNA,Other,,
82,54984,3,3,,103167313,4735,Unspecified,,,,,Thermal denaturation in sonicated calf thymus DNA (CT DNA),Other,8510102.0,
83,54997,4,1,,103167313,4735,Unspecified,,,,,In vitro binding affinity towards calf thymus (CT DNA),Other,14561095.0,
84,55197,3,3,,103167313,4735,Unspecified,,,,,percentage of controls is reported as the counted oocysts obtained from alimentary tract tissues using a blinded protocol on Cryptosporidium parvum at dose of 62 umol/kg/day,Other,8917643.0,
85,55634,4,1,,103167313,4735,Unspecified,,,,,DNA binding affinity measured as an increase in thermal melting of d(CGCGAATTCGCG)2,Other,12781196.0,
86,55635,4,1,,103167313,4735,Unspecified,,,,,DNA binding affinity measured as an increase in thermal melting of poly(dA.dT)2,Other,12781196.0,
87,72882,3,3,,103167313,4735,Unspecified,,,,,Thermal denaturation in alternating poly(dG-dC)-poly(dG-dC) homopolymer (GC),Other,8510102.0,
88,75731,6,4,,103167313,4735,Unspecified,,,50.0,IC50,In vitro inhibition of rabbit muscle GAPDH.,Confirmatory,11405646.0,
89,91777,8,2,,103167313,4735,Inconclusive,,,,,In vitro cytotoxicity against mouse J774 macrophages; Not determined.,Other,15027874.0,
90,95929,6,2,,103167313,4735,Active,,,0.56,IC50,Concentration of compound provoking 50% inhibition on growth of Leishmania donovani promastigotes,Confirmatory,2470903.0,
91,95931,7,1,,103167313,4735,Active,,,,,Concentration of compound provoking >99% irreversible after removal of drugs from culture medium inhibition on growth of Leishmania donovani promastigotes,Other,2470903.0,
92,99864,6,2,,103167313,4735,Unspecified,,,,,In vitro inhibitory activity against Leishmania amazonensis (PH8),Other,11514152.0,
93,99865,8,2,,103167313,4735,Unspecified,,,,,Inhibitory concentration against Leishmania amazonensis,Other,10509921.0,
94,99867,3,3,,103167313,4735,Active,,,,,In vitro evaluation of leishmanicidal activity against Leishmania amazonensis (PH8) at a dose 10 ug/mL; +++=total lysis of parasites,Other,10509921.0,
95,99982,3,3,,103167313,4735,Active,,,,,In vitro evaluation of leishmanicidal activity against Leishmania amazonensis (PH8) at a dose 100 ug/mL; +++=total lysis of parasites,Other,10509921.0,
96,99985,3,3,,103167313,4735,Active,,,,,In vitro evaluation of leishmanicidal activity against Leishmania amazonensis (PH8) at a dose 25 ug/mL; Total lysis of parasites,Other,10509921.0,
97,99988,3,3,,103167313,4735,Active,,,,,In vitro evaluation of leishmanicidal activity against Leishmania amazonensis (PH8) at a dose 50 ug/mL; Total lysis of parasites,Other,10509921.0,
98,99990,6,2,,103167313,4735,Unspecified,,,,,In vitro inhibitory activity against Leishmania braziliensis (M2903),Other,11514152.0,
99,100133,3,3,,103167313,4735,Active,,,,,In vitro evaluation of leishmanicidal activity against Leishmania brasiliensis (2903) at a dose 10 ug/mL; +++=total lysis of parasites,Other,10509921.0,
100,100137,3,3,,103167313,4735,Active,,,,,In vitro evaluation of leishmanicidal activity against Leishmania brasiliensis (2903) at a dose 100 ug/mL; +++=total lysis of parasites,Other,10509921.0,
101,100140,3,3,,103167313,4735,Active,,,,,In vitro evaluation of leishmanicidal activity against Leishmania brasiliensis (2903) at a dose 25 ug/mLv,Other,10509921.0,
102,100143,3,3,,103167313,4735,Active,,,,,In vitro evaluation of leishmanicidal activity against Leishmania brasiliensis (2903) at a dose 50 ug/mL; +++=total lysis of parasites,Other,10509921.0,
103,100291,5,2,,103167313,4735,Inconclusive,,,,,The compound was evaluated in vitro for its inhibitory affect against Leishmania donovani; No data,Other,10866368.0,
104,100292,3,5,,103167313,4735,Unspecified,,,,,The in vitro leishmanicidal activity by measuring the 3H thymidine incorporation in promastigotes of Leishmania donovani at 100 uM concentration,Other,,
105,100409,3,5,,103167313,4735,Unspecified,,,,,An vitro anti-leishmanial activity against Leishmania donovani promastigotes (25 uM),Other,,
106,100410,6,2,,103167313,4735,Active,,,1.35,IC50,Antileishmanial activity of compound against leishmania donovani was determined in luciferase assay,Confirmatory,13678403.0,
107,100412,6,2,,103167313,4735,Active,,,2.0,IC50,Inhibitory activity against Leishmania donovani amastigotes,Confirmatory,12161141.0,
108,100414,6,2,,103167313,4735,Active,,,1.61,IC50,Inhibitory activity against Leishmania donovani promastigotes,Confirmatory,12161141.0,
109,100420,6,2,,103167313,4735,Unspecified,,,,,In vitro inhibitory activity against Leishmania donovani (PP75),Other,11514152.0,
110,100421,6,2,,103167313,4735,Active,,,2.6,IC50,Inhibitory activity against Leishmania donovani (amastigote),Confirmatory,12781196.0,
111,100422,6,2,,103167313,4735,Active,,,9.3,IC50,Inhibitory activity against Leishmania donovani (macrophage),Confirmatory,12781196.0,
112,100424,6,2,,103167313,4735,Active,,,2.0,IC50,Inhibitory concentration against Leishmania donovani axenic amastigotes was determined in vitro,Confirmatory,15027874.0,
113,100426,8,2,,103167313,4735,Unspecified,,,,,Inhibitory concentration against Leishmania donovani,Other,10509921.0,
114,100430,6,3,,103167313,4735,Active,,,0.76,IC50,The in vitro leishmanicidal activity by measuring the 3H thymidine incorporation in promastigotes of Leishmania donovani,Confirmatory,,
115,100444,3,4,,103167313,4735,Unspecified,,,,,In vitro leishmanicidal activity of compound was determined by measuring 3H thymidine incorporation in promastigotes of Leishmania donovani at concentration of 100 uM,Other,,
116,100577,3,3,,103167313,4735,Active,,,,,In vitro evaluation of leishmanicidal activity against Leishmania donovani (PP75) at a dose 10 ug/mL; +++=total lysis of parasites,Other,10509921.0,
117,100582,3,3,,103167313,4735,Active,,,,,In vitro evaluation of leishmanicidal activity against Leishmania donovani (PP75) at a dose 100 ug/mL; +++=total lysis of parasites,Other,10509921.0,
118,100585,3,3,,103167313,4735,Active,,,,,In vitro evaluation of leishmanicidal activity against Leishmania donovani (PP75) at a dose 25 ug/mL; +++=total lysis of parasites,Other,10509921.0,
119,100588,3,3,,103167313,4735,Active,,,,,In vitro evaluation of leishmanicidal activity against Leishmania donovani (PP75) at a dose 50 ug/mL; +++=total lysis of parasites,Other,10509921.0,
120,101027,8,2,,103167313,4735,Unspecified,,,,,Inhibitory concentration against Leishmania mexicana,Other,10509921.0,
121,101036,5,2,,103167313,4735,Unspecified,,,820.352,IC50,Inhibition on leishmania mexicana amazonensis.,Confirmatory,9435905.0,
122,101042,6,2,,103167313,4735,Active,,,1.35,EC50,Antiparasitic activity against Leishmania promastigotes (Leishmania donovani),Confirmatory,14741254.0,
123,101195,6,2,,103167313,4735,Inconclusive,,,,,Percentage inhibition against Leishmania tubulin in vitro was determined at 20 uM; NT means not tested,Other,12161141.0,
124,108216,6,3,,103167313,4735,Inconclusive,,,,,The in vivo leishmanicidal activity of compound was determined against amastigotes of Leishmania donovani in golden hamsters (Mesocricetus auratus) at dose of 50 mg/kg for 5 days; ND=No data,Other,,
125,108587,7,2,,103167313,4735,Active,,,1.16,Ki,compound was tested for inhibitory activity against Matriptase,Confirmatory,11311057.0,
126,110801,3,5,,103167313,4735,Unspecified,,,,,Tested for antiTrypanosomal activity against Trypanosoma rhodesiense in mice at dose of 1.25 mg/kg expressed as mean survival time (MST) or cures,Other,7381860.0,
127,110802,3,5,,103167313,4735,Unspecified,,,,,Tested for antiTrypanosomal activity against Trypanosoma rhodesiense in mice at dose of 10 mg/kg expressed as mean survival time (MST) or cures,Other,7381860.0,
128,110805,3,5,,103167313,4735,Unspecified,,,,,Tested for antiTrypanosomal activity against Trypanosoma rhodesiense in mice at dose of 160 mg/kg expressed as mean survival time (MST) or cures,Other,7381860.0,
129,110806,3,5,,103167313,4735,Unspecified,,,,,Tested for antiTrypanosomal activity against Trypanosoma rhodesiense in mice at dose of 2.5 mg/kg expressed as mean survival time (MST) or cures,Other,7381860.0,
130,110807,3,5,,103167313,4735,Unspecified,,,,,Tested for antiTrypanosomal activity against Trypanosoma rhodesiense in mice at dose of 20 mg/kg expressed as mean survival time (MST) or cures,Other,7381860.0,
131,110811,3,5,,103167313,4735,Unspecified,,,,,Tested for antiTrypanosomal activity against Trypanosoma rhodesiense in mice at dose of 320 mg/kg expressed as mean survival time (MST) or cures,Other,7381860.0,
132,110812,3,5,,103167313,4735,Unspecified,,,,,Tested for antiTrypanosomal activity against Trypanosoma rhodesiense in mice at dose of 40 mg/kg expressed as mean survival time (MST) or cures,Other,7381860.0,
133,110814,3,5,,103167313,4735,Unspecified,,,,,Tested for antiTrypanosomal activity against Trypanosoma rhodesiense in mice at dose of 5 mg/kg expressed as mean survival time (MST) or cures,Other,7381860.0,
134,110817,3,5,,103167313,4735,Unspecified,,,,,Tested for antiTrypanosomal activity against Trypanosoma rhodesiense in mice at dose of 640 mg/kg expressed as mean survival time (MST) or cures,Other,7381860.0,
135,110818,3,5,,103167313,4735,Unspecified,,,,,Tested for antiTrypanosomal activity against Trypanosoma rhodesiense in mice at dose of 80 mg/kg expressed as mean survival time (MST) or cures,Other,7381860.0,
136,113849,5,3,,103167313,4735,Unspecified,,,,,"Effective dose against Trypanosoma brucei S427/118 infection in mice, administered ip after 24 hr",Other,,
137,114587,4,3,,103167313,4735,Active,,,0.0008,IC50,In vitro inhibitory concentration against mice infected with Trypanosoma brucei pentamidine-sensitive strain (EATRO Lab 110).,Confirmatory,12620080.0,
138,114588,4,3,,103167313,4735,Active,,,0.0031,IC50,In vitro inhibitory concentration against mice infected with Trypanosoma brucei rhodesiense (KETRI 243).,Confirmatory,12620080.0,
139,114589,4,3,,103167313,4735,Active,,,0.0032,IC50,In vitro inhibitory concentration against mouse infected with Trypanosoma brucei rhodesiense (KETRI 269),Confirmatory,12620080.0,
140,114590,4,3,,103167313,4735,Active,,,0.005,IC50,In vitro inhibitory concentration against mouse infected with Trypanosoma brucei rhodesiense (kETRI 243As-10-3),Confirmatory,12620080.0,
141,117932,6,1,,103167313,4735,Unspecified,,,,,In vivo average survival days of mice infected by Trypanosoma brucei rhodesiense was determined for a period of 60 days at i.p. dose of 20 mg/kg,Other,15214792.0,
142,118270,3,4,,103167313,4735,Unspecified,,,,,Number of mice (out of 4) cured from Trypanosoma brucei rhodesiense infection which are parasite free for 60 days was determined at i.p. dose of 20 mg/kg,Other,15214792.0,
143,124114,6,1,,103167313,4735,Unspecified,,,,,In vivo average survival rate of mouse infected by T.b. rhodesiense was determined for a period of 60 days at dose of 20 mg/kg by i.p. administration,Other,14561095.0,
144,124386,3,3,,103167313,4735,Unspecified,,,,,No. of mice that survived T.b. rhodesiense infection and are parasite free for 60 days was determined at dose of 20 mg/kg by i.p. administration; 4 animals tested,Other,14561095.0,
145,144971,9,3,,103167313,4735,Active,,,1.31,IC50,"Inhibition of [3H]MK-801 binding to the NMDA receptor of rat hippocampal membranes, measured in buffer containing 20 mM TRIS acetate, pH 7",Confirmatory,,
146,144972,9,3,,103167313,4735,Active,,,3.06,IC50,"Inhibition of [3H]MK-801 binding to the NMDA receptor of rat hippocampal membranes, measured in buffer containing 50 mM TRIS acetate, pH 7",Confirmatory,,
147,144974,9,5,,103167313,4735,Active,548372.0,24410.0,2.59,IC50,Inhibition of [3H]dizocilpine binding to N-methyl-D-aspartate (NMDA) receptor complex in rat brain membranes,Confirmatory,10340618.0,
148,144974,9,5,,103167313,4735,Active,548374.0,24411.0,2.59,IC50,Inhibition of [3H]dizocilpine binding to N-methyl-D-aspartate (NMDA) receptor complex in rat brain membranes,Confirmatory,10340618.0,
149,144974,9,5,,103167313,4735,Active,548379.0,24408.0,2.59,IC50,Inhibition of [3H]dizocilpine binding to N-methyl-D-aspartate (NMDA) receptor complex in rat brain membranes,Confirmatory,10340618.0,
150,144974,9,5,,103167313,4735,Active,3915771.0,24409.0,2.59,IC50,Inhibition of [3H]dizocilpine binding to N-methyl-D-aspartate (NMDA) receptor complex in rat brain membranes,Confirmatory,10340618.0,
151,144974,9,5,,103167313,4735,Active,18202594.0,24412.0,2.59,IC50,Inhibition of [3H]dizocilpine binding to N-methyl-D-aspartate (NMDA) receptor complex in rat brain membranes,Confirmatory,10340618.0,
152,144974,9,5,,103167313,4735,Active,51701630.0,170796.0,2.59,IC50,Inhibition of [3H]dizocilpine binding to N-methyl-D-aspartate (NMDA) receptor complex in rat brain membranes,Confirmatory,10340618.0,
153,144974,9,5,,103167313,4735,Active,51701631.0,191573.0,2.59,IC50,Inhibition of [3H]dizocilpine binding to N-methyl-D-aspartate (NMDA) receptor complex in rat brain membranes,Confirmatory,10340618.0,
154,145103,4,10,,103167313,4735,Unspecified,,,,,"Effect of spermine on the inhibition of [3H]MK-801 binding to the NMDA receptor TRIS acetate, pH 7",Other,,
155,145104,4,10,,103167313,4735,Unspecified,,,,,"Effect of spermine on the inhibition of [3H]-MK-801 binding to the NMDA receptor TRIS acetate, pH 7",Other,,
156,151199,8,2,,103167313,4735,Inconclusive,,,,,In vitro inhibitory activity against Plasmodium falciparum; Not determined,Other,14561095.0,
157,155965,5,2,,103167313,4735,Inconclusive,,,,,Cytotoxicity against peritoneal macrophages of female CD1 mice culturing amastigote stages of Leishmania donovani; no data,Other,10866368.0,
158,155967,5,2,,103167313,4735,Inconclusive,,,,,Cytotoxicity against peritoneal macrophages of female CD1 mice culturing amastigote stages of Trypanosoma cruzi; no data,Other,10866368.0,
159,156323,8,2,,103167313,4735,Inconclusive,,,,,In vitro cytotoxicity against mouse PC3 prostate cancer cell line; Not determined.,Other,15027874.0,
160,157425,7,1,,103167313,4735,Active,,,,,Compound was tested for anti-P. carinii activity in vitro.,Other,,
161,157426,7,1,,103167313,4735,Active,,,,,Compound was tested for anti-P. carinii activity in vivo.,Other,,
162,158529,4,3,,103167313,4735,Active,,,0.045,IC50,In vitro antiparasitic activity against chloroquine-resistant Plasmodium falciparum Indochina I,Confirmatory,15115412.0,
163,158530,4,3,,103167313,4735,Active,,,0.015,IC50,In vitro antiparasitic activity against chloroquine-sensitive Plasmodium falciparum Haiti 135,Confirmatory,15115412.0,
164,158690,8,2,,103167313,4735,Inconclusive,,,,,In vitro inhibitory activity for Plasmodium falciparum; Not tested,Other,15214792.0,
165,162068,3,3,,103167313,4735,Unspecified,,,,,The compound was tested in vivo against Pneumocystis carinii pneumonia (PCP) in the immunosuppressed rat model at iv dose of 22.0 (umol/kg/day),Other,10508447.0,
166,162082,3,3,,103167313,4735,Unspecified,,,,,Anti-P. carinii activity determined as change in number of Pneumocystis carinii trophozoites from day 1 through day 5 in culture at 1 uM,Other,11591500.0,
167,162086,3,3,,103167313,4735,Unspecified,,,,,Percent of control growth of Pneumocystis carinii trophozoites was determined,Other,11591500.0,
168,162098,3,4,,103167313,4735,Unspecified,,,,,Percentage of control was reported as the counted cysts in lung tissue using blinded protocol of saline-treated controls on Pneumocystis carinii at dose of 22.1 umol/kg/day,Other,8917643.0,
169,162225,3,3,,103167313,4735,Unspecified,,,,,in vivo activity against Pneumocystis carinii at dose of 22.1 umol/kg/day,Other,8917643.0,
170,162412,3,4,,103167313,4735,Unspecified,,,,,Binding affinity for poly dA-dT DNA by measuring the change in midpoint of the thermal denaturation curves,Other,15115412.0,
171,162418,4,1,,103167313,4735,Unspecified,,,,,In vitro binding affinity towards Poly (dA-dT)2,Other,15214792.0,
172,162419,4,1,,103167313,4735,Unspecified,,,,,In vitro binding affinity towards Poly (dA-dT)2,Other,14561095.0,
173,173839,3,3,,103167313,4735,Unspecified,,,,,Percentage control of Pneumocystis carinii pneumonia in immunosuppressed rat at 22 uM/Kg/d administered intravenously,Other,10377232.0,
174,174192,3,3,,103167313,4735,Unspecified,,,,,The cysts/g of lung (% of control ) is calculated at a dose of 13.3 umol/kg/day against Pneumocystis carinii in rats,Other,9438029.0,
175,174195,3,3,,103167313,4735,Unspecified,,,,,The cysts/g of lung (% of control ) is calculated at a dose of 22.0 umol/kg/day against Pneumocystis carinii in rats,Other,9438029.0,
176,174969,2,4,,103167313,4735,Unspecified,,,,,Anti-Pneumocystis carinii Pneumonia activity at intravenous dosage of 10.0 mg/kg/day in rat,Other,,
177,179650,3,3,,103167313,4735,Unspecified,,,,,Evaluated for effectiveness at 10 mg/kg reported as relative to pentamidine in rat,Other,7490723.0,
178,191331,3,3,,103167313,4735,Unspecified,,,,,"In vivo anti-Pneumocystis carinii toxicity in rats administered intravenously at 10 mg/kg/day; 0 indicates no local, clinical, histologic toxicity",Other,7799405.0,
179,191332,2,4,,103167313,4735,Unspecified,,,,,In vivo toxicity against Pneumocystis carinii at intravenous dosage of 10.0 mg/kg/day in rat,Other,,
180,191634,4,2,,103167313,4735,Unspecified,,,,,Toxicity is evaluated according to a five-level scale ranging from 0 to 5+ at the specified iv dose of 22.0 (umol/kg/day);,Other,10508447.0,
181,191647,3,3,,103167313,4735,Unspecified,,,,,"Toxicity was reported in rat; Toxic,",Other,7490723.0,
182,192591,3,5,,103167313,4735,Unspecified,,,,,In vivo evaluation of iv dosage of the furan dications against Pneumocystis carinii in lung tissue of rats at 22 umol/kg/day,Other,9748362.0,
183,194709,4,4,,103167313,4735,Unspecified,,,,,Anti- Pneumocystis carinii activity was measured as percentage of number of cysts counted per gram of lung tissue,Other,7799405.0,
184,196848,4,2,,103167313,4735,Unspecified,,,,,Toxicity in immunosuppressed rat after administration of 22(uM/Kg/d).,Other,10377232.0,
185,208055,5,2,,103167313,4735,Active,,,0.0022,IC50,In vitro inhibitory activity against T. b. rhodesiense,Confirmatory,14561095.0,
186,208056,4,3,,103167313,4735,Active,,,0.035,IC50,Compound was evaluated for anti-parasitic activity against Trypanosoma brucei,Confirmatory,11300872.0,
187,208221,8,1,,103167313,4735,Active,,,0.006,ED50,Effective concentration required to block the growth of bloodstream Trypanosoma brucei,Confirmatory,11405646.0,
188,212720,3,3,,103167313,4735,Unspecified,,,,,Toxicity at a dose of 13.3 umol/kg/day against Pneumocystis carinii in rats,Other,9438029.0,
189,212723,3,3,,103167313,4735,Unspecified,,,,,Toxicity at a dose of 22.0 umol/kg/day against Pneumocystis carinii in rats;,Other,9438029.0,
190,213471,5,2,,103167313,4735,Active,,,0.0022,IC50,In vitro inhibitory activity against Trypanosoma brucei rhodesiense,Confirmatory,15214792.0,
191,213647,5,2,,103167313,4735,Inconclusive,,,,,The compound was evaluated in vitro for its inhibitory affect against Trypanosoma cruzi; No data,Other,10866368.0,
192,213672,6,2,,103167313,4735,Active,,,7.1,IC50,Inhibitory activity against Trypanosoma cruzi,Confirmatory,12781196.0,
193,214648,6,7,,103167313,4735,Inconclusive,136620.0,,,,The compound was evaluated in vitro for its inhibitory affect against trypanothione reductase; No data,Other,10866368.0,
194,214974,6,2,,103167313,4735,Active,,,0.013000000000000001,IC50,Inhibitory concentration against brucei variant 221 was determined in vitro,Confirmatory,15027874.0,
195,215325,5,1,,103167313,4735,Unspecified,,,,,Anti parasitic activity against Trypanosoma brucei,Other,11551771.0,
196,215333,8,1,,103167313,4735,Active,,,0.008,ED50,Effective dose required against Trypanosoma brucei in bloodstream,Confirmatory,11206479.0,
197,215343,5,1,,103167313,4735,Unspecified,,,,,The compound was evaluated in vitro for its inhibitory affect against Trypanosoma brucei; (0.03 mM Sb),Other,10866368.0,
198,215513,3,3,,103167313,4735,Unspecified,,,,,The compound was evaluated for the inhibition of Trypanosoma brucei at 1 (ug/ml).,Other,10866389.0,
199,225921,4,1,,103167313,4735,Unspecified,,,,,Delta Tm (thermal denaturation) in sonicated poly(dA).poly(dT) homopolymer,Other,,
200,226666,6,2,,103167313,4735,Active,,,4.2,IC50,Cell toxicity was evaluated,Confirmatory,12781196.0,
201,227749,3,3,,103167313,4735,Unspecified,,,,,Binding constant obtained in an ethidium displacement assay for the sequence d(CGGAATTCGCG)2,Other,8691476.0,
202,228309,3,4,,103167313,4735,Unspecified,,,,,Binding affinity for Poly (dA-dT) measured as change in melting temperature,Other,11591500.0,
203,233000,4,1,,103167313,4735,Unspecified,,,,,In vitro increase in thermal melting of oligomer d(CGCGAATTCGCG)2,Other,8917643.0,
204,233020,4,1,,103167313,4735,Unspecified,,,,,The compound was tested for the increase in thermal melting of d(CGCGAATTCGCG)2.,Other,10377232.0,
205,233021,4,1,,103167313,4735,Unspecified,,,,,The increase in thermal melting of poly(dA-dT)2 is a measure of binding affinity for DNA,Other,10377232.0,
206,233022,4,1,,103167313,4735,Unspecified,,,,,Thermal melting temperature for (dCGCGAATTCGCG)2 at a concentration of 3*10e-6 M base pairs at a ratio of 0.6 compound per base pair,Other,8691476.0,
207,233023,4,1,,103167313,4735,Unspecified,,,,,Thermal melting temperature determined for (dG-C)4 at a concentration of 3*10e-6 M base pairs at a ratio of 0.6 compound per base pair,Other,8691476.0,
208,233024,4,1,,103167313,4735,Unspecified,,,,,Thermal melting temperature for poly(A).poly(U) at a concentration of 5*10e-5) M base pairs at a ratio of 0.6 compound per base pair,Other,8691476.0,
209,233025,4,1,,103167313,4735,Unspecified,,,,,Thermal melting temperature determined for poly(dA).poly(dT) at a concentration of 5*10e-5) M base pairs at a ratio of 0.6 compound per base pair,Other,8691476.0,
210,233468,4,10,,103167313,4735,Unspecified,548372.0,24410.0,,,Hill coefficient for binding to NMDA receptor,Other,,
211,233468,4,10,,103167313,4735,Unspecified,548374.0,24411.0,,,Hill coefficient for binding to NMDA receptor,Other,,
212,233468,4,10,,103167313,4735,Unspecified,548379.0,24408.0,,,Hill coefficient for binding to NMDA receptor,Other,,
213,233468,4,10,,103167313,4735,Unspecified,3915771.0,24409.0,,,Hill coefficient for binding to NMDA receptor,Other,,
214,233468,4,10,,103167313,4735,Unspecified,18202594.0,24412.0,,,Hill coefficient for binding to NMDA receptor,Other,,
215,233468,4,10,,103167313,4735,Unspecified,51701630.0,170796.0,,,Hill coefficient for binding to NMDA receptor,Other,,
216,233468,4,10,,103167313,4735,Unspecified,51701631.0,191573.0,,,Hill coefficient for binding to NMDA receptor,Other,,
217,233470,4,10,,103167313,4735,Unspecified,548372.0,24410.0,,,Hill coefficient for binding to NMDA receptor in TRIS acetate pH 7,Other,,
218,233470,4,10,,103167313,4735,Unspecified,548374.0,24411.0,,,Hill coefficient for binding to NMDA receptor in TRIS acetate pH 7,Other,,
219,233470,4,10,,103167313,4735,Unspecified,548379.0,24408.0,,,Hill coefficient for binding to NMDA receptor in TRIS acetate pH 7,Other,,
220,233470,4,10,,103167313,4735,Unspecified,3915771.0,24409.0,,,Hill coefficient for binding to NMDA receptor in TRIS acetate pH 7,Other,,
221,233470,4,10,,103167313,4735,Unspecified,18202594.0,24412.0,,,Hill coefficient for binding to NMDA receptor in TRIS acetate pH 7,Other,,
222,233470,4,10,,103167313,4735,Unspecified,51701630.0,170796.0,,,Hill coefficient for binding to NMDA receptor in TRIS acetate pH 7,Other,,
223,233470,4,10,,103167313,4735,Unspecified,51701631.0,191573.0,,,Hill coefficient for binding to NMDA receptor in TRIS acetate pH 7,Other,,
224,233938,3,3,,103167313,4735,Unspecified,,,,,Ratio between poly-dAdT and poly-dGdC binding,Other,8510102.0,
225,237614,3,4,,103167313,4735,Unspecified,,,,,poly(d(A-T)2) binding affinity is measured as change in DNA melting temperature,Other,16107146.0,
226,238034,9,5,,103167313,4735,Active,134138.0,6285.0,1.0,Kd,Binding to holo-S100B protein,Confirmatory,15456252.0,
227,247487,6,2,,103167313,4735,Active,,,24.0,IC50,Cytotoxicity against A549 cell line,Confirmatory,15357989.0,
228,247627,6,2,,103167313,4735,Active,,,0.5,IC50,inhibitory concentration against Pneumocystis carinii,Confirmatory,15357989.0,
229,247973,4,3,,103167313,4735,Active,,,0.0346,IC50,In vitro antiprotozoal activity for Plasmodium falciparum K1,Confirmatory,16107146.0,
230,248158,6,2,,103167313,4735,Active,,,1.2,IC50,Concentration required for 50% growth inhibition of primary malignant melanoma C8146A cell lines,Confirmatory,15456252.0,
231,248239,4,3,,103167313,4735,Active,,,0.0023,IC50,In vitro antiprotozoal activity against Trypanosoma brucei rhodesiense strain STIB900,Confirmatory,16107146.0,
232,249190,8,1,,103167313,4735,Active,,,1.5,TD50,In vitro cytotoxicity evaluated using cultured L6 rat myoblast cells,Confirmatory,16107146.0,
233,249233,3,3,,103167313,4735,Unspecified,,,,,"In vivo antitrypanosomal activity (20 mg/kg for 4 days, i.p.) measured as cured mice infected with Trypanosoma brucei rhodesiense strain STIB900; 0 cured out of 4",Other,16107146.0,
234,251284,6,1,,103167313,4735,Unspecified,,,,,"In vivo antitrypanosomal activity (20 mg/kg for 4 days, i.p.) measured as survival days of mice infected with Trypanosoma brucei rhodesiense strain STIB900",Other,16107146.0,
235,251292,6,1,,103167313,4735,Unspecified,,,,,"In vivo antitrypanosomal activity at a dose of 4*5 mg/kg, i.p., in mice infected with Trypanosoma brucei brucei STIB 795 strain, measured as survival days (control 7 days)",Other,16107157.0,
236,251293,7,1,,103167313,4735,Inconclusive,,,,,"In vivo antitrypanosomal activity at a dose of 4*20 mg/kg, i.p., in mice infected with Trypanosoma brucei brucei STIB 795 strain, measured as survival days (control 7 days)",Other,16107157.0,
237,251298,5,3,,103167313,4735,Inconclusive,,,,,"In vivo antitrypanosomal activity at a dose of 4*5 mg/kg, i.p., in mice infected with Trypanosoma brucei rhodesiense STIB 900 strain, measured as survival days (control 7 days); ND is not determined",Other,16107157.0,
238,251300,7,1,,103167313,4735,Unspecified,,,,,"In vivo antitrypanosomal activity at a dose of 4*20 mg/kg, i.p., in mice infected with Trypanosoma brucei rhodesiense STIB 900 strain, measured as survival days (control 7 days); ND is not determined",Other,16107157.0,
239,251980,3,3,,103167313,4735,Unspecified,,,,,In-vitro antileishmanial activity was tested against intracellular amastigotes of Leishmania donovani at dose 5 ug/mL,Other,15225696.0,
240,252014,3,3,,103167313,4735,Unspecified,,,,,In-vitro antileishmanial activity was tested against extracellular promastigotes of Leishmania donovani at dose of 5 ug/mL,Other,15225696.0,
241,252602,3,4,,103167313,4735,Inconclusive,,,,,"In vivo antitrypanosomal activity at a dose of 4*20 mg/kg, i.p., in mice infected with Trypanosoma brucei brucei STIB 795 strain",Other,16107157.0,
242,252604,3,4,,103167313,4735,Unspecified,,,,,"In vivo antitrypanosomal activity at a dose of 4*5 mg/kg, i.p., in mice infected with Trypanosoma brucei brucei STIB 795 strain; 4/4",Other,16107157.0,
243,252611,3,4,,103167313,4735,Unspecified,,,,,"In vivo antitrypanosomal activity at a dose of 4*20 mg/kg, i.p., in mice infected with Trypanosoma brucei rhodesiense STIB 900 strain, measured as cured/infected; 0/4",Other,16107157.0,
244,252613,3,4,,103167313,4735,Inconclusive,,,,,"In vivo antitrypanosomal activity at a dose of 4*5 mg/kg, i.p., in mice infected with Trypanosoma brucei rhodesiense STIB 900 strain, measured as cured/infected; ND is not determined",Other,16107157.0,
245,261353,6,2,,103167313,4735,Active,,,2.5,IC50,Antileishmanial activity against Leishmania donovani promastigotes,Confirmatory,16509575.0,
246,261761,6,2,,103167313,4735,Active,,,0.011000000000000001,IC50,Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900,Confirmatory,16343898.0,
247,264891,3,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani promastigotes at 2 ug/ml,Other,16503140.0,
248,264892,3,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani amastigotes at 20 ug/ml,Other,16503140.0,
249,265559,4,3,,103167313,4735,Unspecified,,,,,Leishmanicidal activity against Leishmania amazonensis promastigote form at 100 ug/mL,Other,16722639.0,
250,265560,4,3,,103167313,4735,Unspecified,,,,,Leishmanicidal activity against Leishmania infantum promastigote form at 100 ug/mL,Other,16722639.0,
251,265561,4,3,,103167313,4735,Unspecified,,,,,Leishmanicidal activity against Leishmania braziliensis promastigote form at 100 ug/mL,Other,16722639.0,
252,266329,3,3,,103167313,4735,Active,,,,,Binding affinity to Trypanosoma brucei rhodesiense DNA,Other,16759117.0,
253,266442,10,2,,103167313,4735,Unspecified,68566154.0,11156.0,53.6,IC50,Inhibition of human recombinant PRL-3,Confirmatory,16530413.0,
254,269490,8,1,,103167313,4735,Active,,,0.0022,IC50,Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900,Confirmatory,16913722.0,
255,269491,6,2,,103167313,4735,Inconclusive,,,,IC50,Antiprotozoal activity against Plasmodium falciparum K1,Confirmatory,16913722.0,
256,269492,6,2,,103167313,4735,Active,,,2.1,IC50,Cytotoxicity against rat L6 cells,Confirmatory,16913722.0,
257,269493,3,3,,103167313,4735,Inactive,,,,,"Antiprotozoal activity in mouse infected with Trypanosoma brucei rhodesiense STIB900 measured as survival upto 60 days at 20 mg/kg, ip",Other,16913722.0,
258,269497,6,1,,103167313,4735,Unspecified,,,,,"Antiprotozoal activity in mouse infected with Trypanosoma brucei rhodesiense STIB900 measured as average days of survival at 20 mg/kg, ip",Other,16913722.0,
259,270072,6,2,,103167313,4735,Active,,,6.6,IC50,Antileishmanial activity against Leishmania donovani LV9 promastigotes by MTT method,Confirmatory,16879965.0,
260,272981,8,1,,103167313,4735,Active,,,0.001,ED50,Antitrypanosomal activity against Trypanosoma brucei rhodesiense trypomastigotes,Confirmatory,17004723.0,
261,279546,8,1,,103167313,4735,Unspecified,,,1900.0,EC50,Antiproliferative activity against Leishmania donovani DI700 promastigotes,Confirmatory,17116678.0,
262,279547,8,1,,103167313,4735,Unspecified,,,2600.0,EC50,Antiproliferative activity against Leishmania donovani DI700 promastigotes overproducing ODC enzyme,Confirmatory,17116678.0,
263,279548,8,1,,103167313,4735,Unspecified,,,1700.0,EC50,Antiproliferative activity against Leishmania donovani DI700 promastigotes overproducing SPDSYN enzyme,Confirmatory,17116678.0,
264,279549,6,2,,103167313,4735,Unspecified,,,1700.0,EC50,Antiproliferative activity against Leishmania donovani DI700 promastigotes overproducing ADOMETDC enzyme,Confirmatory,17116678.0,
265,279550,6,2,,103167313,4735,Unspecified,,,1900.0,EC50,Antiproliferative activity against Leishmania donovani DI700 promastigotes in presence of 100 uM putrescine,Confirmatory,17116678.0,
266,279551,6,2,,103167313,4735,Unspecified,,,2000.0,EC50,Antiproliferative activity against Leishmania donovani DI700 promastigotes in presence of 100 uM spermidine,Confirmatory,17116678.0,
267,282105,6,2,,103167313,4735,Active,,,2.0,IC50,Antileishmanial activity against Leishmania donovani promastigotes after 72 hrs by Alamar blue assay,Confirmatory,15588096.0,
268,282993,8,1,,103167313,4735,Active,,,28.9,ED50,Antiparasitic activity against Leishmania donovani MHOM/ET/67/HU3 intracellular amastigotes,Confirmatory,16279799.0,
269,282994,10,1,,103167313,4735,Active,,,0.0001,ED50,Antiparasitic activity against Trypanosoma brucei rhodesiense STIB900 blood stream form,Confirmatory,16279799.0,
270,282995,8,1,,103167313,4735,Active,,,4.2,ED50,Antiparasitic activity against Trypanosoma cruzi MHOM/CL/00/Tulahuan-LacZ intracellular amastigotes,Confirmatory,16279799.0,
271,284257,7,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani promastigotes after 48 hrs by Alamar blue assay,Other,17070063.0,
272,284259,7,2,,103167313,4735,Inconclusive,,,,,Cytotoxicity against Vero cells by neutral red assay,Other,17070063.0,
273,284261,7,2,,103167313,4735,Inconclusive,,,,,Cytotoxicity against LLC-PK1 cells by neutral red assay,Other,17070063.0,
274,284263,7,2,,103167313,4735,Inconclusive,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus,Other,17070063.0,
275,284265,7,2,,103167313,4735,Inconclusive,,,,,Antifungal activity against Candida albicans,Other,17070063.0,
276,284267,7,2,,103167313,4735,Inconclusive,,,,,Antifungal activity against Cryptococcus neoformans,Other,17070063.0,
277,284269,7,2,,103167313,4735,Inconclusive,,,,,Antimalarial activity against Plasmodium falciparum D6,Other,17070063.0,
278,284270,7,2,,103167313,4735,Inconclusive,,,,,Antimalarial activity against Plasmodium falciparum W2,Other,17070063.0,
279,284273,3,4,,103167313,4735,Inactive,,,,,Antimicrobial activity against Mycobacterium intracellular,Other,17070063.0,
280,284274,3,3,,103167313,4735,Inactive,,,,,Antifungal activity against Aspergillus fumigatus,Other,17070063.0,
281,284383,6,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani promastigotes by Alamar blue assay,Other,17084633.0,
282,284882,7,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani promastigotes,Other,17134906.0,
283,284887,7,2,,103167313,4735,Inconclusive,,,,,Cytotoxicity against Vero cells,Other,17134906.0,
284,290093,4,3,,103167313,4735,Active,,,0.0028,IC50,Antiparasitic activity against Trypanosoma brucei rhodesiense STIB900,Confirmatory,17178177.0,
285,290094,4,3,,103167313,4735,Active,,,0.0584,IC50,Antiparasitic activity against Plasmodium falciparum K1,Confirmatory,17178177.0,
286,290095,4,3,,103167313,4735,Active,,,0.0019,IC50,Antiparasitic activity against Leishmania donovani,Confirmatory,17178177.0,
287,290096,4,3,,103167313,4735,Active,,,0.00535,IC50,Antiparasitic activity against Trypanosoma cruzi Tulahuen LacZ C4,Confirmatory,17178177.0,
288,290097,4,4,,103167313,4735,Active,,,0.0466,IC50,Cytotoxicity against rat L6 cells by alamar blue assay,Confirmatory,17178177.0,
289,290098,3,3,,103167313,4735,Inactive,,,,,"Antitrypanosomal activity in Trypanosoma brucei rhodesiense STIB900 infected mouse at 20 mg/kg, ip administered for 4 days",Other,17178177.0,
290,290099,6,1,,103167313,4735,Unspecified,,,,,"Survival of Trypanosoma brucei rhodesiense STIB900 infected mouse at 20 mg/kg, ip administered for 4 days",Other,17178177.0,
291,294358,7,2,,103167313,4735,Unspecified,,,,,Antipromastigote activity against Leishmania donovani MHOM IN/Dd8 assessed as luciferase activity after 72 hrs,Other,17306422.0,
292,295175,8,1,,103167313,4735,Unspecified,,,64.18,ED50,Antileishmanial activity against Leishmania braziliensis MCAN/BR/98/R619 promastigotes,Confirmatory,17367894.0,
293,295176,8,1,,103167313,4735,Active,,,27.5,ED50,Antileishmanial activity against Leishmania chagasi MCAN/BR/97/P142 promastigotes,Confirmatory,17367894.0,
294,295177,8,1,,103167313,4735,Active,,,2.21,TD50,Cytotoxicity against BALB/c mouse peritoneal macrophages assessed as cell viability after 24 hrs by MTT assay,Confirmatory,17367894.0,
295,298764,6,2,,103167313,4735,Active,,,0.0046,IC50,Antiproliferative activity against Trypanosoma brucei,Confirmatory,17197182.0,
296,300657,6,2,,103167313,4735,Inconclusive,,,,IC50,Inhibition of Leishmania tarentolae tubulin assembly,Confirmatory,17618122.0,
297,300658,6,2,,103167313,4735,Inconclusive,,,,IC50,Inhibition of porcine tubulin assembly,Confirmatory,17618122.0,
298,300660,6,2,,103167313,4735,Active,,,2.3,IC50,Growth inhibition against Leishmania donovani,Confirmatory,17618122.0,
299,300661,6,2,,103167313,4735,Inconclusive,,,,IC50,Growth inhibition against Trypanosoma brucei brucei,Confirmatory,17618122.0,
300,300662,6,2,,103167313,4735,Inconclusive,,,,IC50,Toxicity against monkey Vero cells,Confirmatory,17618122.0,
301,303243,6,2,,103167313,4735,Active,,,46.6,IC50,Cytotoxicity against rat L6 cells,Confirmatory,17948982.0,
302,303244,6,2,,103167313,4735,Active,,,0.003,IC50,Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900,Confirmatory,17948982.0,
303,303245,6,2,,103167313,4735,Active,,,0.057999999999999996,IC50,Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1,Confirmatory,17948982.0,
304,303246,6,2,,103167313,4735,Active,,,1.83,IC50,Antitrypanosomal activity against Leishmania donovani (MHOM/SD/62/1S-CL2D) axenic amastigotes,Confirmatory,17948982.0,
305,303247,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio for IC50 of rat L6 cells to IC50 of Trypanosoma brucei rhodesiense STIB900",Other,17948982.0,
306,303248,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio for IC50 of rat L6 cells to IC50 of chloroquine-resistant Plasmodium falciparum K1",Other,17948982.0,
307,303249,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio for IC50 of rat L6 cells to IC50 of Leishmania donovani (MHOM/SD/62/1S-CL2D) axenic amastigotes",Other,17948982.0,
308,303250,3,3,,103167313,4735,Unspecified,,,,,Selectivity ratio for IC50 of chloroquine-resistant Plasmodium falciparum K1 over Trypanosoma brucei rhodesiense STIB900,Other,17948982.0,
309,307270,6,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani promastigotes after 72 hrs by Alamar blue assay,Other,17400457.0,
310,307459,6,2,,103167313,4735,Active,,,0.46,IC50,Antileishmanial activity against Leishmania amazonensis promastigote by MTT method,Confirmatory,17445951.0,
311,308327,3,4,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani assessed as inhibition of promastigotes at 10 ug/ml,Other,17548194.0,
312,308329,3,4,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani assessed as inhibition of promastigotes at 0.5 ug/ml,Other,17548194.0,
313,308330,3,4,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani assessed as inhibition of amastigotes at 50 ug/ml,Other,17548194.0,
314,311063,6,2,,103167313,4735,Active,,,0.278,IC50,Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 by LDH reporter assay,Confirmatory,17533134.0,
315,311526,8,1,,103167313,4735,Active,,,0.0025,IC50,Antitrypanosomal activity against Trypanosoma brucei brucei MITat 1.2 variant 221,Confirmatory,17880175.0,
316,311527,6,2,,103167313,4735,Active,,,1.3,IC50,Antileishmanial activity against Leishmania donovani axenic amastigotes,Confirmatory,17880175.0,
317,311528,5,3,,103167313,4735,Inconclusive,,,,,Antileishmanial activity against Leishmania donovani promastigotes at 100 uM,Other,17880175.0,
318,311529,5,3,,103167313,4735,Inconclusive,,,,,Antileishmanial activity against Leishmania donovani promastigotes at 10 uM,Other,17880175.0,
319,311530,5,3,,103167313,4735,Inconclusive,,,,,Antileishmanial activity against Leishmania donovani promastigotes at 1 uM,Other,17880175.0,
320,311531,4,4,,103167313,4735,Inconclusive,,,,,Antileishmanial activity against Leishmania donovani promastigotes in RAW cells assessed as reduction in infection,Other,17880175.0,
321,311532,6,2,,103167313,4735,Active,,,13.7,IC50,Cytotoxicity against african green monkey Vero cells,Confirmatory,17880175.0,
322,313536,6,2,,103167313,4735,Active,,,29.4,IC50,Antileishmanial activity against Leishmania amazonensis IFLA/BR/67 promastigotes at pH 8.0 after 72 hrs,Confirmatory,18024033.0,
323,313537,6,2,,103167313,4735,Active,,,29.4,IC50,Antileishmanial activity against Leishmania braziliensis MHOM/BR/75/M2903 promastigotes after 72 hrs,Confirmatory,18024033.0,
324,313538,6,2,,103167313,4735,Active,,,29.4,IC50,Antileishmanial activity against Leishmania donovani MHOM/BR/74/PP75 promastigotes after 72 hrs,Confirmatory,18024033.0,
325,315116,10,2,,103167313,4735,Unspecified,68566154.0,11156.0,53.6,IC50,Inhibition of human PRL3 expressed in Escherichia coli BL21 (DE3),Confirmatory,18358718.0,
326,316609,3,4,,103167313,4735,Unspecified,,,,,Binding affinity for DNA assessed as thermal melting temperature,Other,18247550.0,
327,322584,6,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani promastigotes after 48 hrs by Alamar blue assay,Other,17976995.0,
328,325355,6,2,,103167313,4735,Active,,,1.1,IC50,Growth inhibition of Trypanosoma cruzi epimastigotes after 72 hrs by Alamar blue assay,Confirmatory,17339374.0,
329,325356,6,2,,103167313,4735,Active,,,1.2,IC50,Growth inhibition of Trypanosoma brucei rhodesiense trypomastigotes after 72 hrs by Alamar blue assay,Confirmatory,17339374.0,
330,325357,6,2,,103167313,4735,Active,,,1.0,IC50,Growth inhibition of Leishmania donovani promastigotes after 72 hrs by Alamar blue assay,Confirmatory,17339374.0,
331,325970,6,2,,103167313,4735,Active,,,0.006,EC50,Antiprotozoal activity against Trypanosoma brucei by Alamar blue assay,Confirmatory,18313921.0,
332,327487,7,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania chagasi promastigotes infected in hamster after 48 hrs by MTT assay,Other,18177008.0,
333,327488,7,2,,103167313,4735,Inconclusive,,,,,Antileishmanial activity against Leishmania chagasi intracellular amastigotes infected in hamster macrophages after 48 hrs by MTT assay,Other,18177008.0,
334,327489,4,4,,103167313,4735,Inconclusive,,,,,Toxicity in BALB/c mouse erythrocytes assessed as hemolysis at 6.25 ug/ml after 2 hrs,Other,18177008.0,
335,327490,6,2,,103167313,4735,Unspecified,,,,,Cytotoxicity against human macrophages after 48 hrs by MTT assay,Other,18177008.0,
336,328789,6,2,,103167313,4735,Active,,,0.5,IC50,Antileishmanial activity against Pneumocystis carinii,Confirmatory,18367395.0,
337,328790,6,2,,103167313,4735,Active,,,0.05,IC50,Antileishmanial activity against Trypanosoma brucei rhodesiense STIB 900 after 3 days,Confirmatory,18367395.0,
338,328791,6,2,,103167313,4735,Active,,,2.2,IC50,Antileishmanial activity against Leishmania donovani by Alamar blue assay,Confirmatory,18367395.0,
339,328792,6,2,,103167313,4735,Unspecified,,,100.0,IC50,Cytotoxicity against african green monkey Vero cells by neutral red assay,Confirmatory,18367395.0,
340,331191,6,2,,103167313,4735,Active,,,3.815,IC50,Antiprotozoal activity against Trichomonas vaginalis,Confirmatory,18486471.0,
341,331192,6,2,,103167313,4735,Active,,,4.079,IC50,Antiprotozoal activity against Giardia lamblia,Confirmatory,18486471.0,
342,331193,6,2,,103167313,4735,Active,,,11.800999999999998,IC50,Antiprotozoal activity against Entamoeba histolytica,Confirmatory,18486471.0,
343,331194,6,2,,103167313,4735,Active,,,9.568,IC50,Antiprotozoal activity against Leishmania mexicana,Confirmatory,18486471.0,
344,331197,3,3,,103167313,4735,Active,,,,,Antiprotozoal activity as cell damage against Plasmodium berghei,Other,18486471.0,
345,333069,7,2,,103167313,4735,Inconclusive,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv,Other,15332848.0,
346,333070,8,2,,103167313,4735,Inconclusive,,,,,Antimalarial activity against Plasmodium falciparum D6,Other,15332848.0,
347,333071,8,2,,103167313,4735,Inconclusive,,,,,Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2,Other,15332848.0,
348,333072,7,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani,Other,15332848.0,
349,333073,6,1,,103167313,4735,Inconclusive,,,,,Cytotoxicity against african green monkey Vero cells,Other,15332848.0,
350,335402,6,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania braziliensis 2903,Other,,
351,336394,3,4,,103167313,4735,Active,,,,,Antiprotozoal activity against promastigotes form of Leishmania donovani pp-75 assessed as total lysis of parasites at 100 ug/ml after 24 hrs,Other,7964785.0,
352,336443,9,1,,103167313,4735,Inconclusive,,,,IC50,Antiprotozoal activity against Plasmodium falciparum K1,Confirmatory,12398543.0,
353,336444,10,1,,103167313,4735,Unspecified,,,,IC50,Antitrypanosomal activity against Trypanosoma brucei brucei S427 blood stream trypomastigotes,Confirmatory,12398543.0,
354,336445,10,1,,103167313,4735,Unspecified,,,,IC50,Cytotoxicity against human KB cells,Confirmatory,12398543.0,
355,336446,9,1,,103167313,4735,Unspecified,,,,IC50,Antileishmanial activity against Leishmania donovani (MHOM/ET/67/L82) promastigotes,Confirmatory,12398543.0,
356,336636,3,4,,103167313,4735,Active,,,,,Antiprotozoal activity against promastigotes form of Leishmania braziliensis 2903 assessed as total lysis of parasites at 100 ug/ml after 24 hrs,Other,7964785.0,
357,336637,3,4,,103167313,4735,Active,,,,,Antiprotozoal activity against promastigotes form of Leishmania amazonensis H-142 assessed as total lysis of parasites at 100 ug/ml after 24 hrs,Other,7964785.0,
358,336639,3,4,,103167313,4735,Active,,,,,Antiprotozoal activity against promastigotes form of Leishmania amazonensis LV79 assessed as total lysis of parasites at 100 ug/ml after 24 hrs,Other,7964785.0,
359,336751,6,2,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma brucei brucei Lab110 EATRO after 48 hrs,Other,12662093.0,
360,336752,6,2,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma brucei rhodesiense KETRI 243 isolate after 48 hrs,Other,12662093.0,
361,336753,6,2,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma brucei rhodesiense KETRI 243 As 10-3 isolate after 48 hrs,Other,12662093.0,
362,337115,4,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania (Viannia) braziliensis 2904 after 48 hrs,Other,1919589.0,
363,337116,4,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania (Viannia) guyanensis M4147 after 48 hrs,Other,1919589.0,
364,337117,4,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania (Viannia) peruviana PERU after 48 hrs,Other,1919589.0,
365,337118,4,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania mexicana mexicana BEL21 after 48 hrs,Other,1919589.0,
366,337119,4,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania mexicana amazonensis PH8 after 48 hrs,Other,1919589.0,
367,337120,4,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania pifanoi LL1 after 48 hrs,Other,1919589.0,
368,337121,4,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania mexicana arislidesi 6331 after 48 hrs,Other,1919589.0,
369,337122,4,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania mexicana garnhami JAP78 after 48 hrs,Other,1919589.0,
370,337123,4,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania mexicana venezuelensis PM H3 after 48 hrs,Other,1919589.0,
371,337124,4,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani donovani HS 70 after 48 hrs,Other,1919589.0,
372,337126,4,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani chagasi LEM 379 after 48 hrs,Other,1919589.0,
373,337127,4,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani infantum LEM 209 after 48 hrs,Other,1919589.0,
374,339570,6,2,,103167313,4735,Active,,,1.06,IC50,Antileishmanial activity against Leishmania donovani promastigotes after 48 hrs by alamar blue assay,Confirmatory,18571927.0,
375,340591,8,2,,103167313,4735,Inconclusive,,,,,Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 as LDH activity,Other,18598080.0,
376,340592,8,2,,103167313,4735,Inconclusive,,,,,Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 by LDH activity,Other,18598080.0,
377,340593,6,1,,103167313,4735,Inconclusive,,,,,Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay,Other,18598080.0,
378,340595,7,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani promastigotes after 72 hrs by almar blue assay,Other,18598080.0,
379,340719,9,1,,103167313,4735,Unspecified,,,,IC50,Antileishmanial activity against wild-type Leishmania major LV39 promastigotes infected in human THP1 cells by luciferase based assay,Confirmatory,17452480.0,
380,340720,9,1,,103167313,4735,Unspecified,,,,IC50,Antileishmanial activity against wild-type Leishmania amazonensis MHOM/BR/1973/MM2269 promastigotes infected in human THP1 cells by luciferase based assay,Confirmatory,17452480.0,
381,340721,9,1,,103167313,4735,Unspecified,,,,IC50,Antileishmanial activity against wild-type Leishmania infantum MHOM/MA/67/ITMAP-263 promastigotes infected in human THP1 cells by luciferase based assay,Confirmatory,17452480.0,
382,340722,3,4,,103167313,4735,Unspecified,,,,,Antileishmanial activity against ABC transporter PRP1 gene expressing Leishmania major LV39 promastigotes infected in human THP1 cells assessed as fold resistance by luciferase based assay relative to control,Other,17452480.0,
383,340723,3,4,,103167313,4735,Unspecified,,,,,Antileishmanial activity against ABC transporter PRP1 gene expressing Leishmania amazonensis MHOM/BR/1973/MM2269 promastigotes infected in human THP1 cells assessed as fold resistance by luciferase based assay relative to control,Other,17452480.0,
384,340724,3,4,,103167313,4735,Unspecified,,,,,Antileishmanial activity against ABC transporter PRP1 gene expressing Leishmania infantum MHOM/MA/67/ITMAP-263 promastigotes infected in human THP1 cells assessed as fold resistance by luciferase based assay relative to control,Other,17452480.0,
385,343392,3,4,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania amazonensis MHOM/BR/76/LTB-012 promastigotes at 100 uM after 72 hrs by alamar blue assay,Other,18558492.0,
386,343396,6,2,,103167313,4735,Active,,,0.29,IC50,Antileishmanial activity against Leishmania amazonensis MHOM/BR/76/LTB-012 promastigotes after 72 hrs by alamar blue assay,Confirmatory,18558492.0,
387,346042,6,2,,103167313,4735,Active,,,2.2,IC50,Antileishmanial activity against Leishmania donovani MHOM/SD/62/1S-CL2D axenic amastigotes after 3 days by tetrazolium dye based colorimetric assay,Confirmatory,19058972.0,
388,346549,6,2,,103167313,4735,Active,,,3.5,IC50,Antileishmanial activity against Leishmania donovani promastigotes after 48 hrs by alamar-blue assay,Confirmatory,19084416.0,
389,352185,6,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani MHOM/IN/Dd8 promastigotes assessed as luciferase activity after 72 hrs,Other,19328690.0,
390,352186,7,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani MHOM/IN/Dd8 amastigotes infected in mouse J774A1 cells assessed as luciferase activity after 48 hrs,Other,19328690.0,
391,352187,9,1,,103167313,4735,Unspecified,,,,,Cytotoxicity against mouse J774A1 cells,Other,19328690.0,
392,352188,3,3,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for mouse J774A1 cells to IC50 for Leishmania donovani MHOM/IN/Dd8 amastigotes",Other,19328690.0,
393,354552,3,3,,103167313,4735,Active,,,,,Antiparasitic activity against Leishmania braziliensis assessed as lysis of parasite at 5 ug/mL,Other,8759169.0,
394,354553,3,3,,103167313,4735,Active,,,,,Antiparasitic activity against Leishmania donovani assessed as lysis of parasite at 5 ug/mL,Other,8759169.0,
395,354554,3,3,,103167313,4735,Active,,,,,Antiparasitic activity against Leishmania amazonensis assessed as lysis of parasite at 5 ug/mL,Other,8759169.0,
396,355951,7,2,,103167313,4735,Inconclusive,,,,,Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2,Other,12828466.0,
397,355962,7,2,,103167313,4735,Inconclusive,,,,,Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6,Other,12828466.0,
398,355964,7,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani promastigotes after 72 hrs,Other,12828466.0,
399,355965,3,4,,103167313,4735,Inconclusive,,,,,Cytotoxicity against african green monkey Vero cells at 4.7 ug/mL,Other,12828466.0,
400,355988,7,2,,103167313,4735,Inconclusive,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv,Other,12828469.0,
401,355989,8,2,,103167313,4735,Inconclusive,,,,,Antimalarial activity against Plasmodium falciparum D6,Other,12828469.0,
402,355990,8,2,,103167313,4735,Inconclusive,,,,,Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2,Other,12828469.0,
403,355991,7,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani promastigotes expressing luciferase,Other,12828469.0,
404,355992,8,1,,103167313,4735,Inconclusive,,,,,Cytotoxicity against african green monkey Vero cells,Other,12828469.0,
405,356092,7,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani promastigotes after 72 hrs,Other,12880315.0,
406,356093,8,2,,103167313,4735,Inconclusive,,,,,Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 by LDH reporter assay,Other,12880315.0,
407,356095,8,2,,103167313,4735,Inconclusive,,,,,Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 by LDH reporter assay,Other,12880315.0,
408,356097,7,2,,103167313,4735,Inconclusive,,,,,Cytotoxicity against african green monkey Vero cells,Other,12880315.0,
409,360902,4,3,,103167313,4735,Active,,,,,Antiparasitic activity against Leishmania amazonensis IFLA/BR/67/PH8 at 10 ug/mL after 72 hrs,Other,11421731.0,
410,360903,4,3,,103167313,4735,Active,,,,,Antiparasitic activity against Leishmania braziliensis MHOM/BR/75/M2903 at 10 ug/mL after 72 hrs,Other,11421731.0,
411,360904,4,3,,103167313,4735,Active,,,,,Antiparasitic activity against Leishmania donovani MHOM/IN/83/HS70 at 10 ug/mL after 72 hrs,Other,11421731.0,
412,360905,4,3,,103167313,4735,Active,,,,,Antiparasitic activity against Trypanosoma cruzi Tulahuen epimastigotes at 10 ug/mL after 48 hrs,Other,11421731.0,
413,362529,6,2,,103167313,4735,Active,,,7.5,IC50,Antileishmanial activity against Leishmania major,Confirmatory,18681480.0,
414,362658,6,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania amazonensis PH8 promastigotes,Other,18712933.0,
415,362659,6,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania braziliensis 2903 promastigotes,Other,18712933.0,
416,362660,6,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani PP75 promastigotes,Other,18712933.0,
417,362759,6,2,,103167313,4735,Active,,,4.32,IC50,Antileishmanial activity against Leishmania major DESTO promastigotes after 72 hrs,Confirmatory,18771242.0,
418,372438,6,2,,103167313,4735,Active,,,0.0024,IC50,Antitrypanosomal activity against wild type Trypanosoma cruzi BS221 infected in mouse macrophage by reporter dye assay,Confirmatory,17698622.0,
419,372439,6,2,,103167313,4735,Active,,,0.006,IC50,Antitrypanosomal activity against tbat1 knockout Trypanosoma cruzi BS221 infected in mouse macrophage by reporter dye assay,Confirmatory,17698622.0,
420,372440,3,3,,103167313,4735,Unspecified,,,,,"Resistance factor, ratio of IC50 for tbat1 knock out Trypanosoma cruzi BS221 to IC50 for wild type Trypanosoma cruzi BS221",Other,17698622.0,
421,372446,6,2,,103167313,4735,Active,,,3.52,IC50,Biphasic antileishmanial activity against Leishmania major promastigotes by alamar blue fluorescent dye assay,Confirmatory,17698622.0,
422,373137,3,4,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania amazonensis MHOM/BR/PH8 promastigote assessed as lysis at 100 ug/mL after 72 hrs,Other,18706738.0,
423,373138,3,4,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania infantum MHOM/FR/91/LEM2259 promastigote assessed as lysis at 100 ug/mL after 72 hrs,Other,18706738.0,
424,373139,3,4,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania braziliensis MHOM/BR/75/M2903 promastigote assessed as lysis at 100 ug/mL after 72 hrs,Other,18706738.0,
425,376610,6,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani promastigotes after 48 hrs by alamar blue assay,Other,16643056.0,
426,376627,6,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania major MRHO/IR/75/ER promastigotes after 72 hrs by alamar blue assay,Other,16643059.0,
427,377050,7,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani MHOM/SD/62/1S-CL2D axenic amastigotes after 3 days by tetrazolium dye method,Other,15679330.0,
428,377051,6,2,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against blood stream-form of Trypanosoma brucei brucei MITat1.2 after 72 hrs by MTT assay,Other,15679330.0,
429,377052,7,2,,103167313,4735,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells after 72 hrs by cell-titer assay,Other,15679330.0,
430,377053,7,2,,103167313,4735,Unspecified,,,,,Cytotoxicity against mouse J774A1 cells after 72 hrs by cell-titer assay,Other,15679330.0,
431,377692,7,2,,103167313,4735,Inconclusive,,,,,Antituberculosis activity against Mycobacterium tuberculosis H37Rv after 24 hrs by alamar blue assay,Other,16872140.0,
432,377694,8,2,,103167313,4735,Inconclusive,,,,,Antimalarial activity after 72 hrs against chloroquine-sensitive Plasmodium falciparum D6 in erythrocytes by LDH reporter assay,Other,16872140.0,
433,377696,8,2,,103167313,4735,Inconclusive,,,,,Antimalarial activity after 72 hrs against chloroquine-resistant Plasmodium falciparum W2 in erythrocytes by LDH reporter assay,Other,16872140.0,
434,377698,7,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani after 72 hrs by alamar blue assay,Other,16872140.0,
435,377700,7,2,,103167313,4735,Inconclusive,,,,,Cytotoxicity against african green monkey Vero cells by neutral red assay,Other,16872140.0,
436,378965,6,2,,103167313,4735,Active,,,1.5,IC50,Antileishmanial activity against Leishmania donovani MHOM/SD/62/IS-CL2D axenic amastigotes after 3 days,Confirmatory,16441066.0,
437,378966,6,2,,103167313,4735,Inconclusive,,,,IC50,Antitrypanosomal activity against Trypanosoma brucei brucei MITat 1.2 variant 221 after 72 hrs,Confirmatory,16441066.0,
438,378967,8,1,,103167313,4735,Inconclusive,,,,IC50,Cytotoxicity against african green monkey Vero cells,Confirmatory,16441066.0,
439,378968,8,1,,103167313,4735,Inconclusive,,,,IC50,Cytotoxicity against human PC3 cells,Confirmatory,16441066.0,
440,380082,6,2,,103167313,4735,Active,,,2.9,IC50,Antileishmanial activity against Leishmania braziliensis MHOM/BR/95/IOCL-2033 promastigotes after 24 hrs,Confirmatory,16499336.0,
441,380083,6,2,,103167313,4735,Active,,,0.9,IC50,Antileishmanial activity against Leishmania guyanensis MHOM/BR/95/IOCL-2092 promastigotes after 24 hrs,Confirmatory,16499336.0,
442,382515,3,3,,103167313,4735,Unspecified,,,,,"Antimicrobial activity against Pneumocystis carinii in immunosuppressed rat assessed as number of cysts/g of lung at 22.0 umol/kg/day, iv relative to control",Other,17499888.0,
443,382516,3,3,,103167313,4735,Unspecified,,,,,"Antimicrobial activity against Pneumocystis carinii in immunosuppressed rat assessed as number of cysts/g of lung at 33.0 umol/kg/day, po relative to control",Other,17499888.0,
444,382522,3,3,,103167313,4735,Unspecified,,,,,"Toxicity against immunosuppressed rat pneumocystis model at 33.0 umol/kg/day, po",Other,17499888.0,
445,389449,6,2,,103167313,4735,Active,,,46.6,IC50,Cytotoxicity against rat L6 cells,Confirmatory,18841956.0,
446,389450,6,2,,103167313,4735,Active,,,0.003,IC50,Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 bloodstream trypomastigotes,Confirmatory,18841956.0,
447,389451,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB 900",Other,18841956.0,
448,389452,6,2,,103167313,4735,Active,,,0.057999999999999996,IC50,Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1,Confirmatory,18841956.0,
449,389453,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for chloroquine-resistant Plasmodium falciparum K1",Other,18841956.0,
450,389454,6,2,,103167313,4735,Active,,,1.8,IC50,Antileishmanial activity against Leishmania donovani MHOM/SD/62/1S-CL2D axenic amastigotes,Confirmatory,18841956.0,
451,389455,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Leishmania donovani MHOM/SD/62/1S-CL2D",Other,18841956.0,
452,389465,6,1,,103167313,4735,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 infected acute mouse model assessed as survival time at 20 mg/kg, ip administered daily for 4 days",Other,18841956.0,
453,389466,6,1,,103167313,4735,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 infected acute mouse model assessed as survival time at 5 mg/kg, ip administered daily for 4 days",Other,18841956.0,
454,392493,3,3,,103167313,4735,Unspecified,,,,,"Antileishmanial activity against Leishmania donovani infected in hamster assessed as inhibition of parasite growth at 40 mg/kg, ip for 10 days",Other,19091566.0,
455,392495,3,3,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for mouse J774A1 cells to IC50 for Leishmania donovani intracellular amastigotes infected in mouse J774A1 cells",Other,19091566.0,
456,392496,6,2,,103167313,4735,Unspecified,,,,,Cytotoxicity against mouse J774A1 cells after 48 hrs by Geimsa staining method,Other,19091566.0,
457,392497,6,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani intracellular amastigotes infected in mouse J774A1 cells after 48 hrs by luciferase activity-based drug susceptibility assay,Other,19091566.0,
458,392498,6,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani extracellular promastigotes after 72 hrs by luciferase activity-based drug susceptibility assay,Other,19091566.0,
459,392499,3,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani intracellular amastigotes infected in mouse J774A1 cells at 10 ug/ml after 48 hrs by luciferase activity-based drug susceptibility assay,Other,19091566.0,
460,392500,3,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani extracellular promastigotes at 10 ug/ml after 72 hrs by luciferase activity-based drug susceptibility assay,Other,19091566.0,
461,396584,6,2,,103167313,4735,Active,,,9.8,IC50,Leishmanicidal activity against Leishmania donovani MHOM/BR/74/PP75 promastigotes after 72 hrs,Confirmatory,18192088.0,
462,396585,6,2,,103167313,4735,Active,,,9.8,IC50,Leishmanicidal activity against Leishmania braziliensis MHOM/BR/75/M2903 promastigotes after 72 hrs,Confirmatory,18192088.0,
463,396586,6,2,,103167313,4735,Active,,,9.8,IC50,Leishmanicidal activity against Leishmania amazonensis IFLA/BR/67/PH8 promastigotes after 72 hrs,Confirmatory,18192088.0,
464,396588,6,2,,103167313,4735,Active,,,0.9,IC50,Antileishmanial activity against Leishmania amazonensis PH8 amastigotes infected in mouse peritoneal macrophages after 48 hrs,Confirmatory,18192088.0,
465,401562,7,2,,103167313,4735,Inconclusive,,,,,Cytotoxicity against african green monkey kidney Vero cells,Other,15165136.0,
466,401570,8,2,,103167313,4735,Inconclusive,,,,,Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 by LDH assay,Other,15165136.0,
467,401571,8,2,,103167313,4735,Inconclusive,,,,,Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 by LDH assay,Other,15165136.0,
468,401574,7,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani promastigotes after 48 hrs by alamar blue assay,Other,15165136.0,
469,403116,3,3,,103167313,4735,Unspecified,,,,,Trypanocidal activity against Trypanosoma cruzi Tulahuen epimastigotes at 10 ug/ml after 48 hrs relative to control,Other,9834160.0,
470,403120,3,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania braziliensis MHOM/BR/75/M2903 promastigotes at 10 ug/ml after 72 hrs relative to control,Other,9834160.0,
471,403124,3,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani chagasi PP75 at 10 ug/ml,Other,9834160.0,
472,403128,3,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania amazonensis MHOM/GF/84/CAY H-142 amastigotes infected in BALB/c mouse peritoneal macrophages at 10 ug/ml after 24 hrs relative to control,Other,9834160.0,
473,409956,4,9,,103167313,4735,Inactive,341940629.0,109731.0,,,Inhibition of mouse brain MAOB,Other,18834112.0,
474,412484,6,2,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma brucei brucei GUTat3.1 after 72 hrs by alamar blue assay,Other,19013823.0,
475,412485,6,2,,103167313,4735,Unspecified,,,,,Cytotoxicity against human MRC5 cells after 7 days by MTT assay,Other,19013823.0,
476,412664,3,4,,103167313,4735,Unspecified,,,,,Selectivity index ratio IC50 for human MRC5 cells to IC50 for Trypanosoma brucei brucei GUTat3.1,Other,19013823.0,
477,416090,6,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani MHOM/IN/1983/AG83 promastigotes after 4 hrs by MTT assay,Other,18538452.0,
478,416091,6,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani MHOM/IN/1983/AG83 amastigotes by Giemsa staining,Other,18538452.0,
479,416092,5,1,,103167313,4735,Unspecified,,,,,Toxicity against golden Syrian hamster peritoneal macrophages,Other,18538452.0,
480,419752,6,2,,103167313,4735,Active,,,46.6,IC50,Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay,Confirmatory,19606902.0,
481,419753,6,2,,103167313,4735,Active,,,0.003,IC50,Antitrypanosomal activity against bloodstream Trypanosoma brucei rhodesiense STIB900 after 70 hrs by alamar blue assay,Confirmatory,19606902.0,
482,419754,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for bloodstream Trypanosoma brucei rhodesiense STIB900",Other,19606902.0,
483,419755,6,2,,103167313,4735,Active,,,0.057999999999999996,IC50,Antiplasmodial activity after 48 hrs against chloroquine-resistant Plasmodium falciparum K1 infected human erythrocytes by [3H]hypoxanthine uptake,Confirmatory,19606902.0,
484,419756,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for chloroquine-resistant Plasmodium falciparum K1",Other,19606902.0,
485,419757,6,2,,103167313,4735,Active,,,1.8,IC50,Antileishmanial activity against axenic amastigotes of Leishmania donovani MHOM/SD/62/1S-CL2D after 72 hrs,Confirmatory,19606902.0,
486,419758,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for axenic amastigotes of Leishmania donovani MHOM/SD/62/1S-CL2D",Other,19606902.0,
487,419765,7,1,,103167313,4735,Unspecified,,,,,"Antitrypanosomal activity against bloodstream Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as survival rate at 20 mg/kg, ip administered 4 consecutive days from day 3 to 6 postinfection",Other,19606902.0,
488,419766,7,1,,103167313,4735,Unspecified,,,,,"Antitrypanosomal activity against bloodstream Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as survival rate at 5 mg/kg, ip administered 4 consecutive days from day 3 to 6 postinfection",Other,19606902.0,
489,420956,3,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 promastigotes at 0.5 ug/ml after 72 hrs,Other,19217698.0,
490,420958,7,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 amastigotes infected in mouse J774A.1 cells after 72 hrs,Other,19217698.0,
491,420959,7,2,,103167313,4735,Unspecified,,,,,Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay,Other,19217698.0,
492,420960,3,3,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for mouse J774A1 cells to IC50 for Leishmania donovani MHOM/IN/80/Dd8 amastigotes",Other,19217698.0,
493,420962,3,3,,103167313,4735,Unspecified,,,,,"Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 amastigotes infected in golden hamster at 20 mg/kg, ip administered 5 times per day for 5 days",Other,19217698.0,
494,422401,7,2,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma brucei rhodesiense trypomastigotes after 72 hrs,Other,19159277.0,
495,422744,8,2,,103167313,4735,Inconclusive,,,,,Antimalarial activity after 72 hrs against chloroquine-sensitive Plasmodium falciparum D6 by pLDH activity,Other,19105653.0,
496,422745,8,2,,103167313,4735,Inconclusive,,,,,Cytotoxicity against african green monkey Vero cells,Other,19105653.0,
497,422747,8,2,,103167313,4735,Inconclusive,,,,,Antimalarial activity after 72 hrs against chloroquine-sensitive Plasmodium falciparum W2 by pLDH activity,Other,19105653.0,
498,422763,7,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani promastigotes after 48 hrs by alamar blue assay,Other,19105653.0,
499,425019,6,2,,103167313,4735,Active,,,3.8,IC50,Antileishmanial activity against Leishmania donovani,Confirmatory,19344127.0,
500,431457,6,2,,103167313,4735,Active,,,46.6,IC50,Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay,Confirmatory,19757840.0,
501,431458,6,2,,103167313,4735,Active,,,0.003,IC50,Antitrypanosomal activity against blood stream form of Trypanosoma brucei rhodesiense STIB900 trypomastigotes after 70 hrs by alamar blue assay,Confirmatory,19757840.0,
502,431459,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for blood stream form of Trypanosoma brucei rhodesiense STIB900 trypomastigotes",Other,19757840.0,
503,431461,6,2,,103167313,4735,Active,,,0.057999999999999996,IC50,Antiplasmodial activity after 48 hrs against chloroquine-resistant Plasmodium falciparum K1 by [3H]hypoxanthine uptake,Confirmatory,19757840.0,
504,431462,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for chloroquine-resistant Plasmodium falciparum K1",Other,19757840.0,
505,431463,6,2,,103167313,4735,Active,,,1.8,IC50,Antileishmanial activity against Leishmania donovani MHOM/SD/62/1S-CL2D axenic amastigotes after 72 hrs by tetrazolium dye-based microplate reader method,Confirmatory,19757840.0,
506,431464,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Leishmania donovani MHOM/SD/62/1S-CL2D axenic amastigotes",Other,19757840.0,
507,432043,6,2,,103167313,4735,Active,,,0.0028,IC50,Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900,Confirmatory,19409677.0,
508,432044,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900",Other,19409677.0,
509,432045,6,2,,103167313,4735,Active,,,0.0464,IC50,Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1,Confirmatory,19409677.0,
510,432046,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for chloroquine-resistant Plasmodium falciparum K1",Other,19409677.0,
511,432047,6,2,,103167313,4735,Active,,,1.84,IC50,Antileishmanial activity against Leishmania donovani MHOM/SD/62/1S-CL2D amastigotes,Confirmatory,19409677.0,
512,432048,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Leishmania donovani MHOM/SD/62/1S-CL2D amastigotes",Other,19409677.0,
513,432049,6,2,,103167313,4735,Active,,,46.6,IC50,Cytotoxicity against rat L6 cells,Confirmatory,19409677.0,
514,432052,3,3,,103167313,4735,Inactive,,,,,"Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected NMRI mouse assessed as infection cure rate at 20 mg/kg, ip dosed for 4 days",Other,19409677.0,
515,432057,7,1,,103167313,4735,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected NMRI mouse assessed mean survival time at 20 mg/kg, ip dosed for 4 days",Other,19409677.0,
516,445250,5,2,,103167313,4735,Active,,,46.6,IC50,Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay,Confirmatory,19928900.0,
517,445251,5,2,,103167313,4735,Active,,,0.003,IC50,Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 after 70 hrs by alamar blue assay,Confirmatory,19928900.0,
518,445252,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900",Other,19928900.0,
519,445253,5,2,,103167313,4735,Active,,,0.057999999999999996,IC50,Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human erythrocytes after 48 hrs assessed as [3H]hypoxanthine incorporation by liquid scintillation counting,Confirmatory,19928900.0,
520,445254,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Plasmodium falciparum K1",Other,19928900.0,
521,445255,5,2,,103167313,4735,Active,,,1.8,IC50,Antileishmanial activity against Leishmania donovani MHOM/SD/62/1S-CL2D,Confirmatory,19928900.0,
522,445256,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Leishmania donovani MHOM/SD/62/1S-CL2D",Other,19928900.0,
523,445266,7,1,,103167313,4735,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as mean parasitemia relaps day at 20 mg/kg, ip",Other,19928900.0,
524,445267,7,1,,103167313,4735,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as mean parasitemia relaps day at 5 mg/kg, ip",Other,19928900.0,
525,446901,4,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani in luciferase-promastigote system at 10 ug/ml,Other,19692240.0,
526,446902,7,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani in luciferase-amastigote system,Other,19692240.0,
527,449703,5,2,,103167313,4735,Active,,,0.0662,EC50,NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay,Confirmatory,18579783.0,
528,449704,5,2,,103167313,4735,Active,,,0.0687,EC50,NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay,Confirmatory,18579783.0,
529,449705,5,2,,103167313,4735,Unspecified,,,6.25,CC50,NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7),Confirmatory,18579783.0,
530,449706,5,2,,103167313,4735,Unspecified,,,,,"NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.",Other,18579783.0,
531,453388,6,2,,103167313,4735,Active,,,2.8,IC50,Antileishmanial activity against Leishmania donovani promastigotes after 48 hrs by alamar blue assay,Confirmatory,19879765.0,
532,454672,3,3,,103167313,4735,Active,,,0.0022,IC50,Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900,Confirmatory,19699098.0,
533,454673,3,3,,103167313,4735,Active,,,0.0464,IC50,Antiplasmodial activity against Plasmodium falciparum K1,Confirmatory,19699098.0,
534,454674,3,3,,103167313,4735,Unspecified,,,,,Selectivity ratio of IC50 for Trypanosoma brucei rhodesiense STIB900 to IC50 for Plasmodium falciparum K1,Other,19699098.0,
535,454675,3,4,,103167313,4735,Active,,,2.1,IC50,Cytotoxicity against rat L6 cells,Confirmatory,19699098.0,
536,454678,6,1,,103167313,4735,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as survival days at 20 mg/kg, ip",Other,19699098.0,
537,454679,6,1,,103167313,4735,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as survival days at 5 mg/kg, ip",Other,19699098.0,
538,454680,3,3,,103167313,4735,Unspecified,,,,,Binding affinity to DNA assessed as change in melting temperature,Other,19699098.0,
539,455184,6,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani amastigotes,Other,19913413.0,
540,455185,6,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani promastigotes,Other,19913413.0,
541,455186,6,2,,103167313,4735,Unspecified,,,,,Cytotoxicity against mouse J774A1 cells by MTT assay,Other,19913413.0,
542,455187,3,3,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for mouse J774A1 cells to IC50 for Leishmania donovani amastigotes",Other,19913413.0,
543,455190,3,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani infected in hamster assessed inhibition of parasite growth at 40 mg/kg,Other,19913413.0,
544,456795,4,1,,103167313,4735,Inconclusive,2498443.0,3065.0,,IC50,Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay,Confirmatory,19914074.0,
545,456795,4,1,,103167313,4735,Inconclusive,3334210.0,8841.0,,IC50,Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay,Confirmatory,19914074.0,
546,456795,4,1,,103167313,4735,Inconclusive,19865267.0,9734.0,,IC50,Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay,Confirmatory,19914074.0,
547,456795,4,1,,103167313,4735,Inconclusive,26394832.0,79885.0,,IC50,Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay,Confirmatory,19914074.0,
548,456795,4,1,,103167313,4735,Inconclusive,27734403.0,83933.0,,IC50,Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay,Confirmatory,19914074.0,
549,456795,4,1,,103167313,4735,Inconclusive,29839394.0,55869.0,,IC50,Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay,Confirmatory,19914074.0,
550,456795,4,1,,103167313,4735,Inconclusive,30913097.0,51564.0,,IC50,Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay,Confirmatory,19914074.0,
551,456795,4,1,,103167313,4735,Inconclusive,68068066.0,3066.0,,IC50,Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay,Confirmatory,19914074.0,
552,456795,4,1,,103167313,4735,Inconclusive,205371758.0,10013.0,,IC50,Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay,Confirmatory,19914074.0,
553,456795,4,1,,103167313,4735,Inconclusive,259016348.0,9759.0,,IC50,Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay,Confirmatory,19914074.0,
554,456795,4,1,,103167313,4735,Inconclusive,296434519.0,10014.0,,IC50,Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay,Confirmatory,19914074.0,
555,456796,6,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani promastigotes after 72 hrs by alamar blue assay,Other,19914074.0,
556,456797,6,3,,103167313,4735,Inconclusive,,,,,Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method,Other,19914074.0,
557,456798,6,2,,103167313,4735,Inconclusive,,,,,Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method,Other,19914074.0,
558,456799,6,2,,103167313,4735,Inconclusive,,,,,Cytotoxicity against african green monkey Vero cells after 1 to 2 days by neutral red assay,Other,19914074.0,
559,456800,3,4,,103167313,4735,Inconclusive,,,,,"Selectivity index, ratio of IC50 for african green monkey (Cercopithecus aethiops) Vero cells to IC50 for chloroquine-sensitive Plasmodium falciparum D6",Other,19914074.0,
560,459128,5,2,,103167313,4735,Active,,,6.5,IC50,Antileishmanial activity against Leishmania donovani promastigotes,Confirmatory,20064723.0,
561,466919,5,2,,103167313,4735,Active,,,0.67,EC50,Antitrypanosomal activity against multidrug-resistant Trypanosoma brucei brucei B48 after 48 hrs by alamar blue assay,Confirmatory,20004045.0,
562,466920,5,2,,103167313,4735,Active,,,3.8,EC50,Antileishmanial activity against Leishmania major Friedlin promastigotes after 48 hrs by alamar blue assay,Confirmatory,20004045.0,
563,466921,5,2,,103167313,4735,Active,,,16.0,EC50,Antileishmanial activity against Leishmania mexicana MNYC/BZ/62/M379 amastigotes after 48 hrs by alamar blue assay,Confirmatory,20004045.0,
564,471976,5,2,,103167313,4735,Active,,,0.002,IC50,Antitrypanosomal activity against pentamidine-sensitive Trypanosoma brucei brucei LAB 110 EATRO,Confirmatory,19736009.0,
565,471977,5,2,,103167313,4735,Active,,,0.002,IC50,Antitrypanosomal activity against Multidrug-resistant Trypanosoma brucei rhodesiense KETRI 243,Confirmatory,19736009.0,
566,471978,5,2,,103167313,4735,Active,,,0.5,IC50,Antipneumocystis activity against Pneumocystis carinii,Confirmatory,19736009.0,
567,471979,5,2,,103167313,4735,Active,,,24.0,IC50,Cytotoxicity against human A549 cells,Confirmatory,19736009.0,
568,471980,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for human A549 cells to IC50 for Trypanosoma brucei",Other,19736009.0,
569,471981,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for human A549 cells to IC50 for Pneumocystis carinii",Other,19736009.0,
570,471984,3,4,,103167313,4735,Unspecified,,,,,Binding affinity to poly(dA-dT)DNA assessed as change in melting temperature,Other,19736009.0,
571,473009,5,2,,103167313,4735,Inconclusive,,,,Ki,Inhibition of Plasmodium falciparum recombinant falcipain-2 using Cbz-Leu-Arg-AMC as substrate by standard fluorescence assay,Confirmatory,20131843.0,
572,473010,5,2,,103167313,4735,Inconclusive,,,,Ki,Inhibition of Plasmodium falciparum recombinant falcipain-3 by standard fluorescence assay,Confirmatory,20131843.0,
573,473011,9,5,,103167313,4735,Inconclusive,74938196.0,,,Ki,Inhibition of Trypanosoma brucei rhodesiense recombinant rhodesain by standard fluorescence assay,Confirmatory,20131843.0,
574,473012,5,2,,103167313,4735,Inconclusive,,,,IC50,Antiplasmodial activity against Plasmodium falciparum W2 by flow cytometry,Confirmatory,20131843.0,
575,475975,5,2,,103167313,4735,Active,,,0.006999999999999999,IC50,Antitrypanosomal activity against Trypanosoma brucei brucei 427-221a after 40 hrs by bioluminescence assay,Confirmatory,20303767.0,
576,475976,5,2,,103167313,4735,Inconclusive,,,,IC50,Inhibition of Trypanosoma brucei brucei recombinant rhodesain after 5 mins by spectrofluorimetry,Confirmatory,20303767.0,
577,475977,5,2,,103167313,4735,Inconclusive,,,,IC50,Inhibition of Trypanosoma brucei brucei recombinant cathepsin B assessed after 5 mins by spectrofluorimetry,Confirmatory,20303767.0,
578,475980,5,2,,103167313,4735,Active,,,3.8,IC50,Cytotoxicity against rat L6 cells,Confirmatory,20303767.0,
579,475983,3,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei brucei",Other,20303767.0,
580,477769,5,2,,103167313,4735,Active,,,48.5,IC50,Antileishmanial activity against Leishmania (Viannia) braziliensis promastigotes,Confirmatory,20116908.0,
581,478754,3,4,,103167313,4735,Unspecified,,,,,Binding affinity to d(CGCGAATTCGCG)2 dodecamer assessed as change in melting temperature,Other,20153561.0,
582,478755,3,4,,103167313,4735,Unspecified,,,,,Binding affinity to d(CGCGATATCGCG)2 dodecamer assessed as change in melting temperature,Other,20153561.0,
583,481842,3,4,,103167313,4735,Unspecified,,,,,Binding affinity to poly(dA.dT) assessed as change in melting temperature by spectrophotometry,Other,20403703.0,
584,481843,3,3,,103167313,4735,Active,,,0.0028,IC50,Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900,Confirmatory,20403703.0,
585,481844,3,3,,103167313,4735,Active,,,0.0464,IC50,Antiplasmodial activity against Plasmodium falciparum K1,Confirmatory,20403703.0,
586,481845,5,2,,103167313,4735,Active,,,46.6,IC50,Cytotoxicity against rat L6 cells,Confirmatory,20403703.0,
587,481848,3,3,,103167313,4735,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 in infected mouse model assessed as host survival time at 5 mg/kg, ip for 4 days",Other,20403703.0,
588,482884,4,9,,103167313,4735,Inconclusive,74938196.0,,,,Inhibition of Trypanosoma brucei rhodesiense rhodesain after 12 hrs by fluorescence spectroscopy-based on-bead assay,Other,19715342.0,
589,482885,4,9,,103167313,4735,Inconclusive,74938196.0,,,,Inhibition of Trypanosoma brucei rhodesiense recombinant rhodesain at 100 uM,Other,19715342.0,
590,482886,8,5,,103167313,4735,Inconclusive,74938196.0,,,Ki,Inhibition of Trypanosoma brucei rhodesiense recombinant rhodesain,Confirmatory,19715342.0,
591,482887,5,2,,103167313,4735,Active,,,0.0029,IC50,Antitrypanosomal activity against Trypanosoma brucei brucei,Confirmatory,19715342.0,
592,482888,4,8,,103167313,4735,Inconclusive,68067549.0,1508.0,,,Inhibition of human liver cathepsin B at 100 uM,Other,19715342.0,
593,482889,8,5,,103167313,4735,Inconclusive,68067549.0,1508.0,,Ki,Inhibition of human liver cathepsin B,Confirmatory,19715342.0,
594,482893,3,10,,103167313,4735,Unspecified,74938196.0,,,,Inhibition of Trypanosoma brucei rhodesiense recombinant rhodesain at 200 uM,Other,19715342.0,
595,486918,6,2,,103167313,4735,Unspecified,,,,,Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay,Other,20199824.0,
596,486920,6,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani MHOM/IN/Dd8 promastigote carrying firefly luciferase gene assessed as relative luminescence unit after 72 hrs,Other,20199824.0,
597,486921,6,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani MHOM/IN/Dd8 amastigote carrying firefly luciferase gene infected in mouse J774A1 cells assessed as relative luminescence unit after 72 hrs,Other,20199824.0,
598,486922,3,3,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for mouse J774A1 cells to IC50 for Leishmania donovani MHOM/IN/Dd8 amastigote",Other,20199824.0,
599,486925,3,3,,103167313,4735,Unspecified,,,,,"Antileishmanial activity against Leishmania donovani MHOM/IN/Dd8 amastigote infected in hamster assessed as inhibition of amastigote multiplication at 40 mg/kg, ip for 5 days",Other,20199824.0,
600,487937,5,2,,103167313,4735,Unspecified,,,52.82,CC50,Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay,Confirmatory,20371140.0,
601,487938,6,2,,103167313,4735,Active,,,20.43,IC50,Antileishmanial activity against Leishmania donovani (MHOM/IN/Dd8) amastigote infected in mouse J774 cells assessed as after 72 hrs by luminometry,Confirmatory,20371140.0,
602,487939,3,3,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for mouse J774A1 cells to IC50 for IC50 Leishmania donovani MHOM/IN/Dd8",Other,20371140.0,
603,487940,3,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani MHOM/IN/Dd8 promastigote carrying firefly luciferase gene infected in mouse J774A1 cells assessed as relative luminescence unit at 0.5 ug/mL after 72 hrs,Other,20371140.0,
604,489459,5,2,,103167313,4735,Active,,,0.006999999999999999,IC50,Antitrypanosomal activity against Trypanosoma brucei brucei,Confirmatory,20558060.0,
605,489466,3,5,,103167313,4735,Unspecified,,,,,Cytotoxicity against HEK239 cells at 70 uM after 72 hrs by Alamar blue assay,Other,20558060.0,
606,490816,5,2,,103167313,4735,Inconclusive,,,,IC50,Antiprotozoal activity against Giardia intestinalis IMSS:0989:1 after 48 hrs,Confirmatory,20430484.0,
607,490817,5,2,,103167313,4735,Inconclusive,,,,IC50,Antiprotozoal activity against Entamoeba histolytica HM-1:IMSS after 48 hrs,Confirmatory,20430484.0,
608,490818,5,2,,103167313,4735,Inconclusive,,,,IC50,Antiprotozoal activity against Trichomonas vaginalis G3 after 48 hrs,Confirmatory,20430484.0,
609,490819,5,2,,103167313,4735,Active,,,2.421,IC50,Antileishmanial activity against Leishmania mexicana MHOM/MX92/UAY68 after 48 hrs,Confirmatory,20430484.0,
610,490820,3,3,,103167313,4735,Inconclusive,,,,,Antitrichinellosis activity against Trichinella spiralis ML assessed as reduction of parasites viability at 0.18 uM after 3 days by MTT assay,Other,20430484.0,
611,490821,3,3,,103167313,4735,Inconclusive,,,,,Antitrichinellosis activity against Trichinella spiralis ML assessed as reduction of parasites viability at 0 37 uM after 3 days by MTT assay,Other,20430484.0,
612,490822,3,3,,103167313,4735,Inconclusive,,,,,Antitrichinellosis activity against Trichinella spiralis ML assessed as reduction of parasites viability at 1.8 uM after 3 days by MTT assay,Other,20430484.0,
613,492162,5,2,,103167313,4735,Active,,,0.084,IC50,Antifungal activity against Pneumocystis carinii after 4 days by RAL-555 staining based microscopy,Confirmatory,20590148.0,
614,492163,7,1,,103167313,4735,Inconclusive,,,,IC50,Cytotoxicity against imatinib-resistant human K562 cells after 72 hrs by MTT assay,Confirmatory,20590148.0,
615,492164,7,1,,103167313,4735,Inconclusive,,,,IC50,Cytotoxicity against imatinib and dasatinib-resistant mouse DA1-3b/M2 cells after 72 hrs by MTT assay,Confirmatory,20590148.0,
616,492165,5,3,,103167313,4735,Inconclusive,,,,IC50,Cytotoxicity against hematopoietic mouse EML-C1 cells after 72 hrs by MTT assay,Confirmatory,20590148.0,
617,492166,5,3,,103167313,4735,Inconclusive,,,,IC50,Cytotoxicity against human bone marrow cells after 72 hrs by MTT assay,Confirmatory,20590148.0,
618,494328,2,3,,103167313,4735,Unspecified,,,,,Antileishmanial activity against promastigotes of Leishmania donovani MHOM/IN/80/Dd8 after 72 hrs by luciferase reporter gene assay relative to control,Other,20457476.0,
619,494329,5,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against amastigote of Leishmania donovani MHOM/IN/80/Dd8 infected in mouse J774A1 cells after 72 hrs by luciferase reporter gene assay,Other,20457476.0,
620,494330,5,2,,103167313,4735,Unspecified,,,,,Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay,Other,20457476.0,
621,494331,2,3,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for mouse J774A1 cells to IC50 for amastigote of Leishmania donovani MHOM/IN/80/Dd8",Other,20457476.0,
622,496818,4,2,,103167313,4735,Unspecified,,,,IC50,Antimicrobial activity against Trypanosoma brucei brucei,Confirmatory,20185316.0,
623,496819,4,2,,103167313,4735,Unspecified,,,,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
624,496825,4,2,,103167313,4735,Active,,,1.0,IC50,Antimicrobial activity against Leishmania mexicana,Confirmatory,20185316.0,
625,496828,4,2,,103167313,4735,Active,,,1.0,IC50,Antimicrobial activity against Leishmania donovani,Confirmatory,20185316.0,
626,496907,7,1,,103167313,4735,Unspecified,,,,IC50,Antimalarial activity against Plasmodium falciparum,Confirmatory,20466465.0,
627,499808,5,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani promastigotes after 72 hrs by alamar blue assay,Other,20669972.0,
628,499809,5,3,,103167313,4735,Inconclusive,,,,,Antimalarial activity against Plasmodium falciparum D6 after 72 hrs by alamar blue assay,Other,20669972.0,
629,499810,5,2,,103167313,4735,Inconclusive,,,,,Antimalarial activity against Plasmodium falciparum W2 after 72 hrs by alamar blue assay,Other,20669972.0,
630,499811,5,2,,103167313,4735,Inconclusive,,,,,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTS assay,Other,20669972.0,
631,499812,2,4,,103167313,4735,Inconclusive,,,,,"Selectivity index, ratio of IC50 for african green monkey (Cercopithecus aethiops) Vero cells to IC50 for Plasmodium falciparum D6",Other,20669972.0,
632,499813,2,4,,103167313,4735,Inconclusive,,,,,"Selectivity index, ratio of IC50 for african green monkey (Cercopithecus aethiops) Vero cells to IC50 for Plasmodium falciparum W2",Other,20669972.0,
633,502041,4,2,,103167313,4735,Active,,,13.32,IC50,Antimicrobial activity against promastigotes form of Leishmania mexicana MHOM/MX/ISETGS after 72 hrs,Confirmatory,20674375.0,
634,515925,1,5,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for human THP1 cells to IC50 for promastigotes of Leishmania donovani HOM/IN/01/2001",Other,20833057.0,
635,515926,4,2,,103167313,4735,Active,,,31.2,IC50,Cytotoxicity against human THP1 cells after 72 hrs by flow cytometry,Confirmatory,20833057.0,
636,515927,4,2,,103167313,4735,Active,,,11.2,IC50,Antileishmanial activity against promastigotes of Leishmania donovani HOM/IN/01/2001 after 72 hrs by flow cytometry,Confirmatory,20833057.0,
637,521208,4,2,,103167313,4735,Active,,,0.8220000000000001,EC50,Antiproliferative activity against mouse neural precursor cells by MTT assay,Confirmatory,17417631.0,
638,521209,4,3,,103167313,4735,Active,,,1.995,EC50,Antiproliferative activity against mouse astrocyte cells by MTT assay,Confirmatory,17417631.0,
639,521210,4,1,,103167313,4735,Unspecified,,,,,Ratio of EC50 for mouse astrocytes to EC50 for mouse neural precursor cells by MTT assay,Other,17417631.0,
640,526299,4,2,,103167313,4735,Active,,,20.43,IC50,Antileishmanial activity against Leishmania donovani amastigotes infected in mouse J774A1 cells assessed as inhibition of parasite growth after 72 hrs by luciferase reporter gene assay,Confirmatory,20850302.0,
641,526300,4,2,,103167313,4735,Unspecified,,,52.82,CC50,Toxicity in mouse J774A1 cells,Confirmatory,20850302.0,
642,526301,1,5,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for mouse J774A1 cells to IC50 for Leishmania donovani amastigotes",Other,20850302.0,
643,533153,4,2,,103167313,4735,Active,,,1.8,IC50,Antileishmanial activity against Leishmania donovani axenic amastigotes,Confirmatory,20368397.0,
644,533154,4,2,,103167313,4735,Unspecified,,,50.0,IC50,Antileishmanial activity against intracellular Leishmania donovani LV82 amastigotes,Confirmatory,20368397.0,
645,533155,4,2,,103167313,4735,Active,,,0.83,IC50,Antileishmanial activity against intracellular Leishmania amazonensis amastigotes,Confirmatory,20368397.0,
646,533156,4,2,,103167313,4735,Inconclusive,,,,IC50,Antileishmanial activity against intracellular Leishmania major amastigotes,Confirmatory,20368397.0,
647,533157,4,2,,103167313,4735,Active,,,14.0,IC50,Antileishmanial activity against intracellular Leishmania donovani LV82 amastigotes infected in CD-1 mouse peritoneal macrophage,Confirmatory,20368397.0,
648,536811,4,2,,103167313,4735,Active,,,0.003,IC50,Antitrypanosomal activity against Trypanosoma brucei brucei,Confirmatory,20850207.0,
649,537130,4,2,,103167313,4735,Active,,,1.11,IC50,Antileishmanial activity against promastigotes of Leishmania chagasi MHOM/BR/1972/LD after 18 hrs by MTT assay,Confirmatory,20934347.0,
650,537131,4,2,,103167313,4735,Inconclusive,,,,IC50,Antileishmanial activity against amastigotes of Leishmania chagasi MHOM/BR/1972/LD after 24 hrs by MTT assay,Confirmatory,20934347.0,
651,537132,4,2,,103167313,4735,Active,,,0.49,IC50,Antileishmanial activity against promastigotes of Leishmania amazonensis WHO/BR/00/LT0016 after 18 hrs by MTT assay,Confirmatory,20934347.0,
652,537133,4,2,,103167313,4735,Active,,,0.47,IC50,Antileishmanial activity against promastigotes of Leishmania major MHOM/1L/80/Fredlin after 18 hrs by MTT assay,Confirmatory,20934347.0,
653,537134,4,2,,103167313,4735,Active,,,0.15,IC50,Antileishmanial activity against promastigotes of Leishmania braziliensis MHO/BR/75/M2903 after 18 hrs by MTT assay,Confirmatory,20934347.0,
654,537135,4,2,,103167313,4735,Inconclusive,,,,IC50,Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi infected in rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay,Confirmatory,20934347.0,
655,537136,4,2,,103167313,4735,Active,,,25.61,IC50,Cytotoxicity against rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay,Confirmatory,20934347.0,
656,537139,2,5,,103167313,4735,Unspecified,,,,,Cytotoxicity in BALB/c mouse erythrocytes assessed as hemolysis at 50 uM after 3 hrs,Other,20934347.0,
657,540209,4,3,,103167313,4735,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
658,540210,4,3,,103167313,4735,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
659,540212,4,3,,103167313,4735,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
660,540213,4,3,,103167313,4735,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
661,540276,1,2,,50123735,4735,Inconclusive,420597.0,,23.1093,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
662,540276,1,2,,50123736,4735,Inconclusive,420597.0,,23.1093,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
663,548086,4,2,,103167313,4735,Unspecified,,,12302.7,IC50,Antimalarial activity against chloroquine and pyrimethamine -resistant Plasmodium falciparum K1 after 48 hrs by [3H]hypoxanthine incorporation assay,Confirmatory,20884090.0,
664,548087,4,2,,103167313,4735,Unspecified,,,56234.1,IC50,Antimalarial activity against drug -sensitive Plasmodium falciparum NF54 after 48 hrs by [3H]hypoxanthine incorporation assay,Confirmatory,20884090.0,
665,548280,6,1,,103167313,4735,Active,,,0.00095,EC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20439607.0,
666,548281,5,2,,103167313,4735,Active,,,2.6,EC50,Antimicrobial activity against Trypanosoma brucei NfxR1,Confirmatory,20439607.0,
667,548282,7,1,,103167313,4735,Active,,,0.0017,EC50,Antimicrobial activity against Trypanosoma brucei NfxR2,Confirmatory,20439607.0,
668,548283,2,3,,103167313,4735,Unspecified,,,,,Selectivity ratio of EC50 for Trypanosoma brucei NfxR1 to EC50 for Trypanosoma brucei,Other,20439607.0,
669,548284,2,3,,103167313,4735,Unspecified,,,,,Selectivity ratio of EC50 for Trypanosoma brucei NfxR2 to EC50 for Trypanosoma brucei,Other,20439607.0,
670,549914,4,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against promastigotes of Leishmania donovani by alamar blue assay,Other,21172735.0,
671,551685,1,6,,103167313,4735,Unspecified,,,,,Binding affinity to Poly d(A-T)n DNA assessed as change in melting temperature,Other,21194955.0,
672,551686,2,5,,103167313,4735,Active,,,0.0022,IC50,Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 after 70 hrs by alamar blue assay,Confirmatory,21194955.0,
673,551687,4,3,,103167313,4735,Active,,,6.0,IC50,Cytotoxicity against rat L6 cells by alamar blue assay,Confirmatory,21194955.0,
674,551688,1,5,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900",Other,21194955.0,
675,551689,2,5,,103167313,4735,Active,,,0.0064,IC50,Antiplasmodial activity against Plasmodium falciparum K1 infected in human RBC after 48 hrs by [3H]-hypoxanthine incorporation assay,Confirmatory,21194955.0,
676,551690,1,5,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Plasmodium falciparum K1",Other,21194955.0,
677,551692,2,5,,103167313,4735,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as effect on survival days at 5 mg/kg, ip administered 2 days after post infection for 4 consecutive days measured up to 60 days",Other,21194955.0,
678,552695,4,2,,103167313,4735,Active,,,25.0,IC50,Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay,Confirmatory,21112788.0,
679,552696,4,2,,103167313,4735,Active,,,0.012,IC50,Antitrypanosomal activity against bloodstream form of Trypanosoma brucei s427 after 72 hrs by MTT assay,Confirmatory,21112788.0,
680,552697,4,2,,103167313,4735,Active,,,0.0013,IC50,Antitrypanosomal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB900 after 70 hrs by alamar blue assay,Confirmatory,21112788.0,
681,552700,2,3,,103167313,4735,Active,,,,,"Antitrypanosomal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as suppression of parasitemia level in mouse tail blood at 5 mg/kg, ip qd for 4 consecutive days measured 5 days post infection",Other,21112788.0,
682,559250,2,3,,103167313,4735,Unspecified,,,,,"Trypanocidal activity against Trypanosoma brucei brucei EATRO infected in mouse assessed as mean survival time at 2 mg/kg, ip QD for 4 days",Other,19451291.0,
683,559449,2,3,,103167313,4735,Active,,,,,"Trypanocidal activity against Trypanosoma brucei rhodesiense KETRI2002 infected in mouse assessed as protection against trypanosomal infection at 2 mg/kg, ip QD administered 24 hrs postinfection",Other,19451291.0,
684,559457,2,3,,103167313,4735,Inactive,,,,,"Trypanocidal activity against Trypanosoma brucei rhodesiense KETRI1992 infected in mouse assessed as protection against trypanosomal infection at 2 mg/kg, ip QD administered 24 hrs postinfection",Other,19451291.0,
685,559462,2,3,,103167313,4735,Unspecified,,,,,"Trypanocidal activity against Trypanosoma brucei rhodesiense KETRI1992 infected in mouse assessed as average survival time at 2 mg/kg, ip QD administered 24 hrs postinfection",Other,19451291.0,
686,559469,2,3,,103167313,4735,Inactive,,,,,"Trypanocidal activity against Trypanosoma brucei rhodesiense KETRI243 infected in mouse assessed as protection against trypanosomal infection at 2 mg/kg, ip QD administered 24 hrs postinfection",Other,19451291.0,
687,559474,2,3,,103167313,4735,Unspecified,,,,,"Trypanocidal activity against Trypanosoma brucei rhodesiense KETRI243 infected in mouse assessed as average survival time at 2 mg/kg, ip QD administered 24 hrs postinfection",Other,19451291.0,
688,562034,2,3,,103167313,4735,Unspecified,,,,,"Antiparasitic activity against Trypanosoma brucei brucei LAB 110 EATRO infected in mouse assessed as mean survival days at 2 mg/kg, ip qd for 4 days administered on 1st day of infection and measured through day 40 post infection",Other,19289530.0,
689,562041,2,3,,103167313,4735,Active,,,,,"Antiparasitic activity against Trypanosoma brucei brucei LAB 110 EATRO infected in mouse assessed as parasitemia cure incidence at 2 mg/kg, ip qd for 4 days administered on 1st day of infection and measured through day 40 post infection",Other,19289530.0,
690,562240,5,2,,103167313,4735,Active,,,23.53,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry,Confirmatory,19786608.0,
691,562241,5,2,,103167313,4735,Active,,,11.05,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry,Confirmatory,19786608.0,
692,562242,5,2,,103167313,4735,Active,,,9.1,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry,Confirmatory,19786608.0,
693,562243,5,2,,103167313,4735,Active,,,23.53,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay,Confirmatory,19786608.0,
694,562244,5,2,,103167313,4735,Active,,,11.05,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay,Confirmatory,19786608.0,
695,562245,5,2,,103167313,4735,Active,,,9.1,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay,Confirmatory,19786608.0,
696,562484,5,2,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against wild-type Trypanosoma brucei rhodesiense STIB900 by Alamar blue assay,Other,19620327.0,
697,562485,5,2,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against pentamidine-resistant Trypanosoma brucei rhodesiense STIB900 by Alamar blue assay,Other,19620327.0,
698,562486,5,2,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against melasoprol-resistant Trypanosoma brucei rhodesiense STIB900 by Alamar blue assay,Other,19620327.0,
699,562487,5,2,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma brucei gambiense K03048 by Alamar blue assay,Other,19620327.0,
700,562488,5,2,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma brucei gambiense ITMAP141267 by Alamar blue assay,Other,19620327.0,
701,562489,5,2,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma brucei gambiense STIB930 by Alamar blue assay,Other,19620327.0,
702,562490,5,2,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma brucei brucei BS221 by Alamar blue assay,Other,19620327.0,
703,562491,5,2,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma brucei brucei AT1KO by Alamar blue assay,Other,19620327.0,
704,562492,1,3,,103167313,4735,Unspecified,,,,,Ratio of IC50 for pentamidine-resistant Trypanosoma brucei rhodesiense STIB900 to IC50 for wild-type Trypanosoma brucei rhodesiense STIB900,Other,19620327.0,
705,562493,1,3,,103167313,4735,Unspecified,,,,,Ratio of IC50 for melasoprol-resistant Trypanosoma brucei rhodesiense STIB900 to IC50 for wild-type Trypanosoma brucei rhodesiense STIB901,Other,19620327.0,
706,562494,1,3,,103167313,4735,Unspecified,,,,,Ratio of IC50 for Trypanosoma brucei gambiense K03048 to IC50 for wild-type Trypanosoma brucei rhodesiense STIB902,Other,19620327.0,
707,562495,1,3,,103167313,4735,Unspecified,,,,,Ratio of IC50 for Trypanosoma brucei gambiense ITMAP141267 to IC50 for wild-type Trypanosoma brucei rhodesiense STIB903,Other,19620327.0,
708,562496,1,3,,103167313,4735,Unspecified,,,,,Ratio of IC50 for Trypanosoma brucei gambiense STIB930 to IC50 for wild-type Trypanosoma brucei rhodesiense STIB904,Other,19620327.0,
709,562497,1,3,,103167313,4735,Unspecified,,,,,Ratio of IC50 for Trypanosoma brucei brucei AT1KO to IC50 for Trypanosoma brucei brucei BS221,Other,19620327.0,
710,562502,2,4,,103167313,4735,Unspecified,,,,,"Antitrypanosomal activity against wild-type Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as survival of mouse at 20 mg/kg, ip for 4 days",Other,19620327.0,
711,562504,2,4,,103167313,4735,Unspecified,,,,,"Antitrypanosomal activity against wild-type Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as survival of mouse at 5 mg/kg, ip for 4 days",Other,19620327.0,
712,567091,2,6,,103167313,4735,Unspecified,,,,,Drug absorption in human assessed as human intestinal absorption rate,Other,21112128.0,
713,578276,4,2,,103167313,4735,Inactive,,,,IC50,Antitrypanosomal activity against TbAT1-deficient Trypanosoma brucei brucei after 48 hrs by alamar blue assay,Confirmatory,21306904.0,
714,578277,4,2,,103167313,4735,Inactive,,,,IC50,Antitrypanosomal activity against TbAT1 and HAPT1-deficient Trypanosoma brucei brucei B48 after 48 hrs by alamar blue assay,Confirmatory,21306904.0,
715,586923,1,3,,103167313,4735,Unspecified,,,,,"Resistant index, ratio of EC50 for tafenoquine-resistant promastigotes of Leishmania major R4 to EC50 for promastigotes of Leishmania major MHOM/JL/80/Friedlin",Other,21199921.0,
716,586924,4,2,,103167313,4735,Active,,,0.45,EC50,Antileishmanial activity against tafenoquine-resistant promastigotes of Leishmania major R4 assessed as inhibition of parasite growth after 72 hrs by MTT assay,Confirmatory,21199921.0,
717,586925,4,2,,103167313,4735,Active,,,0.28,EC50,Antileishmanial activity against wild type promastigotes of Leishmania major MHOM/JL/80/Friedlin assessed as inhibition of parasite growth after 72 hrs by MTT assay,Confirmatory,21199921.0,
718,588172,4,2,,103167313,4735,Active,,,0.026000000000000002,IC50,Antitrypanosomal activity against bloodstream-form Trypanosoma brucei brucei 427 after 72 hrs,Confirmatory,21322634.0,
719,588214,2,3,,103167313,4735,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
720,588215,2,3,,103167313,4735,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
721,588216,2,3,,103167313,4735,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
722,588217,2,3,,103167313,4735,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
723,588218,2,3,,103167313,4735,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
724,588219,2,3,,103167313,4735,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
725,593435,1,6,,103167313,4735,Unspecified,,,,,Binding affinity to poly(dA-dT)2DNA assessed as change in melting temperature,Other,21421317.0,
726,593436,3,3,,103167313,4735,Active,,,46.0,IC50,Cytotoxicity against rat L6 cells,Confirmatory,21421317.0,
727,593437,1,5,,103167313,4735,Active,,,0.0022,IC50,Antiparasitic activity against Trypanosoma brucei rhodesiense STIB900,Confirmatory,21421317.0,
728,593438,1,5,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900",Other,21421317.0,
729,593439,1,5,,103167313,4735,Active,,,0.0464,IC50,Antiparasitic activity against Plasmodium falciparum K1,Confirmatory,21421317.0,
730,593440,1,5,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Plasmodium falciparum K1",Other,21421317.0,
731,593471,1,5,,103167313,4735,Unspecified,,,,,"Antiparasitic activity against Trypanosoma brucei rhodesiense STIB900 infected in mouse assessed as mean relapse day of parasitemia at 5 mg/kg, ip for 4 days",Other,21421317.0,
732,598105,1,4,,103167313,4735,Unspecified,,,,,Binding affinity to poly(dA-dT)n DNA assessed as change in melting temperature at 0.3:1 molar compound/DNA ratio by spectrophotometry,Other,20031421.0,
733,598106,3,2,,103167313,4735,Active,,,46.0,IC50,Cytotoxicity against rat L6 cells,Confirmatory,20031421.0,
734,598107,1,3,,103167313,4735,Active,,,0.0022,IC50,Antiparasitic activity against Trypanosoma brucei rhodesiense STIB900,Confirmatory,20031421.0,
735,598108,1,3,,103167313,4735,Active,,,0.0464,IC50,Antiparasitic activity against Plasmodium falciparum K1,Confirmatory,20031421.0,
736,598109,1,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900",Other,20031421.0,
737,598110,1,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Plasmodium falciparum K1",Other,20031421.0,
738,598281,3,2,,103167313,4735,Active,,,4.079,IC50,Antiprotozoan activity against Giardia intestinalis IMSS:0696:1 trophozoites after 48 hrs,Confirmatory,21397502.0,
739,598282,3,2,,103167313,4735,Active,,,3.815,IC50,Antiprotozoan activity against Trichomonas vaginalis GT3 trophozoites after 48 hrs,Confirmatory,21397502.0,
740,598283,3,2,,103167313,4735,Active,,,11.8,IC50,Antiprotozoan activity against Entamoeba histolytica HM1-IMSS trophozoites after 48 hrs,Confirmatory,21397502.0,
741,598284,3,2,,103167313,4735,Active,,,13.32,IC50,Antileishmanial activity against Leishmania mexicana MHOM/MX/ISETGS promastigotes after 72 hrs by neubauer chamber,Confirmatory,21397502.0,
742,598285,3,2,,103167313,4735,Unspecified,,,50.0,IC50,Antitrypanosomal activity against Trypanosoma cruzi MHOM/MX/1994/Ninoa epimastigotes after 72 hrs by neubauer chamber,Confirmatory,21397502.0,
743,598286,3,2,,103167313,4735,Active,,,2.9419999999999997,IC50,Antimalarial activity against Plasmodium berghei schizonts isolated from parasitized erythrocytes infected Wistar rat measured 16 hrs post compound exposure,Confirmatory,21397502.0,
744,598287,3,2,,103167313,4735,Active,,,47.0,CC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,21397502.0,
745,602156,1,1,,131332989,4735,Inactive,,,,IC50,Novartis GNF Liver Stage Dataset: Malariabox Annotation,Other,22096101.0,
746,604069,3,2,,103167313,4735,Active,,,6.29,IC50,Antileishmanial activity against Leishmania donovani MHOM/IN/00/DEVI promastigote after 72 hrs by MTT assay,Confirmatory,21555166.0,
747,604070,3,2,,103167313,4735,Active,,,1.03,IC50,Cytotoxic activity against mouse J774A1 cells after 72 hrs by MTT assay,Confirmatory,21555166.0,
748,604071,1,4,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse J774A1 cells to IC50 for Leishmania donovani MHOM/IN/OO/DEVI promastigote",Other,21555166.0,
749,612696,3,2,,103167313,4735,Active,,,6.0,IC50,Antileishmanial activity against promastigotes form of Leishmania braziliensis MHOM/BR/75/M2904 after 72 hrs,Confirmatory,21757358.0,
750,624349,1,2,,92308870,4735,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
751,625144,5,5,,103167313,4735,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
752,625145,4,7,,103167313,4735,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
753,625146,5,5,,103167313,4735,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
754,625147,4,7,,103167313,4735,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
755,625148,4,7,,103167313,4735,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
756,625149,4,7,,103167313,4735,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
757,625150,5,5,,103167313,4735,Active,113978.0,4128.0,0.7929999999999999,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
758,625151,4,7,,103167313,4735,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
759,625152,4,7,,103167313,4735,Active,113122.0,1129.0,1.425,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
760,625153,4,7,,103167313,4735,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
761,625154,4,7,,103167313,4735,Active,23503039.0,1132.0,1.58,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
762,625155,4,7,,103167313,4735,Active,543761.0,1133.0,2.885,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
763,625156,1,9,,103167313,4735,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
764,625157,6,2,,103167313,4735,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
765,625158,3,4,,103167313,4735,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
766,625159,5,5,,103167313,4735,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
767,625160,1,9,,103167313,4735,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
768,625161,4,7,,103167313,4735,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
769,625162,4,7,,103167313,4735,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
770,625163,4,7,,103167313,4735,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
771,625164,1,6,,103167313,4735,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
772,625165,3,4,,103167313,4735,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
773,625166,3,4,,103167313,4735,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
774,625167,5,5,,103167313,4735,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
775,625168,4,7,,103167313,4735,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
776,625169,1,6,,103167313,4735,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
777,625170,3,4,,103167313,4735,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
778,625171,4,7,,103167313,4735,Active,7531135.0,3757.0,15.7215,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
779,625172,4,7,,103167313,4735,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
780,625173,5,5,,103167313,4735,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
781,625174,5,5,,103167313,4735,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
782,625175,5,5,,103167313,4735,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
783,625176,1,9,,103167313,4735,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
784,625177,5,5,,103167313,4735,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
785,625178,5,5,,103167313,4735,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
786,625179,1,9,,103167313,4735,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
787,625180,5,5,,103167313,4735,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
788,625181,5,5,,103167313,4735,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
789,625182,5,5,,103167313,4735,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
790,625183,5,5,,103167313,4735,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
791,625184,5,5,,103167313,4735,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
792,625185,5,5,,103167313,4735,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
793,625186,5,5,,103167313,4735,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
794,625187,5,5,,103167313,4735,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
795,625188,1,9,,103167313,4735,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
796,625189,1,7,,103167313,4735,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
797,625190,4,5,,103167313,4735,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
798,625191,4,7,,103167313,4735,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
799,625192,4,7,,103167313,4735,Active,543727.0,3356.0,1.639,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
800,625193,5,5,,103167313,4735,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
801,625194,4,7,,103167313,4735,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
802,625195,4,7,,103167313,4735,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
803,625196,5,6,,103167313,4735,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
804,625197,3,4,,103167313,4735,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
805,625198,4,7,,103167313,4735,Active,1168247.0,29412.0,1.212,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
806,625199,4,7,,103167313,4735,Active,543734.0,24173.0,0.9670000000000001,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
807,625200,4,7,,103167313,4735,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
808,625201,4,7,,103167313,4735,Active,1351829.0,150.0,1.375,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
809,625202,4,7,,103167313,4735,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
810,625203,4,7,,103167313,4735,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
811,625204,4,7,,103167313,4735,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
812,625205,4,7,,103167313,4735,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
813,625206,4,7,,103167313,4735,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
814,625207,4,7,,103167313,4735,Active,128616.0,6530.0,2.214,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
815,625208,5,5,,103167313,4735,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
816,625209,4,7,,103167313,4735,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
817,625210,3,4,,103167313,4735,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
818,625211,1,6,,103167313,4735,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
819,625212,3,4,,103167313,4735,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
820,625213,4,7,,103167313,4735,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
821,625214,1,9,,103167313,4735,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
822,625215,3,4,,103167313,4735,Active,,,2.208,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
823,625216,3,4,,103167313,4735,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
824,625217,4,7,,103167313,4735,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
825,625218,4,7,,103167313,4735,Active,112816.0,3358.0,3.278,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
826,625219,3,4,,103167313,4735,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
827,625220,4,7,,103167313,4735,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
828,625221,4,7,,103167313,4735,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
829,625222,4,7,,103167313,4735,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
830,625223,4,7,,103167313,4735,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
831,625224,3,4,,103167313,4735,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
832,625225,3,4,,103167313,4735,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
833,625226,4,7,,103167313,4735,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
834,625227,4,7,,103167313,4735,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
835,625228,4,7,,103167313,4735,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
836,625229,5,5,,103167313,4735,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
837,625230,1,6,,103167313,4735,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
838,625231,4,7,,103167313,4735,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
839,625232,1,9,,103167313,4735,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
840,625233,4,7,,103167313,4735,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
841,625234,3,4,,103167313,4735,Active,,,1.391,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
842,625235,4,7,,103167313,4735,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
843,625236,5,5,,103167313,4735,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
844,625237,4,7,,103167313,4735,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
845,625238,4,7,,103167313,4735,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
846,625239,4,7,,103167313,4735,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
847,625240,1,9,,103167313,4735,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
848,625241,4,7,,103167313,4735,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
849,625242,4,7,,103167313,4735,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
850,625243,5,5,,103167313,4735,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
851,625244,5,5,,103167313,4735,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
852,625245,5,5,,103167313,4735,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
853,625246,1,9,,103167313,4735,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
854,625247,5,5,,103167313,4735,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
855,625248,5,5,,103167313,4735,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
856,625249,5,5,,103167313,4735,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
857,625250,5,5,,103167313,4735,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
858,625251,5,5,,103167313,4735,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
859,625252,4,7,,103167313,4735,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
860,625253,4,7,,103167313,4735,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
861,625254,4,7,,103167313,4735,Active,1169206.0,1814.0,3.998,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
862,625255,4,7,,103167313,4735,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
863,625256,4,7,,103167313,4735,Active,266667.0,6531.0,3.159,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
864,625257,4,7,,103167313,4735,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
865,625258,4,7,,103167313,4735,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
866,625259,4,7,,103167313,4735,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
867,625260,3,4,,103167313,4735,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
868,625261,3,4,,103167313,4735,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
869,625262,3,4,,103167313,4735,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
870,625263,4,7,,103167313,4735,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
871,625264,3,4,,103167313,4735,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
872,625265,1,6,,103167313,4735,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
873,625266,3,4,,103167313,4735,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
874,625267,3,4,,103167313,4735,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
875,625268,4,2,,103167313,4735,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
876,625268,4,2,,103167313,4735,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
877,625268,4,2,,103167313,4735,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
878,625268,4,2,,103167313,4735,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
879,625269,4,7,,103167313,4735,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
880,625270,4,7,,103167313,4735,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
881,625271,5,5,,103167313,4735,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
882,625272,3,4,,103167313,4735,Active,,,3.5239999999999996,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
883,625273,4,6,,103167313,4735,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
884,625274,1,6,,103167313,4735,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
885,625275,3,4,,103167313,4735,Active,,,0.242,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
886,628473,3,2,,103167313,4735,Active,,,15.1,IC50,Antitrypanosomal activity against Trypanosoma brucei brucei after 48 hrs by by alamar blue assay,Confirmatory,21705225.0,
887,628474,3,2,,103167313,4735,Unspecified,,,71.0,IC50,Cytotoxicity against human HEK293 cells after 48 hrs by by alamar blue assay,Confirmatory,21705225.0,
888,629040,1,4,,103167313,4735,Unspecified,,,,,Binding affinity to poly(dA-dT) DNA assessed as change in melting temperature at compound/polynucleotide ratio 0.3 in in MES10 buffer by spectrophotometry,Other,22005186.0,
889,629041,1,3,,103167313,4735,Active,,,0.0022,IC50,Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 after 72 hrs using alamar blue staining by microplate fluorometric analysis,Confirmatory,22005186.0,
890,629042,1,3,,103167313,4735,Active,,,0.0464,IC50,Antiplasmodial activity against Plasmodium falciparum K1 infected in human red blood cells assessed as [3H]hypoxanthine incorporation after 48 hrs by liquid scintillation counting,Confirmatory,22005186.0,
891,629043,1,3,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for Trypanosoma brucei rhodesiense STIB900 to IC50 for Plasmodium falciparum K1",Other,22005186.0,
892,629044,3,2,,103167313,4735,Active,,,2.1,IC50,Cytotoxicity against rat L6 cells after 72 hrs by alamar blue staining-based microplate fluorometric analysis,Confirmatory,22005186.0,
893,631937,3,2,,103167313,4735,Active,,,10.0,IC50,Antileishmanial activity against extracellular promastigotes form of Leishmania amazonensis MHOM/ BR/77/LTB0016 after 24 hrs by neubauer chamber analysis,Confirmatory,22055204.0,
894,631938,3,2,,103167313,4735,Unspecified,,,50.0,IC50,Antileishmanial activity against extracellular promastigotes form of Leishmania braziliensis MCAN/BR/97/P142 after 24 hrs by neubauer chamber analysis,Confirmatory,22055204.0,
895,631939,3,2,,103167313,4735,Unspecified,,,100.0,IC50,Antileishmanial activity against extracellular promastigotes form of Leishmania infantum MCAN/BR/98R619 after 24 hrs by neubauer chamber analysis,Confirmatory,22055204.0,
896,631940,1,4,,103167313,4735,Unspecified,,,,,Cytotoxicity against mouse peritoneal macrophages at IC50 for Leishmania amazonensis MHOM/ BR/77/LTB0016,Other,22055204.0,
897,636823,3,2,,103167313,4735,Inconclusive,,,,,Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum FcB1/Colombia infected in human A+ve erythrocytes assessed as inhibition of [G-3H]hypoxanthine uptake preincubated for 24 hrs prior to [G-3H]hypoxanthine addition measured after 18 hrs by liquid scintillation counting,Other,21985060.0,
898,636824,3,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani MHOM/ET/L82/LV9 promastigotes after 3 days by MTT assay,Other,21985060.0,
899,636825,3,2,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma brucei brucei,Other,21985060.0,
900,636826,3,2,,103167313,4735,Inconclusive,,,,,Cytotoxicity against african green monkey Vero cells,Other,21985060.0,
901,636857,3,2,,103167313,4735,Active,,,2.2,IC50,Antileishmanial activity against Leishmania amazonensis promastigotes after 72 hrs by MTT assay,Confirmatory,22000949.0,
902,636858,3,2,,103167313,4735,Active,,,1.5,IC50,Antileishmanial activity against Leishmania amazonensis amastigotes infected in BALB/c mouse peritoneal macrophages after 72 hrs by microscopy,Confirmatory,22000949.0,
903,636859,3,2,,103167313,4735,Unspecified,,,70.0,IC50,Cytotoxicity against mouse J774 cells after 72 hrs by MTT assay,Confirmatory,22000949.0,
904,636860,3,2,,103167313,4735,Active,,,46.0,IC50,"Selectivity index, ratio of IC50 for mouse J774 cells to IC50 for Leishmania amazonensis amastigotes infected in BALB/c mouse macrophages",Confirmatory,22000949.0,
905,644196,5,1,,103167313,4735,Active,,,0.008,EC50,Antitrypanosomal activity against blood stream form of Trypanosoma brucei after 69 hrs by resazurin-based fluorescence assay,Confirmatory,22264753.0,
906,647778,3,2,,103167313,4735,Active,,,6.2,IC50,Antileishmanial activity against Leishmania donovani S1 promastigotes after 72 hrs by alamar blue assay,Confirmatory,22248858.0,
907,651828,1,2,,92308870,4735,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
908,659704,2,2,,103167313,4735,Active,,,2.84,IC50,Antikinetoplastid activity against Leishmania donovani MHOM/ET/67/HU3 promastigotes after 3 days incubation at 27 degC under dark condition and 5% CO2 atmosphere by MTT assay,Confirmatory,22472166.0,
909,659705,1,3,,103167313,4735,Active,,,,,Antikinetoplastid activity against Trypanosoma brucei brucei CMP by drug incubation infectivity test,Other,22472166.0,
910,659706,1,3,,103167313,4735,Unspecified,,,,,Cytotoxicity against mouse RAW264.7 cells assessed as cell survival at 100 uM after 24 hrs incubation by trypan blue exclusion method,Other,22472166.0,
911,659708,2,2,,103167313,4735,Active,,,6.6,IC50,Antikinetoplastid activity against Leishmania donovani MHOM/ET/67/HU3 amastigotes after 3 days incubation at 37 degC under dark condition and 5% CO2 atmosphere by SYBR green I dye based assay,Confirmatory,22472166.0,
912,660299,2,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani promastigote by by Alamar Blue assay,Other,22483965.0,
913,660873,2,3,,103167313,4735,Active,,,0.0014,EC50,Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei 427 (BS221) after 72 hrs by alamar blue assay,Confirmatory,24900279.0,
914,660874,2,3,,103167313,4735,Active,,,0.0032,EC50,Antitrypanosomal activity against TbAt1-deficient bloodstraem form of Trypanosoma brucei brucei 427 (BS221) after 72 hrs by alamar blue assay,Confirmatory,24900279.0,
915,660875,2,3,,103167313,4735,Active,,,0.066,EC50,Antitrypanosomal activity against TbAt1-deficient bloodstraem form Trypanosoma brucei brucei B48 after 72 hrs by alamar blue assay,Confirmatory,24900279.0,
916,662818,2,3,,103167313,4735,Active,,,4.3,EC50,Antileishmanial activity against promastigotes of Leishmania major Friedlin after 72 hrs by alamar blue assay,Confirmatory,24900279.0,
917,662819,2,3,,103167313,4735,Active,,,8.8,EC50,Antileishmanial activity against amastigotes of Leishmania mexicana MNYC/BZ/62/M379 after 72 hrs by alamar blue assay,Confirmatory,24900279.0,
918,666701,2,2,,103167313,4735,Active,,,0.008,EC50,Antitrypanosomal activity against wild type Trypanosoma brucei brucei Lister 427 after 3 days by alamar blue assay,Confirmatory,22390399.0,
919,666702,2,2,,103167313,4735,Active,,,0.009000000000000001,EC50,Antitrypanosomal activity against diminazene aceturate-resistant TbAT1 gene-deficient Trypanosoma brucei brucei AT1-KO after 3 days by alamar blue assay,Confirmatory,22390399.0,
920,666703,1,2,,103167313,4735,Unspecified,,,,,"Resistance factor, ratio of EC50 for diminazene aceturate-resistant TbAT1 gene-deficient Trypanosoma brucei brucei AT1-KO to EC50 for wild type Trypanosoma brucei brucei Lister 427",Other,22390399.0,
921,666704,2,2,,103167313,4735,Active,,,0.5670000000000001,EC50,"Antitrypanosomal activity against diminazene-, pentamidine-, and melaminophenyl arsenical-resistant HAPT1-deficient Trypanosoma brucei brucei B48 after 3 days by alamar blue assay",Confirmatory,22390399.0,
922,666705,1,2,,103167313,4735,Unspecified,,,,,"Resistance factor, ratio of EC50 for diminazene-, pentamidine-, and melaminophenyl arsenical-resistant HAPT1-deficient Trypanosoma brucei brucei B48 to EC50 for wild type Trypanosoma brucei brucei Lister 427",Other,22390399.0,
923,666711,2,2,,103167313,4735,Active,,,0.036000000000000004,Ki,Inhibition of Trypanosoma brucei brucei HAPT1 assessed as [3H]-pentamidine uptake after 60 secs by scintillation counting,Confirmatory,22390399.0,
924,666712,2,2,,103167313,4735,Unspecified,,,56.2,Ki,Inhibition of Trypanosoma brucei brucei LAPT1 assessed as [3H]-pentamidine uptake after 120 secs by scintillation counting,Confirmatory,22390399.0,
925,668283,2,2,,103167313,4735,Active,,,6.0,IC50,Antileishmanial activity against Leishmania donovani MHOM/IN/00/DEVI promastigotes after 72 hrs by MTT assay,Confirmatory,22608675.0,
926,668284,2,2,,103167313,4735,Active,,,8.2,IC50,Antileishmanial activity against Leishmania infantum MCAN/ES/98/LLM-877 promastigotes after 72 hrs by MTT assay,Confirmatory,22608675.0,
927,668285,2,2,,103167313,4735,Unspecified,,,20.0,IC50,Antileishmanial activity against Leishmania donovani MHOM/IN/00/DEVI amastigotes infected in mouse J774A.1 cells after 120 hrs by Giemsa staining-based microscopic analysis,Confirmatory,22608675.0,
928,668288,2,2,,103167313,4735,Active,,,1.0,CC50,Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay,Confirmatory,22608675.0,
929,668289,2,2,,103167313,4735,Active,,,2.3,CC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,22608675.0,
930,668290,1,3,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for mouse J774A1 cells to IC50 for Leishmania donovani MHOM/IN/00/DEVI promastigotes",Other,22608675.0,
931,668291,1,3,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for human HepG2 cells to IC50 for Leishmania donovani MHOM/IN/00/DEVI promastigotes",Other,22608675.0,
932,669325,2,2,,103167313,4735,Active,,,2.9,IC50,Antileishmanial activity against Leishmania donovani promastigotes,Confirmatory,22530813.0,
933,669380,2,2,,103167313,4735,Active,,,7.0,IC50,Antileishmanial activity against Leishmania amazonensis MPRO/BR/1972/M1841-LV-79 after 72 hrs by MTT assay,Confirmatory,22559947.0,
934,669381,2,2,,103167313,4735,Active,,,5.1,IC50,Antileishmanial activity against Leishmania chagasi MHOM/BR/1974/PP75 after 72 hrs by MTT assay,Confirmatory,22559947.0,
935,669382,2,2,,103167313,4735,Inconclusive,,,,IC50,Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi after 72 hrs by MTT assay,Confirmatory,22559947.0,
936,669383,2,2,,103167313,4735,Inconclusive,,,,IC50,Cytotoxicity against Balb/c mouse peritoneal macrophages after 24 hrs by MTT assay,Confirmatory,22559947.0,
937,686977,2,1,,49698900,4735,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
938,693602,1,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against amastigote form of Leishmania major MHOM/IL/81/BNI infected in Balb/c mouse peritoneal macrophages assessed as inhibition of intracellular amastigote burden at 10 uM after 48 hrs by May-Grunwald-Geimsa staining,Other,23164660.0,
939,693603,2,2,,103167313,4735,Active,,,15.0,IC50,Cytotoxicity against human HeLa cells after 96 hrs by resazurin-based spectrofluorimetric method,Confirmatory,23164660.0,
940,693604,1,2,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for human HeLa cells to IC50 for promastigote form of Leishmania major MHOM/IL/81/BNI",Other,23164660.0,
941,693605,2,2,,103167313,4735,Active,,,4.8,IC50,Antileishmanial activity against promastigote form of Leishmania major MHOM/IL/81/BNI after 96 hrs by resazurin-based spectrofluorimetric method,Confirmatory,23164660.0,
942,703475,1,2,,103167313,4735,Unspecified,,,,,Selectivity ratio of IC50 for compound-resistant Leishmania donovani AG83PentR50 promastigote to IC50 for wild-type Leishmania donovani AG83 promastigote,Other,22989363.0,
943,703476,1,2,,103167313,4735,Unspecified,,,,,"Therapeutic index, ratio of IC50 for mouse Peritoneal macrophages to IC50 for SSG-resistant Leishmania donovani 39 amastigote infected in mouse peritoneal macrophages",Other,22989363.0,
944,703481,1,2,,103167313,4735,Unspecified,,,,,"Therapeutic index, ratio of IC50 for mouse Peritoneal macrophages to IC50 for SSG-resistant Leishmania donovani 39 promastigote",Other,22989363.0,
945,703482,1,2,,103167313,4735,Unspecified,,,,,"Therapeutic index, ratio of IC50 for mouse Peritoneal macrophages to IC50 for pentamidine-resistant Leishmania donovani AG83PentR50 promastigote",Other,22989363.0,
946,703483,1,2,,103167313,4735,Unspecified,,,,,"Therapeutic index, ratio of IC50 for mouse PEM cells to IC50 for wild-type Leishmania donovani AG83 promastigote",Other,22989363.0,
947,703484,2,3,,103167313,4735,Active,,,30.4,IC50,Cytotoxicity against mouse Peritoneal macrophages cells after 72 hrs by MTS assay,Confirmatory,22989363.0,
948,703485,2,2,,103167313,4735,Active,,,30.0,IC50,Cytotoxicity against mouse RAW264.7 cells after 72 hrs by MTS assay,Confirmatory,22989363.0,
949,703486,2,2,,103167313,4735,Unspecified,,,30.0,IC50,Antimicrobial activity against SSG-resistant Leishmania donovani 39 amastigote infected in mouse peritoneal macrophages assessed as inhibition of parasite growth after 72 hrs by Giemsa staining method,Confirmatory,22989363.0,
950,703487,2,2,,103167313,4735,Unspecified,,,54.8,IC50,Antimicrobial activity against pentamidine-resistant Leishmania donovani AG83PentR50 promastigote assessed as inhibition of parasite growth after 72 hrs by MTS assay,Confirmatory,22989363.0,
951,703620,2,2,,103167313,4735,Active,,,5.3,IC50,Antimicrobial activity against SSG-resistant Leishmania donovani 39 promastigote assessed as inhibition of parasite growth after 72 hrs by MTS assay,Confirmatory,22989363.0,
952,703621,2,2,,103167313,4735,Active,,,13.9,IC50,Antimicrobial activity against wild-type Leishmania donovani AG83 promastigote assessed as inhibition of parasite growth after 72 hrs by MTS assay,Confirmatory,22989363.0,
953,712199,1,4,,103167313,4735,Unspecified,,,,,Destabilization of rat/bovine S100B assessed as change in melting temperature by differential scanning calorimetry,Other,23264854.0,
954,712200,2,3,,103167313,4735,Active,,,40.0,Kd,Binding affinity to rat/bovine recombinant S100B at weaker site expressed in Escherichia coli [HMS174(DE3)strain] by NMR spectroscopy,Confirmatory,23264854.0,
955,712201,2,3,,103167313,4735,Active,,,0.13,Kd,Binding affinity to rat/bovine recombinant S100B at tight site expressed in Escherichia coli [HMS174(DE3)strain] by NMR spectroscopy,Confirmatory,23264854.0,
956,712267,2,3,,103167313,4735,Active,,,12.2,IC50,Growth inhibition of human MALME-3M cells transfected with S100B siRNA after 4 days by SYBR green assay,Confirmatory,23264854.0,
957,712268,2,3,,103167313,4735,Active,,,10.2,IC50,Growth inhibition of human MALME-3M cells overexpressing calcium-binding protein S100B after 4 days by SYBR green assay,Confirmatory,23264854.0,
958,717248,2,3,,103167313,4735,Active,,,0.0052,IC50,Antimicrobial activity against bloodstream forms of Trypanosoma brucei gambiense Feo after 72 hrs by resazurin assay,Confirmatory,23084895.0,
959,717249,2,3,,103167313,4735,Active,,,0.0032,IC50,Antimicrobial activity against bloodstream forms of Trypanosoma brucei brucei 90-13 after 72 hrs by resazurin assay,Confirmatory,23084895.0,
960,720641,1,2,,92308870,4735,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
961,720717,1,3,,92308870,4735,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
962,720844,1,2,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Plasmodium falciparum NF54",Other,23301592.0,
963,720845,1,3,,103167313,4735,Active,,,0.027000000000000003,IC50,Antimalarial activity against erythrocytic stage of Plasmodium falciparum NF54 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counting analysis,Confirmatory,23301592.0,
964,720846,1,2,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900",Other,23301592.0,
965,720847,1,2,,103167313,4735,Active,,,0.002,IC50,Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 after 70 hrs by resazurin reduction assay,Confirmatory,23301592.0,
966,720848,1,2,,103167313,4735,Active,,,1.51,IC50,Cytotoxicity against rat L6 cells after 70 hrs by resazurin reduction assay,Confirmatory,23301592.0,
967,720849,1,3,,103167313,4735,Unspecified,,,,,Binding affinity to poly(dA-dT) DNA (unknown origin) in Tris-Hcl buffer assessed as change in melting temperature,Other,23301592.0,
968,720850,1,4,,103167313,4735,Unspecified,,,,,Binding affinity to calf thymus DNA in MES buffer assessed as change in melting temperature,Other,23301592.0,
969,720852,1,4,,103167313,4735,Unspecified,,,,,Binding affinity to calf thymus DNA in in Tris-Hcl buffer assessed as change in melting temperature,Other,23301592.0,
970,720853,1,3,,103167313,4735,Unspecified,,,,,Binding affinity to poly(dA-dT) DNA (unknown origin) in PIPES buffer assessed as change in melting temperature,Other,23301592.0,
971,721742,1,2,,103167313,4735,Unspecified,,,,,Ratio of Cmax unbound to IC50 for human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells,Other,23241029.0,
972,721743,1,2,,103167313,4735,Unspecified,,,,,Ratio of Cmax unbound to IC50 for human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells,Other,23241029.0,
973,721745,1,2,,103167313,4735,Unspecified,,,,,Ratio of Cmax unbound to IC50 for human MATE1-mediated ASP+ uptake expressed in HEK293 cells,Other,23241029.0,
974,721746,2,5,,103167313,4735,Active,74731723.0,55244.0,0.41,IC50,Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis,Confirmatory,23241029.0,
975,721747,2,5,,103167313,4735,Active,74731723.0,55244.0,2.0,IC50,Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis,Confirmatory,23241029.0,
976,721748,2,5,,103167313,4735,Active,74727585.0,146802.0,2.7,IC50,Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay,Confirmatory,23241029.0,
977,721749,2,5,,103167313,4735,Active,24212063.0,6581.0,9.5,IC50,Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay,Confirmatory,23241029.0,
978,721750,2,5,,103167313,4735,Active,313104181.0,6580.0,22.1,IC50,Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay,Confirmatory,23241029.0,
979,721751,2,5,,103167313,4735,Active,313104182.0,6582.0,1.2,IC50,Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay,Confirmatory,23241029.0,
980,721752,2,5,,103167313,4735,Active,74727585.0,146802.0,10.4,IC50,Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay,Confirmatory,23241029.0,
981,721754,2,5,,103167313,4735,Active,74731723.0,55244.0,2.7,IC50,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay,Confirmatory,23241029.0,
982,723219,1,2,,103167313,4735,Unspecified,,,,,Selectivity ratio of EC50 for bloodstream form of nifurtimox-resistant Trypanosoma brucei to EC50 for bloodstream form of wild type Trypanosoma brucei brucei 427,Other,23281892.0,
983,723302,1,2,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for human KB cells to IC50 for amastigote stage of Leishmania donovani infected in mouse J774A.1 cells",Other,23182089.0,
984,723303,1,4,,103167313,4735,Unspecified,,,52.7,CC50,Cytotoxicity against human KB cells after 72 hrs by MTT assay,Confirmatory,23182089.0,
985,723305,1,2,,103167313,4735,Active,,,20.43,IC50,Antileishmanial activity against amastigote stage of Leishmania donovani infected in mouse J774A.1 cells assessed as intracellular parasite growth inhibition after 72 hrs by luciferase reporter gene assay,Confirmatory,23182089.0,
986,723480,3,1,,103167313,4735,Active,,,0.0011,EC50,Trypanocidal activity against bloodstream form of N-(4-(allyloxy)-3-(trifluoromethyl)phenyl)-5-nitrofuran-2-carboxamide-resistant Trypanosoma brucei after 72 hrs by Alamar blue assay,Confirmatory,23281892.0,
987,727830,1,4,,103167313,4735,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as change in melting temperature,Other,23252648.0,
988,728604,1,2,,103167313,4735,Active,,,0.051,EC50,Antitrypanosomal activity against Trypanosoma brucei gambiense KO48 after 70 hrs by Alamar Blue assay,Confirmatory,23484493.0,
989,728605,1,2,,103167313,4735,Active,,,0.0009,EC50,Antitrypanosomal activity against Trypanosoma brucei gambiense DAL 898R after 70 hrs by Alamar Blue assay,Confirmatory,23484493.0,
990,728606,1,2,,103167313,4735,Active,,,0.0007,EC50,Antitrypanosomal activity against Trypanosoma brucei gambiense STIB930 after 70 hrs by Alamar Blue assay,Confirmatory,23484493.0,
991,728609,1,2,,103167313,4735,Active,,,0.0006,EC50,Antitrypanosomal activity against bloodstream forms of wild type Trypanosoma brucei rhodesiense STIB900 after 70 hrs by Alamar Blue assay,Confirmatory,23484493.0,
992,728616,1,2,,103167313,4735,Active,,,0.012,EC50,Antitrypanosomal activity against Trypanosoma brucei brucei 221 after 48 hrs by Cell Titre Glo assay,Confirmatory,23484493.0,
993,734553,1,3,,103167313,4735,Active,,,4.8,IC50,Cytotoxicity against human WM115 cells assessed as growth inhibition measured after 72 hrs by crystal violet assay,Confirmatory,23375094.0,
994,734554,1,6,,103167313,4735,Unspecified,134138.0,6285.0,,,Inhibition of human S100B/humanTAMRA-p53(367-388) interaction assessed as inhibition rate at 93 uM by fluorescence polarization assay,Other,23375094.0,
995,734556,1,6,,103167313,4735,Unspecified,134138.0,6285.0,100.0,IC50,Inhibition of human S100B/human TAMRA-p53(367-388) interaction by fluorescence polarization assay,Confirmatory,23375094.0,
996,736304,1,2,,103167313,4735,Active,,,0.03,IC50,Antiparasitic activity against Trypanosoma brucei assessed as growth inhibition,Confirmatory,23445522.0,
997,739090,1,2,,103167313,4735,Active,,,0.0035,EC50,Antitrypanosomal activity against bloodstream form Trypanosoma brucei brucei Lister 427 after 48 hrs by hemocytometer,Confirmatory,23597080.0,
998,743344,1,1,,174007138,4735,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
999,743345,1,1,,174007138,4735,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
1000,743346,1,1,,174007138,4735,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
1001,743347,1,1,,174007138,4735,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
1002,744547,1,1,,103167313,4735,Active,,,2.9,IC50,Antileishmanial activity against axenic amastigote of Leishmania donovani after 72 hrs by alamar blue assay,Confirmatory,23517732.0,
1003,744548,1,1,,103167313,4735,Active,,,3.29,IC50,Antileishmanial activity against promastigote of Leishmania donovani after 72 hrs by alamar blue assay,Confirmatory,23517732.0,
1004,747454,1,1,,103167313,4735,Active,,,5.09,IC50,Antileishmanial activity against promastigotes of Leishmania major after 72 hrs by Neubauer counting chamber-based microscopic analysis,Confirmatory,23608761.0,
1005,756883,1,2,,103167313,4735,Unspecified,,,,,"Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as host mean survival days at 5 mg/kg, ip qd for 4 days",Other,23795673.0,
1006,756886,1,2,,103167313,4735,Active,,,46.6,IC50,Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay,Confirmatory,23795673.0,
1007,756890,1,2,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Plasmodium falciparum K1",Other,23795673.0,
1008,756891,1,2,,103167313,4735,Active,,,0.046,IC50,Antiprotozoal activity against chloroquine-resistant Plasmodium falciparum K1 after 48 hrs by [3H]-hypoxanthine incorporation assay,Confirmatory,23795673.0,
1009,756894,1,2,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900",Other,23795673.0,
1010,756895,1,2,,103167313,4735,Active,,,0.003,IC50,Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB900 after 72 hrs by Alamar Blue assay,Confirmatory,23795673.0,
1011,757792,1,1,,103167313,4735,Unspecified,,,,,"Safety index, ratio of IC50 for african green monkey Vero cells to IC50 for bloodstream stage of Trypanosoma brucei brucei 93",Other,23727538.0,
1012,757795,1,1,,103167313,4735,Unspecified,,,57.0,IC50,Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTS assay,Confirmatory,23727538.0,
1013,757800,1,1,,103167313,4735,Active,,,0.005,IC50,Antitrypanosomal activity against bloodstream stage of Trypanosoma brucei brucei 93 assessed as parasite growth inhibition after 72 hrs by resazurin reduction assay,Confirmatory,23727538.0,
1014,763095,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for mouse peritoneal macrophages to IC50 for promastigote form of Leishmania amazonensis MHOM/BR/71973/M2269",Other,23623672.0,
1015,763097,1,1,,103167313,4735,Unspecified,,,,,Cytotoxicity against mouse peritoneal macrophages after 72 hrs by MTT assay,Other,23623672.0,
1016,763098,1,1,,103167313,4735,Unspecified,,,,,Leishmanicidal activity against promastigote form of Leishmania amazonensis MHOM/BR/71973/M2269 after 72 hrs by cell counting,Other,23623672.0,
1017,763920,1,1,,103167313,4735,Active,,,0.0032,IC50,Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei 90-13 assessed as parasite growth inhibition after 72 hrs by resazurin-based fluorescence assay,Confirmatory,23811085.0,
1018,763921,1,1,,103167313,4735,Active,,,0.0053,IC50,Antitrypanosomal activity against bloodstream form of Trypanosoma brucei gambiense Feo assessed as parasite growth inhibition after 72 hrs by resazurin-based fluorescence assay,Confirmatory,23811085.0,
1019,765192,1,1,,103167313,4735,Active,,,0.011000000000000001,IC50,Antitrypanosomal activity against Trypanosoma brucei gambiense Feo bloodstream form after 72 hrs by fluorescence assay,Confirmatory,23902828.0,
1020,765718,1,2,,103167313,4735,Unspecified,,,46600.0,IC50,Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay,Confirmatory,23871911.0,
1021,765719,1,2,,103167313,4735,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as mean survival days at 5 mg/kg, ip administered for 4 days",Other,23871911.0,
1022,765720,1,2,,103167313,4735,Active,,,1.84,IC50,Antileishmanial activity against amastigotes of Leishmania donovani MHOM/SD/62/IS-CL2D,Confirmatory,23871911.0,
1023,765721,1,2,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for amastigotes of Leishmania donovani",Other,23871911.0,
1024,765722,1,2,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for chloroquine-resistant Plasmodium falciparum K1",Other,23871911.0,
1025,765723,1,2,,103167313,4735,Active,,,0.0464,IC50,Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1,Confirmatory,23871911.0,
1026,765724,1,2,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900",Other,23871911.0,
1027,765725,1,2,,103167313,4735,Active,,,0.003,IC50,Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 after 72 hrs by Alamar blue assay,Confirmatory,23871911.0,
1028,768740,1,1,,103167313,4735,Active,,,26.3,CC50,Cytotoxicity against Swiss mouse peritoneal macrophages at 20 uM after 5 days by MTT assay,Confirmatory,23851117.0,
1029,768741,1,1,,103167313,4735,Active,,,,,Trypanocidal activity against Trypanosoma brucei brucei by drug incubation infectivity test,Other,23851117.0,
1030,768743,1,1,,103167313,4735,Active,,,3.1,IC50,Antileishmanial activity against promastigote forms of Leishmania donovani MHOM/ET/67/HU3 after 3 days by MTT assay,Confirmatory,23851117.0,
1031,768744,1,1,,103167313,4735,Unspecified,,,,,Cytotoxicity against macrophages (unknown origin) at 320 ug/ml,Other,23851118.0,
1032,768745,1,1,,103167313,4735,Active,,,1.76,IC50,Antileishmanial activity against Leishmania chagasi promastigotes after 24 hrs by cell counting,Confirmatory,23851118.0,
1033,768746,1,1,,103167313,4735,Active,,,1.36,IC50,Antileishmanial activity against Leishmania braziliensis promastigotes after 24 hrs by cell counting,Confirmatory,23851118.0,
1034,768747,1,1,,103167313,4735,Active,,,1.05,IC50,Antileishmanial activity against Leishmania amazonensis MHOM/BR/77/LTB0016 promastigotes after 24 hrs by cell counting,Confirmatory,23851118.0,
1035,774785,1,1,,103167313,4735,Active,,,0.03,IC50,Antiprotozoal activity against Leishmania tarentolae assessed as parasite growth inhibition,Confirmatory,23968432.0,
1036,779102,1,2,,103167313,4735,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as mouse survival at 5 mg/kg, ip administered on day 3 post infection for 4 days measured up to 60 days",Other,24012380.0,
1037,779103,1,2,,103167313,4735,Unspecified,,,,,"Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as mouse survival at 20 mg/kg, ip administered on day 3 post infection for 4 days measured up to 60 days",Other,24012380.0,
1038,779106,1,2,,103167313,4735,Active,,,2.1,IC50,Cytotoxicity against rat L6 cells assessed as cell viability after 70 hrs by Alamar blue assay,Confirmatory,24012380.0,
1039,779107,1,2,,103167313,4735,Active,,,0.0022,IC50,Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 assessed as parasite growth inhibition after 70 hrs by Alamar blue assay,Confirmatory,24012380.0,
1040,779108,1,3,,103167313,4735,Unspecified,,,,,Binding affinity to poly(dA-dT)2 DNA (unknown origin) assessed as change in melting temperature by spectrophotometric analysis,Other,24012380.0,
1041,779109,1,2,,103167313,4735,Active,,,0.0464,IC50,Antiplasmodial activity against Plasmodium falciparum K1 assessed as [3H]-hypoxanthine incorporation after 48 hrs by liquid scintillation counting analysis,Confirmatory,24012380.0,
1042,780204,1,1,,103167313,4735,Unspecified,,,20.0,IC50,Antimicrobial activity against Leishmania donovani MHOM/IN/00/DEVI amastigotes infected in mouse J774.1 cells after 120 hrs by microscopic analysis,Confirmatory,24080103.0,
1043,780205,1,1,,103167313,4735,Active,,,8.2,IC50,Antimicrobial activity against Leishmania infantum MCAN/ES/98/LLM-877 promastigotes after 72 hrs by MTT assay,Confirmatory,24080103.0,
1044,780207,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for human HepG2 cells to IC50 for Leishmania donovani MHOM/IN/00/DEVI",Other,24080103.0,
1045,780208,1,1,,103167313,4735,Active,,,2.3,CC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,24080103.0,
1046,780209,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for mouse J774.1 cells to IC50 for Leishmania donovani MHOM/IN/00/DEVI",Other,24080103.0,
1047,780210,1,2,,103167313,4735,Active,,,1.0,CC50,Cytotoxicity against mouse J774.1 cells after 72 hrs by MTT assay,Confirmatory,24080103.0,
1048,780211,1,1,,103167313,4735,Active,,,6.0,IC50,Antimicrobial activity against Leishmania donovani MHOM/IN/00/DEVI promastigotes after 72 hrs by MTT assay,Confirmatory,24080103.0,
1049,781181,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for mouse RAW264.7 cells to IC50 for Leishmania braziliensis MCAN/BR/98/R619",Other,24125880.0,
1050,781182,1,1,,103167313,4735,Active,,,25.5,CC50,Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay,Confirmatory,24125880.0,
1051,781183,1,1,,103167313,4735,Active,,,3.38,IC50,Antipromastigote activity against Leishmania amazonensis MHOM/BR/77/LTB0016 after 24 hrs by MTT assay,Confirmatory,24125880.0,
1052,781184,1,1,,103167313,4735,Active,,,13.0,IC50,Antipromastigote activity against Leishmania braziliensis MCAN/BR/98/R619 after 24 hrs by MTT assay,Confirmatory,24125880.0,
1053,940294,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020909,Other,,
1054,940295,1,3,,103167313,4735,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020909",Other,,
1055,940296,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020909,Other,,
1056,940297,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020909,Other,,
1057,940298,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020909,Other,,
1058,942318,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020909,Other,,
1059,942319,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020909,Other,,
1060,942320,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020909,Other,,
1061,942321,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020909,Other,,
1062,942322,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020909,Other,,
1063,942323,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020909,Other,,
1064,942324,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020909,Other,,
1065,942325,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020909,Other,,
1066,942326,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020909,Other,,
1067,942327,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020909,Other,,
1068,942956,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020909,Other,,
1069,942957,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020909,Other,,
1070,942958,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020909,Other,,
1071,942959,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020909,Other,,
1072,967477,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020909,Other,,
1073,967478,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020909,Other,,
1074,967479,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020909,Other,,
1075,967480,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020909,Other,,
1076,967481,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020909,Other,,
1077,967482,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020909,Other,,
1078,967483,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020909,Other,,
1079,975527,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020909,Other,,
1080,975528,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020909,Other,,
1081,975529,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020909,Other,,
1082,975530,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020909,Other,,
1083,975531,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020909,Other,,
1084,975532,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020909,Other,,
1085,975533,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020909,Other,,
1086,975534,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020909,Other,,
1087,975535,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020909,Other,,
1088,975536,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020909,Other,,
1089,975537,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020909,Other,,
1090,975538,1,3,,103167313,4735,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020909,Other,,
1091,1056390,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 to African green monkey Vero cells to IC50 for amastigote stage of Leishmania donovani MHOM/IN/80/Dd8",Other,24900613.0,
1092,1056391,1,3,,103167313,4735,Unspecified,,,85.86,CC50,Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24900613.0,
1093,1056392,1,1,,103167313,4735,Active,,,13.68,IC50,Antileishmanial activity against amastigote stage of Leishmania donovani MHOM/IN/80/Dd8 infected in mouse J-774A.1 cells after 72 hrs by luciferase reporter gene assay,Confirmatory,24900613.0,
1094,1062617,1,1,,103167313,4735,Unspecified,,,,,"Trypanocidal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB900 infected in NMRI mouse assessed as mean survival days at 5 mg/kg, ip qd administered for 4 days",Other,24268543.0,
1095,1062625,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for chloroquine/pyrimethamine-resistant Plasmodium falciparum K1 infected in human red blood cells",Other,24268543.0,
1096,1062626,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900",Other,24268543.0,
1097,1062627,1,2,,103167313,4735,Active,,,46.6,IC50,Cytotoxicity against rat L6 cells assessed as cell viability after 70 hrs by Alamar blue assay,Confirmatory,24268543.0,
1098,1062628,1,1,,103167313,4735,Active,,,0.046,IC50,Antiplasmodial activity against chloroquine/pyrimethamine-resistant Plasmodium falciparum K1 infected in human red blood cells assessed as [3H]-hypoxanthine incorporation incubated for 48 hrs prior to [3H]-hypoxanthine addition measured after 24 hrs by liquid scintillation counting analysis,Confirmatory,24268543.0,
1099,1062629,1,1,,103167313,4735,Active,,,0.003,IC50,Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 assessed as growth inhibition after 70 hrs by Alamar blue assay,Confirmatory,24268543.0,
1100,1064271,1,1,,103167313,4735,Active,,,0.0041,IC50,Antileishmanial activity against Leishmania donovani by AlamarBlue assay,Confirmatory,24387625.0,
1101,1064495,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for Trypanosoma brucei brucei GUTat 3.1",Other,24388808.0,
1102,1064496,1,2,,103167313,4735,Unspecified,,,,,Cytotoxicity against human MRC5 cells,Other,24388808.0,
1103,1064497,1,1,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma brucei brucei GUTat 3.1 after 72 hrs by AlamarBlue assay,Other,24388808.0,
1104,1067348,1,1,,103167313,4735,Active,,,14.32,IC50,Antimicrobial activity against promastigote stage of Leishmania amazonensis IFLA/BR/67/PH-8 clinical isolate after 72 hrs by Neubauer chamber analysis,Confirmatory,24529307.0,
1105,1067349,3,1,,103167313,4735,Active,,,3.815,IC50,Antimicrobial activity against Trichomonas vaginalis GT3 incubated for 48 hrs followed by compound washout measured after 48 hrs,Confirmatory,24529307.0,
1106,1067350,3,1,,103167313,4735,Active,,,4.079,IC50,Antimicrobial activity against Giardia intestinalis IMSS:0696:1 incubated for 48 hrs followed by compound washout measured after 48 hrs,Confirmatory,24529307.0,
1107,1067357,1,2,,103167313,4735,Active,,,47.0,CC50,Cytotoxicity against African green monkey Vero cells assessed as cell viability after 48 hrs by SRB assay,Confirmatory,24529307.0,
1108,1067358,1,1,,103167313,4735,Unspecified,,,50.0,IC50,Antimicrobial activity against epimastigote stage of Trypanosoma cruzi MHOM/MX/1994/Ninoa clinical isolate after 72 hrs by Neubauer chamber analysis,Confirmatory,24529307.0,
1109,1067819,1,1,,103167313,4735,Active,,,1.74,EC50,Antiparasitic activity against Trypanosoma brucei brucei BF427 assessed as growth inhibition by Alamar Blue assay,Confirmatory,24354316.0,
1110,1076004,1,1,,103167313,4735,Active,,,16.15,IC50,Antileishmanial activity against Leishmania donovani NHOM/IN/80/DD8 promastigotes assessed as decrease in parasite growth after 72 hrs by MTT assay,Confirmatory,24513045.0,
1111,1077477,1,2,,103167313,4735,Active,,,0.011000000000000001,IC50,Antiparasitic activity against bloodstream forms of Trypanosoma brucei brucei 93 after 72 hrs by resazurin assay,Confirmatory,,
1112,1077515,1,2,,103167313,4735,Active,,,,IC50,Antileishmanial activity against Leishmania donovani promastigotes after 48 hrs by Alamar Blue assay,Confirmatory,,
1113,1077516,1,2,,103167313,4735,Inconclusive,,,,,"Selectivity index, ratio of IC50 for pig LLC-PK1 cells to IC50 for Plasmodium falciparum W2",Other,,
1114,1077517,1,2,,103167313,4735,Inconclusive,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for Plasmodium falciparum W2",Other,,
1115,1077518,1,2,,103167313,4735,Inconclusive,,,,,"Selectivity index, ratio of IC50 for human HepG2 cells to IC50 for Plasmodium falciparum W2",Other,,
1116,1077519,1,2,,103167313,4735,Inconclusive,,,,,"Selectivity index, ratio of IC50 for pig LLC-PK1 cells to IC50 for Plasmodium falciparum D6",Other,,
1117,1077520,1,2,,103167313,4735,Inconclusive,,,,,"Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for Plasmodium falciparum D6",Other,,
1118,1077521,1,2,,103167313,4735,Inconclusive,,,,,"Selectivity index, ratio of IC50 for human HepG2 cells to IC50 for Plasmodium falciparum D6",Other,,
1119,1077522,1,2,,103167313,4735,Inconclusive,,,,IC50,Cytotoxicity against a pig LLC-PK1 cells after 48 hrs by Neutral Red assay,Confirmatory,,
1120,1077523,1,2,,103167313,4735,Inconclusive,,,,IC50,Cytotoxicity against african green monkey Vero cells after 48 hrs by Neutral Red assay,Confirmatory,,
1121,1077524,1,2,,103167313,4735,Inconclusive,,,,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by Neutral Red assay,Confirmatory,,
1122,1077525,1,2,,103167313,4735,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum W2 after 72 hrs by LDH activity assay,Confirmatory,,
1123,1077526,1,2,,103167313,4735,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum D6 after 72 hrs by LDH activity assay,Confirmatory,,
1124,1079931,1,1,,103167313,4735,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
1125,1079932,1,1,,103167313,4735,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
1126,1079933,1,1,,103167313,4735,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
1127,1079934,1,1,,103167313,4735,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
1128,1079935,1,1,,103167313,4735,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
1129,1079936,1,1,,103167313,4735,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
1130,1079937,1,1,,103167313,4735,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
1131,1079938,1,1,,103167313,4735,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
1132,1079939,1,1,,103167313,4735,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
1133,1079940,1,1,,103167313,4735,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
1134,1079941,1,1,,103167313,4735,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
1135,1079942,1,1,,103167313,4735,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
1136,1079943,1,1,,103167313,4735,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
1137,1079944,1,1,,103167313,4735,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
1138,1079945,1,1,,103167313,4735,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
1139,1079946,1,1,,103167313,4735,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
1140,1079947,1,1,,103167313,4735,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
1141,1079948,1,1,,103167313,4735,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
1142,1079949,1,1,,103167313,4735,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
1143,1085761,1,2,,103167313,4735,Inconclusive,,,,,Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 48 hr by neutral red assay,Other,23024574.0,
1144,1085762,1,1,,103167313,4735,Inconclusive,,,,,Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 after 72 hr by plasmodial LDH assay,Other,23024574.0,
1145,1085763,1,1,,103167313,4735,Inconclusive,,,,,Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 after 72 hr by plasmodial LDH assay,Other,23024574.0,
1146,1085764,1,1,,103167313,4735,Unspecified,,,,,Antileishmanial activity against promastigote form of Leishmania donovani after 48 hr by alamar blue assay,Other,23024574.0,
1147,1093457,1,2,,103167313,4735,Active,,,5.0,EC50,Antileishmanial activity against Leishmania donovani promastigotes after 72 hr by alamar blue assay,Confirmatory,,
1148,1093477,1,2,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of GI50 for human tumor cells to IC50 for Pneumocystis carini",Other,,
1149,1093483,2,1,,103167313,4735,Unspecified,,,,,Binding affinity to Poly (dA-dT) DNA at 1:5 compound to DNA base pair ratio,Other,,
1150,1093488,1,2,,103167313,4735,Active,,,0.5,IC50,Antimicrobial activity against Pneumocystis carinii assessed as ATP level detection by bioluminescence assay,Confirmatory,,
1151,1093490,2,1,,103167313,4735,Unspecified,,,,,Binding affinity to Bos taurus (calf) thymus DNA at 1:5 compound to DNA base pair ratio,Other,,
1152,1093663,1,2,,103167313,4735,Active,,,1.35,EC50,Antileishmanial activity against Leishmania donovani promastigotes after 72 hr by alamar blue assay,Confirmatory,,
1153,1096778,1,2,,103167313,4735,Unspecified,,,,,Antiparasitic activity against Leishmania amazonensis MHOM/BR /77/LTB0016 promastigote at 16.8 uM,Other,,
1154,1096779,1,2,,103167313,4735,Active,,,0.46,EC50,Antiparasitic activity against Leishmania amazonensis MHOM/BR /77/LTB0016 after 24 hr,Confirmatory,,
1155,1106988,1,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against promastigote form of Leishmania donovani after 48 hrs by Alamar Blue assay,Other,,
1156,1115388,1,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against amastigote form of Leishmania donovani MHOH/IN/1983/AG83 infected BALB/c mouse peritoneal macrophages after 48 hr by Geimsa staining method,Other,,
1157,1115389,1,2,,103167313,4735,Unspecified,,,,,Antileishmanial activity against promastigote form of Leishmania donovani MHOH/IN/1983/AG83 after 2 hr by MTT assay,Other,,
1158,1115392,3,1,,103167313,4735,Unspecified,,,,,Toxicity against BALB/c Mus musculus (mouse) peritoneal macrophages assessed as concentration required for cell lysis after 48 hr,Other,,
1159,1118189,1,1,,103167313,4735,Unspecified,,,,,Antileishmanial activity against Leishmania donovani promastigotes by Alamar Blue assay,Other,,
1160,1120594,1,1,,103167313,4735,Inconclusive,,,,IC50,Antifungal activity against Candida glabrata ATCC 90030 assessed as growth inhibition after 46 to 50 hrs by modified CLSI method,Confirmatory,,
1161,1120595,1,1,,103167313,4735,Inconclusive,,,,IC50,Antifungal activity against Candida krusei ATCC 6258 assessed as growth inhibition after 46 to 50 hrs by modified CLSI method,Confirmatory,,
1162,1120596,1,1,,103167313,4735,Inconclusive,,,,IC50,Antifungal activity against Cryptococcus neoformans ATCC 90113 assessed as growth inhibition after 70 to 74 hrs by modified CLSI method,Confirmatory,,
1163,1120597,1,1,,103167313,4735,Active,,,,IC50,Antiparasitic activity against Leishmania donovani S1 promastigotes assessed as growth inhibition after 72 hrs by alamar blue assay,Confirmatory,,
1164,1120598,1,1,,103167313,4735,Inconclusive,,,,TC50,Cytotoxicity against African green monkey Vero cells by neutral red assay,Confirmatory,,
1165,1120599,1,1,,103167313,4735,Inactive,,,,,Antifungal activity against Candida albicans ATCC 90028 assessed as growth inhibition after 46 to 50 hrs by modified CLSI method,Other,,
1166,1120893,1,1,,103167313,4735,Active,,,0.011000000000000001,IC50,Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei strain 93 assessed as parasite growth inhibition after 72 hrs by redox-sensitive dye (resazurin) fluorescence assay,Confirmatory,,
1167,1124783,1,1,,103167313,4735,Unspecified,,,159.71,IC50,Cytotoxicity against human HepG2 cells by MTT assay,Confirmatory,24630563.0,
1168,1124784,1,1,,103167313,4735,Active,,,6.43,IC50,Antimicrobial activity against procyclic stage of Trypanosoma brucei 427 after 24 hrs by MTT assay,Confirmatory,24630563.0,
1169,1124785,1,1,,103167313,4735,Unspecified,,,,,"Safety index, ratio of IC50 for human HepG2 cells to IC50 for procyclic stage of Trypanosoma brucei 427",Other,24630563.0,
1170,1124786,1,1,,103167313,4735,Active,,,6.43,IC50,Antimicrobial activity against epimastigote stage of Trypanosoma brucei 29-13 after 24 hrs by MTT assay,Confirmatory,24630563.0,
1171,1124787,1,1,,103167313,4735,Unspecified,,,,,"Safety index, ratio of IC50 for human HepG2 cells to IC50 for epimastigote stage of Trypanosoma brucei 29-13",Other,24630563.0,
1172,1124788,1,1,,103167313,4735,Active,,,4.58,IC50,Antimicrobial activity against epimastigote stage of Trypanosoma cruzi Y after 72 hrs by MTT assay,Confirmatory,24630563.0,
1173,1124789,1,1,,103167313,4735,Unspecified,,,,,"Safety index, ratio of IC50 for human HepG2 cells to IC50 for epimastigote stage of Trypanosoma cruzi Y",Other,24630563.0,
1174,1124803,1,3,,103167313,4735,Active,548377.0,2902.0,0.72,IC50,Antagonist activity at NR1/NR2A receptor (unknown origin) expressed in Xenopus laevis oocytes assessed as inhibition of glutamate/glycine-induced current at pH 7.6 at -40mV holding potential by two-electrode voltage-clamp electrophysiology,Confirmatory,24630693.0,
1175,1124803,1,3,,103167313,4735,Active,14285603.0,2903.0,0.72,IC50,Antagonist activity at NR1/NR2A receptor (unknown origin) expressed in Xenopus laevis oocytes assessed as inhibition of glutamate/glycine-induced current at pH 7.6 at -40mV holding potential by two-electrode voltage-clamp electrophysiology,Confirmatory,24630693.0,
1176,1124807,1,1,,103167313,4735,Active,,,38.0,IC50,Inhibition of mouse hippocampal neurons ASIC transfected in CHO cells assessed as inhibition of acid-evoked current at -60 mV holding potential by two-electrode voltage-clamp electrophysiology assay,Confirmatory,24630693.0,
1177,1124808,1,3,,103167313,4735,Unspecified,81892078.0,11419.0,,,Inhibition of mouse hippocampal neurons ASIC1a transfected in CHO cells assessed as reduction of acid-evoked current at 3 uM at -60 mV holding potential by two-electrode voltage-clamp electrophysiology assay,Other,24630693.0,
1178,1124809,1,3,,103167313,4735,Unspecified,81892078.0,11419.0,,,Inhibition of mouse hippocampal neurons ASIC1b transfected in CHO cells assessed as reduction of acid-evoked current at 3 uM at -60 mV holding potential by two-electrode voltage-clamp electrophysiology assay,Other,24630693.0,
1179,1124810,1,3,,103167313,4735,Unspecified,48428127.0,11418.0,,,Inhibition of mouse hippocampal neurons ASIC2a transfected in CHO cells assessed as reduction of acid-evoked current at 3 uM at -60 mV holding potential by two-electrode voltage-clamp electrophysiology assay,Other,24630693.0,
1180,1124811,1,3,,103167313,4735,Unspecified,82582993.0,171209.0,,,Inhibition of mouse hippocampal neurons ASIC3 transfected in CHO cells assessed as reduction of acid-evoked current at 3 uM at -60 mV holding potential by two-electrode voltage-clamp electrophysiology assay,Other,24630693.0,
1181,1124812,1,1,,103167313,4735,Unspecified,,,,,Inhibition of human KIR2.X channel assessed as remaining inward current at 0.2 uM,Other,24630693.0,
1182,1124813,1,1,,103167313,4735,Unspecified,,,,,Inhibition of human KIR2.X channel assessed as remaining outward current at 0.2 uM,Other,24630693.0,
1183,1124814,1,3,,103167313,4735,Active,251757489.0,26.0,0.29,Ki,Mixed type inhibition of recombinant human DAO expressed in drosophila S2 cells,Confirmatory,24630693.0,
1184,1124815,1,1,,103167313,4735,Active,,,7.6,Ki,Inhibition of mouse polyamine oxidase assessed as conversion of N-acetylspermine to N-acetylspermidine,Confirmatory,24630693.0,
1185,1124816,1,3,,103167313,4735,Active,114322.0,6303.0,2.0,Ki,Inhibition of human SSAT using spermidine as substrate,Confirmatory,24630693.0,
1186,1124817,1,1,,103167313,4735,Unspecified,,,1000.0,IC50,Binding affinity to r(CUG)6 (unknown origin) assessed as inhibition of RNA-MBNL1 interaction by quantitative TR-FRET assay,Confirmatory,24630693.0,
1187,1124818,1,3,,103167313,4735,Unspecified,46577705.0,9971.0,,,Activation of FXR (unknown origin) at 10 uM,Other,24630693.0,
1188,1124819,1,1,,103167313,4735,Active,,,1.2,IC50,Antiproliferative activity against human C8146A cells assessed as growth inhibition,Confirmatory,24630693.0,
1189,1133059,1,3,,103167313,4735,Active,97535584.0,397098.0,2.3,Ki,Reversible competitive inhibition of boar spermatozoa acrosin using BzArgOEt as substrate by Dixon plot analysis,Confirmatory,722718.0,
1190,1136520,1,1,,103167313,4735,Active,,,,,Antitrypanosomal activity against Trypanosoma rhodesiense CT infected in ICR/HA Swiss mouse assessed as 30-day increase in survival time at 5 mg/kg relative to control,Other,321783.0,
1191,1136521,1,1,,103167313,4735,Active,,,,,Antitrypanosomal activity against Trypanosoma rhodesiense CT infected in ICR/HA Swiss mouse assessed as 30-day increase in survival time at 10 mg/kg relative to control,Other,321783.0,
1192,1136522,1,1,,103167313,4735,Active,,,,,Antitrypanosomal activity against Trypanosoma rhodesiense CT infected in ICR/HA Swiss mouse assessed as 30-day increase in survival time at 20 mg/kg relative to control,Other,321783.0,
1193,1136523,1,1,,103167313,4735,Active,,,,,Antitrypanosomal activity against Trypanosoma rhodesiense CT infected in ICR/HA Swiss mouse assessed as 30-day increase in survival time at 40 mg/kg relative to control,Other,321783.0,
1194,1136524,1,1,,103167313,4735,Active,,,,,Antitrypanosomal activity against Trypanosoma rhodesiense CT infected in ICR/HA Swiss mouse assessed as 30-day increase in survival time at 80 mg/kg relative to control,Other,321783.0,
1195,1136525,1,1,,103167313,4735,Active,,,,,Antitrypanosomal activity against Trypanosoma rhodesiense CT infected in ICR/HA Swiss mouse assessed as 30-day increase in survival time at 160 mg/kg relative to control,Other,321783.0,
1196,1136526,1,1,,103167313,4735,Active,,,,,Antitrypanosomal activity against Trypanosoma rhodesiense CT infected in ICR/HA Swiss mouse assessed as 30-day increase in survival time at 320 mg/kg relative to control,Other,321783.0,
1197,1136527,1,1,,103167313,4735,Active,,,,,Antitrypanosomal activity against Trypanosoma rhodesiense CT infected in ICR/HA Swiss mouse assessed as 30-day increase in survival time at 640 mg/kg relative to control,Other,321783.0,
1198,1143363,3,1,,103167313,4735,Active,,,0.026000000000000002,IC50,Antitrypanosomal activity against Trypanosoma brucei brucei 427 after 72 hrs by alamar blue assay,Confirmatory,24826816.0,
1199,1143799,1,1,,103167313,4735,Active,,,4.3,IC50,Antimicrobial activity against Leishmania major MHOM/IL/81/BNI promastigotes after 96 hrs by resazurin-based assay,Confirmatory,24858543.0,
1200,1143800,1,1,,103167313,4735,Active,,,2.4,IC50,Antimicrobial activity against Leishmania mexicana MHOM/MX/95/NAN1 promastigotes after 96 hrs by resazurin-based assay,Confirmatory,24858543.0,
1201,1143801,1,1,,103167313,4735,Active,,,5.5,IC50,Antimicrobial activity against Leishmania donovani MHOM/IN/00/DEVI promastigotes after 72 hrs by MTT assay,Confirmatory,24858543.0,
1202,1143802,1,1,,103167313,4735,Active,,,0.56,CC50,Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay,Confirmatory,24858543.0,
1203,1143803,1,1,,103167313,4735,Active,,,2.3,CC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,24858543.0,
1204,1143804,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for human HepG2 cells to IC50 for Leishmania major MHOM/IL/81/BNI promastigotes",Other,24858543.0,
1205,1143805,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for human HepG2 cells to IC50 for Leishmania mexicana MHOM/MX/95/NAN1 promastigotes",Other,24858543.0,
1206,1143806,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for human HepG2 cells to IC50 for Leishmania donovani MHOM/IN/00/DEVI promastigotes",Other,24858543.0,
1207,1143807,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for mouse J774A1 cells to IC50 for Leishmania major MHOM/IL/81/BNI promastigotes",Other,24858543.0,
1208,1143808,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for mouse J774A1 cells to IC50 for Leishmania mexicana MHOM/MX/95/NAN1 promastigotes",Other,24858543.0,
1209,1143809,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for mouse J774A1 cells to IC50 for Leishmania donovani MHOM/IN/00/DEVI promastigotes",Other,24858543.0,
1210,1143811,1,1,,103167313,4735,Active,,,0.05,IC50,Antimicrobial activity against Trypanosoma brucei brucei Antat 1.1 after 24 hrs by haemocytometric analysis,Confirmatory,24858543.0,
1211,1143812,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for human HepG2 cells to IC50 for Trypanosoma brucei brucei Antat 1.1",Other,24858543.0,
1212,1146852,1,1,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma rhodesiense infected in mouse assessed as increase in survival time by 30 days at 2.5 mg/kg relative to control,Other,336890.0,
1213,1146854,1,1,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma rhodesiense infected in mouse assessed as increase in survival time by 30 days at 5 mg/kg relative to control,Other,336890.0,
1214,1146855,1,1,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma rhodesiense infected in mouse assessed as increase in survival time by 30 days at 10 mg/kg relative to control,Other,336890.0,
1215,1146856,1,1,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma rhodesiense infected in mouse assessed as increase in survival time by 30 days at 20 mg/kg relative to control,Other,336890.0,
1216,1146857,1,1,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma rhodesiense infected in mouse assessed as increase in survival time by 30 days at 40 mg/kg relative to control,Other,336890.0,
1217,1146858,1,1,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma rhodesiense infected in mouse assessed as increase in survival time by 30 days at 80 mg/kg relative to control,Other,336890.0,
1218,1146859,1,1,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma rhodesiense infected in mouse assessed as increase in survival time by 30 days at 160 mg/kg relative to control,Other,336890.0,
1219,1146860,1,1,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma rhodesiense infected in mouse assessed as increase in survival time by 30 days at 320 mg/kg relative to control,Other,336890.0,
1220,1146861,1,1,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma rhodesiense infected in mouse assessed as increase in survival time by 30 days at 640 mg/kg relative to control,Other,336890.0,
1221,1156603,1,1,,103167313,4735,Active,,,46.6,IC50,Cytotoxicity against rat L6 cells after 3 days by Alamar blue assay,Confirmatory,24956553.0,
1222,1156604,1,1,,103167313,4735,Active,,,7.1,IC50,Antiparasitic activity against Trypanosoma cruzi Tulahen LacZ/C4 amastigotes after 4 days by beta-galactosidase reporter gene assay,Confirmatory,24956553.0,
1223,1156605,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma cruzi Tulahen LacZ/C4 amastigotes",Other,24956553.0,
1224,1156606,1,1,,103167313,4735,Active,,,0.83,IC50,Antiparasitic activity against Leishmania amazonensis infected in CD-1 mouse macrophages after 72 hrs by spectrophotometric analysis,Confirmatory,24956553.0,
1225,1156607,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Leishmania amazonensis",Other,24956553.0,
1226,1156608,1,1,,103167313,4735,Active,,,0.0023,IC50,Antiparasitic activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes after 3 days by Alamar blue assay,Confirmatory,24956553.0,
1227,1156609,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900 trypomastigotes",Other,24956553.0,
1228,1156610,1,1,,103167313,4735,Active,,,0.0464,IC50,Antiparasitic activity against chloroquine-resistant Plasmodium falciparum K1 after 3 days by [3H]-hypoxanthine incorporation assay,Confirmatory,24956553.0,
1229,1156611,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of IC50 for rat L6 cells to IC50 for chloroquine-resistant Plasmodium falciparum K1",Other,24956553.0,
1230,1159580,2,1,,268736525,4735,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1231,1159607,2,1,,312596434,4735,Active,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1232,1159620,1,1,,103167313,4735,Active,,,,,Summary of drug indications.,Other,,
1233,1165104,1,1,,103167313,4735,Unspecified,,,,,Antileishmanial activity against promastigote stage of Leishmania donovani after 72 hrs by Alamar blue assay,Other,25240614.0,
1234,1165105,1,1,,103167313,4735,Unspecified,,,,,Antileishmanial activity against axenic amastigote stage of Leishmania donovani after 72 hrs by Alamar blue assay,Other,25240614.0,
1235,1165109,1,1,,103167313,4735,Unspecified,,,,,Antileishmanial activity against amastigote stage of Leishmania donovani infected in human THP1 cells after 48 hrs by Alamar blue assay,Other,25240614.0,
1236,1165110,1,2,,103167313,4735,Unspecified,,,,,Cytotoxicity against human THP1 cells after 48 hrs by Alamar blue assay,Other,25240614.0,
1237,1167368,1,1,,103167313,4735,Unspecified,,,,,Antileishmanial activity against axenically cultured Leishmania infantum chagasi MHOM/BR/00/1669 promastigotes infected in mouse RAW264.7 cells assessed as inhibition of parasite growth after 48 hrs,Other,25281268.0,
1238,1167369,1,1,,103167313,4735,Inconclusive,,,,,Antileishmanial activity against intracellular Leishmania infantum chagasi MHOM/BR/00/1669 amastigotes infected in mouse RAW264.7 cells assessed as inhibition of parasite growth after 48 hrs,Other,25281268.0,
1239,1167370,1,1,,103167313,4735,Unspecified,,,,,Cytotoxicity against mouse RAW264.7 cells assessed as cell survival at 100 ug/ml after 48 hrs by MTT assay,Other,25281268.0,
1240,1167551,1,1,,103167313,4735,Active,,,5.52,IC50,Antileishmanial activity Leishmania donovani MHOM/IN/00/DEVI promastigotes incubated for 72 hrs by MTT assay,Confirmatory,25282267.0,
1241,1167552,1,1,,103167313,4735,Active,,,0.56,CC50,Cytotoxicity against mouse J774A1 cells incubated for 72 hrs by MTT assay,Confirmatory,25282267.0,
1242,1167553,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for mouse J774A1 cells to IC50 for Leishmania donovani MHOM/IN/00/DEVI promastigotes",Other,25282267.0,
1243,1176207,1,1,,103167313,4735,Active,,,0.011000000000000001,IC50,Antikinetoplastid activity against Trypanosoma brucei gambiense assessed as parasite growth inhibition,Confirmatory,25499437.0,
1244,1176208,1,1,,103167313,4735,Active,,,4.21,IC50,Antikinetoplastid activity against Leishmania donovani LV9 axenic amastigotes in mouse RAW264.7 cells assessed as viability measured 24 hrs by SYBR green assay,Confirmatory,25499437.0,
1245,1181619,1,1,,103167313,4735,Unspecified,,,,,Trypanocidal activity against Trypanosoma brucei brucei after 24 hrs by hemocytometry relative to control,Other,24978605.0,
1246,1181620,1,1,,103167313,4735,Unspecified,,,,,Trypanocidal activity against Trypanosoma brucei brucei after 48 hrs by hemocytometry relative to control,Other,24978605.0,
1247,1181621,1,1,,103167313,4735,Unspecified,,,,,Trypanocidal activity against Trypanosoma brucei brucei after 72 hrs by hemocytometry relative to control,Other,24978605.0,
1248,1181720,1,1,,103167313,4735,Active,,,,IC50,Antimicrobial activity against promastigote stage of Leishmania donovani after 72 hrs by Alamar Blue assay,Confirmatory,24980054.0,
1249,1181721,1,1,,103167313,4735,Unspecified,,,,IC50,Antimicrobial activity against axenic amastigote stage of Leishmania donovani after 72 hrs by Alamar Blue assay,Confirmatory,24980054.0,
1250,1181722,1,1,,103167313,4735,Active,,,,IC50,Antimicrobial activity against promastigote stage of Leishmania donovani infected in human THP1 cells after 72 hrs by Alamar Blue assay,Confirmatory,24980054.0,
1251,1181723,1,1,,103167313,4735,Active,,,,IC50,Antimicrobial activity against trypamastigote stage of Trypanosoma brucei after 72 hrs by Alamar Blue assay,Confirmatory,24980054.0,
1252,1185950,1,1,,103167313,4735,Active,,,7.02,IC50,Antileishmanial activity against Leishmania major JISH118 promastigotes infected in human THP1 cells by Giemsa staining method,Confirmatory,25069019.0,
1253,1186380,1,1,,103167313,4735,Active,,,,IC50,Antileishmanial activity against promastigote forms of Leishmania donovani by alamar blue assay,Confirmatory,25084548.0,
1254,1189129,1,1,,103167313,4735,Active,,,4.44,IC50,"DNDI: Chagas in Vitro, 96 hour",Confirmatory,,
1255,1189130,1,1,,103167313,4735,Active,,,8.87,IC50,"DNDI: Cytotoxicity in Vitro, 72 hour, in rat skeletal myoblast cells",Confirmatory,,
1256,1189131,1,1,,103167313,4735,Unspecified,,,29.37,IC50,"DNDI: Cytotoxicity in Vitro, 96 hour, in mouse macrophages (infected-amastigotes)",Confirmatory,,
1257,1189132,1,1,,103167313,4735,Active,,,7.78,IC50,"DNDI: Cytotoxicity in Vitro, 96 hour, in primary peritoneal mouse macrophages",Confirmatory,,
1258,1189133,1,1,,103167313,4735,Active,,,0.01,IC50,"DNDI: HAT in Vitro, 72 hour",Confirmatory,,
1259,1189134,1,1,,103167313,4735,Active,,,19.77,IC50,"DNDI: Leish (axenic) in Vitro, 72 hour",Confirmatory,,
1260,1189135,1,1,,103167313,4735,Active,,,2.63,IC50,"DNDI: Leish (macro) in Vitro, 96 hour",Confirmatory,,
1261,1194918,1,1,,103167313,4735,Active,,,6.0,IC50,Antileishmanial activity against promastigote stage of Leishmania donovani MHOM/IN/00/DEVI assessed as inhibition of metabolic activity after 72 hrs by MTT assay,Confirmatory,25846065.0,
1262,1194919,1,1,,103167313,4735,Active,,,2.3,CC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,25846065.0,
1263,1194920,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, CC50 for human HepG2 cells to IC50 for promastigote stage of Leishmania donovani MHOM/IN/00/DEVI",Other,25846065.0,
1264,1194921,1,1,,103167313,4735,Unspecified,,,20.0,IC50,Antileishmanial activity against intracellular amastigote stage of Leishmania donovani MHOM/IN/00/DEVI infected in human THP1 cells assessed as decrease infected macrophages after 120 hrs by microscopy,Confirmatory,25846065.0,
1265,1194922,1,1,,103167313,4735,Unspecified,,,20.0,IC50,Antileishmanial activity against intracellular amastigote stage of Leishmania infantum MHOM/MA/67/ITMAP-263 expressing luciferase infected in mouse J774A1 cells assessed as inhibition of metabolic activity after 120 hrs by luminescence assay,Confirmatory,25846065.0,
1266,1194923,1,1,,103167313,4735,Active,,,1.0,IC50,Cytotoxicity against mouse J774A.1 cells after 72 hrs by MTT assay,Confirmatory,25846065.0,
1267,1194924,1,2,,103167313,4735,Active,,,31.2,IC50,Cytotoxicity against human THP1 cells after 72 hrs by MTT assay,Confirmatory,25846065.0,
1268,1196492,1,1,,103167313,4735,Active,,,6.0,IC50,Antileishmanial activity against Leishmania donovani MHOM/IN/00/DEVI promastigotes assessed as reduction in parasite growth incubated for 72 hrs by MTT assay,Confirmatory,25559208.0,
1269,1196493,1,1,,103167313,4735,Active,,,2.3,CC50,Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay,Confirmatory,25559208.0,
1270,1196494,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for human HepG2 cells to IC50 for Leishmania donovani MHOM/IN/00/DEVI promastigotes",Other,25559208.0,
1271,1196495,1,1,,103167313,4735,Unspecified,,,20.0,IC50,Antileishmanial activity against Leishmania donovani MHOM/IN/00/DEVI intracellular amastigotes infected in human THP1 cells assessed as reduction in parasite-infected macrophages incubated for 120 hrs by Giemsa staining based microscopy,Confirmatory,25559208.0,
1272,1196496,1,2,,103167313,4735,Active,,,31.2,CC50,Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay,Confirmatory,25559208.0,
1273,1196716,1,1,,103167313,4735,Unspecified,,,400.0,IC50,Inhibition of Escherichia coli UPPS using FPP/IPP as substrate by spectrophotometry,Confirmatory,25574764.0,
1274,1196717,1,1,,103167313,4735,Unspecified,,,240.0,IC50,Inhibition of Staphylococcus aureus UPPS using FPP/IPP as substrate by spectrophotometry,Confirmatory,25574764.0,
1275,1196718,1,1,,103167313,4735,Active,,,12.0,EC50,Antimicrobial activity against Escherichia coli K-12 after 3 hrs by broth microdilution method,Confirmatory,25574764.0,
1276,1196719,1,1,,103167313,4735,Active,,,4.2,EC50,Antimicrobial activity against Staphylococcus aureus Newman after 9 hrs by spectrophotometry,Confirmatory,25574764.0,
1277,1196720,1,2,,103167313,4735,Unspecified,,,,,Binding affinity to DNA dodecamer complex (CGCGAATTCGCG)2 (unknown origin) assessed as change in melting temperature by differential scanning calorimetry,Other,25574764.0,
1278,1198230,1,1,,103167313,4735,Active,,,0.006999999999999999,IC50,Antitrypanosomal activity against Trypanosoma brucei gambiense Feo assessed as parasite growth inhibition after 72 hrs by fluorescence assay,Confirmatory,25659770.0,
1279,1202923,1,1,,103167313,4735,Active,,,0.01,EC50,Antitrypanosomal activity against wild type Trypanosoma brucei brucei s427 trypomastigotes assessed as cell viability after 48 hrs by alamar blue assay,Confirmatory,25699142.0,
1280,1202924,1,1,,103167313,4735,Active,,,0.006,EC50,Antitrypanosomal activity against AT1 knock out Trypanosoma brucei brucei assessed as cell viability after 48 hrs by alamar blue assay,Confirmatory,25699142.0,
1281,1202925,1,1,,103167313,4735,Unspecified,,,,,"Resistance factor, ratio of EC50 for AT1 knock out Trypanosoma brucei brucei to EC50 for wild type Trypanosoma brucei brucei s427 trypomastigotes",Other,25699142.0,
1282,1202926,1,1,,103167313,4735,Active,,,0.32899999999999996,EC50,Antitrypanosomal activity against Trypanosoma brucei brucei B48 with nonfunctional high affinity pentamidine transporter assessed as cell viability after 48 hrs by alamar blue assay,Confirmatory,25699142.0,
1283,1202927,1,1,,103167313,4735,Unspecified,,,,,"Resistance factor, ratio of EC50 for Trypanosoma brucei brucei B48 to EC50 for wild type Trypanosoma brucei brucei s427 trypomastigotes",Other,25699142.0,
1284,1224824,1,1,,174007138,4735,Inactive,,,18.6548,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
1285,1224825,1,1,,174007138,4735,Inactive,,,16.6261,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
1286,1224857,2,1,,174007138,4735,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1287,1224859,2,1,,174007138,4735,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1288,1224863,1,1,,176484210,4735,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1289,1224863,1,1,,316919732,4735,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1290,1224905,2,1,,92308870,4735,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1291,1224905,2,1,,92308870,4735,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1292,1236469,1,1,,103167313,4735,Active,,,,,Trypanocidal activity against Trypanosoma brucei brucei assessed as killing of parasite densities of 10'4 to 10'6 cells/ml at 2.2 uM by clonal dilution method,Other,25637120.0,
1293,1236473,1,1,,103167313,4735,Active,,,,,Cmax in human,Other,25637120.0,
1294,1236474,1,1,,103167313,4735,Unspecified,,,,,Half-life in human,Other,25637120.0,
1295,1237962,1,1,,103167313,4735,Active,,,0.0049,IC50,Antitrypanosomal activity against Trypanosoma brucei gambiense FeoITMAP/1893 assessed as inhibition of parasite growth after 72 hrs by resazurin dye based microplate reader analysis,Confirmatory,25835356.0,
1296,1238019,1,1,,103167313,4735,Active,,,10.19,EC50,Anti-leishmanial activity against Leishmania amazonensis MPRO/BR/1972/M1841-LV-79 promastigotes assessed as parasite growth inhibition incubated for 72 hrs by MTT assay,Confirmatory,26055530.0,
1297,1238020,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of EC50 for BALB/c mouse peritoneal macrophages to EC50 for Leishmania amazonensis MPRO/BR/1972/M1841-LV-79 promastigotes",Other,26055530.0,
1298,1238021,1,1,,103167313,4735,Active,,,6.25,EC50,Anti-leishmanial activity against Leishmania amazonensis MPRO/BR/1972/M1841-LV-79 amastigotes infected in BALB/c mouse peritoneal macrophages assessed as reduction in the infection index incubated for 24 hrs by Giemsa staining method,Confirmatory,26055530.0,
1299,1238022,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of EC50 for BALB/c mouse peritoneal macrophages to EC50 for Leishmania amazonensis MPRO/BR/1972/M1841-LV-79 amastigotes",Other,26055530.0,
1300,1238023,1,1,,103167313,4735,Unspecified,,,67.71,EC50,Anti-leishmanial activity against Leishmania infantum MHOM/BR/72 promastigotes assessed as parasite growth inhibition incubated for 72 hrs by MTT assay,Confirmatory,26055530.0,
1301,1238024,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of EC50 for BALB/c mouse peritoneal macrophages to EC50 for Leishmania infantum MHOM/BR/72 promastigotes",Other,26055530.0,
1302,1238025,1,1,,103167313,4735,Active,,,19.77,EC50,Anti-leishmanial activity against Leishmania infantum MHOM/BR/72 amastigotes infected in BALB/c mouse peritoneal macrophages assessed as reduction in the infection index incubated for 24 hrs by Giemsa staining method,Confirmatory,26055530.0,
1303,1238026,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of EC50 for BALB/c mouse peritoneal macrophages to EC50 for Leishmania infantum MHOM/BR/72 amastigotes",Other,26055530.0,
1304,1238027,1,1,,103167313,4735,Inconclusive,,,,EC50,Anti-trypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as parasite growth inhibition incubated for 72 hrs by MTT assay,Confirmatory,26055530.0,
1305,1238028,1,1,,103167313,4735,Inconclusive,,,,,"Selectivity index, ratio of EC50 for BALB/c mouse peritoneal macrophages to EC50 for Trypanosoma cruzi Y epimastigotes",Other,26055530.0,
1306,1238029,1,1,,103167313,4735,Active,,,35.69,EC50,Cytotoxicity against BALB/c mouse peritoneal macrophages incubated for 24 hrs by MTT assay,Confirmatory,26055530.0,
1307,1238920,1,1,,103167313,4735,Unspecified,,,,,Antifungal activity against Candida albicans WTBF-50 by microbroth dilution method,Other,26209266.0,
1308,1238921,1,1,,103167313,4735,Unspecified,,,,,Antifungal activity against Candida krusei WTBF-51 by microbroth dilution method,Other,26209266.0,
1309,1238922,1,1,,103167313,4735,Unspecified,,,,,Antifungal activity against Candida glabrata ATCC 90030 WTBF-86 by microbroth dilution method,Other,26209266.0,
1310,1238923,1,1,,103167313,4735,Unspecified,,,,,Antifungal activity against Candida parapsilosis ATCC 90018 WTBF-88 by microbroth dilution method,Other,26209266.0,
1311,1238924,1,1,,103167313,4735,Unspecified,,,,,Antifungal activity against Cryptococcus neoformans Cn18 (Serotype C) WTBF-106 by microbroth dilution method,Other,26209266.0,
1312,1238929,1,1,,103167313,4735,Unspecified,,,,,Fungicidal activity against Candida albicans WTBF-50 assessed as inhibition of DNA and RNA biosynthesis after 90 mins by [3H]-adenine incorporation assay,Other,26209266.0,
1313,1238932,1,1,,103167313,4735,Unspecified,,,,,Fungicidal activity against Candida albicans WTBF-50 assessed as inhibition of RNA biosynthesis after 90 mins by [3H]-uridine incorporation assay,Other,26209266.0,
1314,1238933,1,1,,103167313,4735,Unspecified,,,,,Fungicidal activity against Candida albicans WTBF-50 assessed as inhibition of protein biosynthesis after 90 mins by [3H]-leucine incorporation assay,Other,26209266.0,
1315,1238934,1,1,,103167313,4735,Unspecified,,,,,Fungicidal activity against Candida albicans WTBF-50 assessed as inhibition of cell wall biosynthesis after 90 mins by [3H]-glucosamine incorporation assay,Other,26209266.0,
1316,1238935,1,1,,103167313,4735,Unspecified,,,,,Fungicidal activity against Candida albicans WTBF-50 assessed as inhibition of lipid biosynthesis after 90 mins by [3H]-acetate incorporation assay,Other,26209266.0,
1317,1240165,1,1,,103167313,4735,Active,,,6.7,IC50,Antileishmanial activity against promastigotes of Leishmania amazonensis MPRO/BR/1972/M1841-LV-79 after 72 hrs by MTT assay,Confirmatory,26169126.0,
1318,1240166,1,1,,103167313,4735,Active,,,35.7,CC50,Cytotoxicity against Swiss albino mouse peritoneal macrophages after 24 hrs by MTT assay,Confirmatory,26169126.0,
1319,1240167,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for Swiss albino mouse peritoneal macrophages to IC50 for promastigotes of Leishmania amazonensis MPRO/BR/1972/M1841-LV-79",Other,26169126.0,
1320,1243739,1,1,,103167313,4735,Active,,,0.06,IC50,Leishmanicidal activity against Leishmania braziliensis MHOM/BR/01/BA788 after 48 hrs,Confirmatory,26107111.0,
1321,1243740,1,1,,103167313,4735,Unspecified,,,,,Leishmanicidal activity against Leishmania braziliensis MHOM/BR/01/BA788 after 48 hrs relative to control,Other,26107111.0,
1322,1243741,1,1,,103167313,4735,Active,,,1.8,IC50,Leishmanicidal activity against Leishmania amazonensis MHOM/BR/87/BA125 after 48 hrs,Confirmatory,26107111.0,
1323,1243742,1,1,,103167313,4735,Unspecified,,,,,Leishmanicidal activity against Leishmania amazonensis MHOM/BR/87/BA125 after 48 hrs relative to control,Other,26107111.0,
1324,1243743,1,1,,103167313,4735,Unspecified,,,100.0,LC50,Cytotoxicity against mouse J774 cells after 48 hrs by MTT assay,Confirmatory,26107111.0,
1325,1243744,1,1,,103167313,4735,Unspecified,,,,,Cytotoxicity against mouse J774 cells at 100 uM after 48 hrs by MTT assay,Other,26107111.0,
1326,1243756,1,1,,103167313,4735,Active,,,6.62,IC50,Leishmanicidal activity against Leishmania amazonensis MHOM/BR/71973/M2269 amastigotes infected in mouse peritoneal macrophages assessed as reduction in surviving parasites incubated for 72 hrs by Giemsa staining based optical light microscopy,Confirmatory,26112378.0,
1327,1243757,1,1,,103167313,4735,Active,,,11.22,CC50,Cytotoxicity against mouse peritoneal macrophages assessed as reduction in cell viability incubated for 72 hrs by MTT assay,Confirmatory,26112378.0,
1328,1243758,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of CC50 for mouse peritoneal macrophages to IC50 for Leishmania amazonensis MHOM/BR/71973/M2269 amastigotes infected in mouse peritoneal macrophages",Other,26112378.0,
1329,1243759,1,1,,103167313,4735,Inconclusive,,,,IC50,Inhibition of Leishmania mexicana cysteine protease r-CPB2.8 using Z-FR-AMC fluorogenic substrate by spectrofluorometry,Confirmatory,26112378.0,
1330,1244566,1,1,,103167313,4735,Active,,,0.00011,EC50,Trypanocidal activity against wild type bloodstream form of Trypanosoma brucei brucei s427 trypomastigotes after 70 hrs by Alamar Blue assay,Confirmatory,26231081.0,
1331,1244567,1,1,,103167313,4735,Active,,,0.55,EC50,Trypanocidal activity against diminazene/pentamidine/melaminophenyl arsenicals-resistant bloodstream form of Trypanosoma brucei brucei B48 trypomastigotes after 70 hrs by Alamar Blue assay,Confirmatory,26231081.0,
1332,1244568,1,1,,103167313,4735,Unspecified,,,,,"Resistant factor, ratio of EC50 for diminazene/pentamidine/melaminophenyl arsenicals-resistant Trypanosoma brucei brucei B48 to EC50 for wild type bloodstream form of Trypanosoma brucei brucei s427 trypomastigotes",Other,26231081.0,
1333,1247107,1,1,,103167313,4735,Active,,,3.05,IC50,Displacement of [3H]MK-801 from NMDA receptor in Wistar rat brain membranes by scintillation counting analysis,Confirmatory,26296478.0,
1334,1247108,1,1,,103167313,4735,Unspecified,,,,,Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of 30 uM spermine to IC50 for NMDA receptor in Wistar rat brain membranes in absence of 30 uM spermine,Other,26296478.0,
1335,1247109,1,1,,103167313,4735,Unspecified,,,,,Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of 10 to 50 mM Tris to IC50 for NMDA receptor in Wistar rat brain membranes in absence of 10 to 50 mM Tris,Other,26296478.0,
1336,1247110,1,1,,103167313,4735,Unspecified,,,,,Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of H+ at pH 6.4 to 8.2 to IC50 for NMDA receptor in Wistar rat brain membranes in absence of H+ at pH 6.4 to 8.2,Other,26296478.0,
1337,1247111,1,1,,103167313,4735,Unspecified,,,,,Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of 3 to 50 mM Na+ to IC50 for NMDA receptor in Wistar rat brain membranes in absence of 3 to 50 mM Na+,Other,26296478.0,
1338,1247112,1,1,,103167313,4735,Unspecified,,,,,Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of 50 mM K+ to IC50 for NMDA receptor in Wistar rat brain membranes in absence of 50 mM K+,Other,26296478.0,
1339,1247113,1,1,,103167313,4735,Unspecified,,,,,Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of 20 mM NH4+ to IC50 for NMDA receptor in Wistar rat brain membranes in absence of 20 mM NH4+,Other,26296478.0,
1340,1247114,1,1,,103167313,4735,Unspecified,,,,,Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of 1.3 mM Mg2+ to IC50 for NMDA receptor in Wistar rat brain membranes in absence of 1.3 mM Mg2+,Other,26296478.0,
1341,1250597,1,1,,103167313,4735,Active,,,0.0016,IC50,Antiparasitic activity against bloodstream form of Trypanosoma brucei brucei 427 infected in macrophages differentiated from human THP1 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay,Confirmatory,26322631.0,
1342,1254986,1,1,,103167313,4735,Unspecified,,,,IC50,Antileishmanial activity against Leishmania amazonensis MHOM/BR/77/LTB0016 assessed as inhibition of parasite growth incubated for 72 hrs by MTT assay,Confirmatory,26375353.0,
1343,1254987,1,1,,103167313,4735,Active,,,1.9,IC50,Antileishmanial activity against Leishmania amazonensis Leishmania amazonensis MHOM/BR/77/LTB0016 intracellular amastigotes infected in BALB/c mouse macrophages incubated for 72 hrs by microscopy,Confirmatory,26375353.0,
1344,1254988,1,1,,103167313,4735,Active,,,8.5,LD50,Cytotoxicity against BALB/c mouse peritoneal macrophages assessed as cell viability after 72 hrs by resazurin assay,Confirmatory,26375353.0,
1345,1254989,1,1,,103167313,4735,Unspecified,,,,,"Selectivity index, ratio of LD50 for BALB/c mouse peritoneal macrophages to IC50 for Leishmania amazonensis MHOM/BR/77/LTB0016 intracellular amastigotes infected in BALB/c mouse peritoneal macrophages",Other,26375353.0,
1346,1255035,1,1,,103167313,4735,Active,,,4.6,IC50,Antileishmanial activity against promastigote form of Leishmania major MHOM/IL/81/BNI after 96 hrs by spectrofluorimetric micromethod,Confirmatory,26383125.0,
1347,1255036,1,1,,103167313,4735,Active,,,3.0,IC50,Antileishmanial activity against amastigote form of Leishmania major MHOM/IL/81/BNI amastigote in Balb/c mouse peritoneal macrophages after 4 days by May-Grunwald-Giemsa staining-based microscopic analysis,Confirmatory,26383125.0,
1348,1255037,1,1,,103167313,4735,Unspecified,,,152.7,IC50,Cytotoxicity against BALB/c mouse peritoneal macrophages assessed as cell viability after 48 hrs by trypan blue dye exclusion method,Confirmatory,26383125.0,
1349,1255038,1,1,,103167313,4735,Unspecified,,,,,"Therapeutic index, ratio of IC50 for BALB/c mouse peritoneal macrophages to IC50 for promastigote form of Leishmania major (MHOM/IL/81/BNI)",Other,26383125.0,
1350,1255039,1,1,,103167313,4735,Inconclusive,,,,IC50,Cytotoxicity against BALB/c mouse 3T3 clone A31 cells after 48 hrs by SRB assay method,Confirmatory,26383125.0,
1351,1255040,1,1,,103167313,4735,Inconclusive,,,,,"Therapeutic index, ratio of IC50 for BALB/c mouse 3T3 clone A31 cells to IC50 for promastigote form of Leishmania major (MHOM/IL/81/BNI)",Other,26383125.0,
1352,1255041,1,1,,103167313,4735,Unspecified,,,,,"Therapeutic index, ratio of IC50 for BALB/c mouse peritoneal macrophages to IC50 for amastigote form of Leishmania major (MHOM/IL/81/BNI) in BALB/c mouse peritoneal macrophages",Other,26383125.0,
1353,1257054,1,1,,103167313,4735,Unspecified,,,,,Antileishmanial activity against axenic amastigote stage of Leishmania donovani assessed as growth inhibition after 72 hrs by Alamar Blue assay,Other,26520665.0,
1354,1257055,1,1,,103167313,4735,Unspecified,,,,,Antitrypanosomal activity against trypamastigote stage of Trypanosoma brucei assessed as growth inhibition after 72 hrs by Alamar Blue assay,Other,26520665.0,
1355,1259252,1,1,,174007138,4735,Active,169655958.0,,18.6548,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
1356,1259253,1,1,,174007138,4735,Active,169655958.0,,8.3328,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
1357,1259255,1,1,,174007138,4735,Active,169655958.0,,14.818,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
1358,1259256,1,1,,174007138,4735,Inconclusive,169655958.0,,2.9566,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
1359,1259336,1,3,,340126050,4735,Inactive,,,,,Small molecule activity in anthelmintic screen (C. elegans growth),Screening,,
1360,1259407,1,1,,363901775,4735,Inactive,,,,,CCRIS mutagenicity studies,Other,,
1361,1259416,1,2,,340080392,4735,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1362,1259416,1,2,,375174575,4735,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1363,1259421,1,1,,340080392,4735,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1364,1259421,1,1,,375174575,4735,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1365,1259423,1,2,,354928627,4735,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1366,1259423,1,2,,354943736,4735,Active,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1367,1259423,1,2,,354962330,4735,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
